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Apoptosis is a tightly regulated cellular process essential for normal development and 
tissue homeostasis. Perturbations to apoptotic signaling underscores numerous pathogenic 
processes emphasizing the importance of apoptotic regulation.  During apoptosis, caspases 
orchestrate cellular degradation through proteolytic cleavage of key structural and enzymatic 
proteins.  In a different manner, protein kinases regulate apoptosis by catalyzing the post-
translational phosphorylation of substrate proteins to facilitate either pro- or anti-apoptotic 
signal transduction pathways.  Emerging paradigms have indicated that bidirectional 
crosstalk between protein kinases and caspases serves to globally fine-tune the equilibrium 
between signals directing cell survival and cell death.  In this regard, identifying points of 
intersection between the apoptotic phosphoproteome and degradome is valuable considering 
both enzyme families are targeted for therapeutic intervention in a variety of pathologies. 
In this thesis, we employed diverse strategies to study the amplitude of 
phosphorylation and proteolysis in apoptotic cells.  First, using a bioinformatics approach, 
we revealed that a considerable proportion of the human kinome and phosphatome is 
degraded in response to various apoptotic stimuli across distinct cell types.  As a logical 
extension, we used quantitative proteomics strategies to explore both the apoptotic kinome 
and phosphoproteome of HeLa cells treated with doxorubicin.  Using these strategies, we 
observed distinct variations within the kinome and extensive hypo- and hyper-
phosphorylation of numerous phosphosites.  In parallel, we investigated the complementary 
apoptotic degradome by applying a quantitative N-terminomics approach where we identified 
a number of previously validated protease cleavage products and indexed numerous novel 
neo-N-termini.  Finally, to expand the biochemical toolbox for defining the spatial and 
temporal evolution of kinase–caspase networks, we investigated the impact of serine and 
phosphoserine determinants within caspase cleavage motifs and developed a number of 
prospective FRET biosensors to monitor the relationship between protein kinase CK2 




Collectively, using complementary strategies, we investigated the functional 
relationship between post-translational phosphorylation and proteolysis and provided insight 
into bidirectional communication between protein kinases and proteases during apoptosis.  
Keywords: apoptosis, protein kinase, protease, caspase, phosphorylation, proteolysis, 
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Chapter 1  
1 INTRODUCTION1 
1.1 General Background 
Cells exist in a dynamic environment and depend on tightly-regulated signaling 
pathways in order to maintain homeostasis. A vast network of proteins responds to 
internal cues and external stimuli to regulate cellular fate by initiating and executing 
signaling pathways controlling proliferation, differentiation and cellular death.  Post-
translational modifications, such as phosphorylation, have central roles in propagating 
vital signaling cascades.  Post-translational phosphorylation of substrate proteins is 
catalyzed by a family of enzymes called protein kinases, collectively referred to as the 
kinome, which transfer the gamma-phosphate from ATP to serine, threonine or tyrosine 
residues (1, 2).  Protein kinase-catalyzed phosphorylation of substrate proteins transduces 
pivotal signals through a variety of mechanisms including activation or inhibition of 
enzymes or transcription factors, influencing protein conformation and by mediating or 
disrupting protein–protein interactions (3–8).  More than 500 genes encode protein 
kinases representing approximately 2% of the human genome and approximately 700,000 
potentially phosphorylatable residues exist in the human proteome (1, 9).  
Pathophysiological rewiring of kinase signaling underscores many diseases, 
including cancers, where deviations to the phosphorylation landscape disrupt the balance 
                                                
1 Excerpts of this chapter are reproduced with permission from: 
Zukowski, SA and Litchfield, DW. (2015). Protein kinases and caspases: bidirectional interactions in 
apoptosis. In Kinomics: Approaches and Applications. Edited by Kraatz, HB and Martic, S. Wiley-VCH 
Verlag GmbH & Co., Weinheim, Germany. pp 85-114. 
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of signals regulating cell survival and apoptotic programmed cell death (10).  Apoptosis 
is a vital cellular process essential during normal development and in the routine turnover 
of cells.  Defects in apoptotic signaling that permit cells to persist inappropriately are 
considered a hallmark of cancer cells (11, 12). During apoptosis, the kinome is 
reprogrammed to simultaneously alleviate survival signaling and facilitate pro-apoptotic 
pathways.  In the process of malignant transformation, oncogenic protein kinases often 
contribute to pathways that allow cancer cells to resist apoptotic induction.  
Consequently, protein kinases exhibiting aberrant regulation or activity are often targets 
of therapeutic inhibitors designed to restore normal kinase function and combat 
oncogenesis. 
Apoptosis is a complex and elegantly orchestrated process.  In addition to 
apoptotic protein kinase signaling, a family of proteases, termed caspases (cysteine-
dependent aspartate-directed proteases), is recruited to execute cellular degradation.  
Mounting evidence suggests that functional crosstalk between protein kinases and 
caspases contributes to apoptotic regulation; consequently, alterations to kinase signaling 
can disrupt apoptotic induction and contribute to apoptotic evasion in cancer cells (13–
17).  With the development of novel therapeutics targeting protein kinases, it is important 
to decipher bidirectional relationships between protein kinases and caspases in order to 
understand the downstream outcomes of these treatments with respect to apoptotic 
signaling (18–20). 
1.2 Apoptosis: Caspase-Dependent Pathways  
Apoptosis is a critical event in organ and tissue development and in the normal 
turnover of cells.  Morphologically, apoptosis is characterized by cell shrinkage, 
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membrane blebbing, chromatin condensation (pyknosis), nuclear and DNA fragmentation 
(karyorrhexis) and the formation of apoptotic bodies (21–26).  Central to apoptotic 
signaling is a family of proteases termed ‘caspases’ that are subdivided into two classes: 
initiators and executioners.  Initiator caspases (caspase-8, -9, and -10) are activated by 
homodimerization of pro-domain regions and subsequent auto-proteolysis (27).  
Executioner caspases (caspase-3, -6, and -7) exist as zymogens (inactive enzyme 
precursors) until activated by linker-region proteolysis catalyzed predominantly by 
initiator caspases (27) (Figure 1.1).  Caspases are classified as cysteine proteases that 
catalyze irreversible cleavage of peptide bonds C-terminal to aspartic acid residues (27–
29).  A salient feature of caspases is that proteolytic cleavage is specific and contingent 
on the target site being located in an extended loop conformation with an aspartic acid 
residue accessible for directing cleavage (28, 30, 31). The activation of caspases, 
specifically the executioner caspases, initiates irreversible apoptotic progression and, as 
such, caspases are stringently regulated. 
1.2.1 Extrinsic Apoptosis 
Caspases are involved in the execution of two distinct subroutines of apoptosis: 
extrinsic apoptosis and caspase-dependent intrinsic apoptosis (32).  Extracellular stress 
conditions trigger extrinsic apoptosis by dispatching pro-apoptotic signals via 
transmembrane receptors classified as either ‘dependence receptors’ or ‘death receptors’ 
(33–36).  Dependence receptors, such as UNC5B (37), Patched (38), and DCC (deleted in 
colorectal cancer, (39)), initiate apoptosis in the absence of their ligands; however, the 
molecular pathways involved in these processes are poorly characterized.  In contrast, 






Figure 1.1 Schematic representation of domain organization for pro-apoptotic 
human caspases. 
Initiator and executioner caspases function in signaling cascades to proteolytically digest 
substrate proteins during apoptosis.  Caspases encode an N-terminal pro-domain and C-
terminal catalytic domain separated by the pro-domain linker.  The pro-domain region 
may include death effector domains (DED, shown in yellow) or caspase-recruitment 
domains (CARD, green) while the catalytic domain is subdivided into a large subunit and 
a small subunit separated by an inter-subunit linker.  Activation of caspases involves 
dimerization and proteolysis at aspartic acid residues located in the pro-domain and inter-
subunit linkers.  Numbering for caspases was sourced from Swiss-Prot entries and 
indicated phylogeny is based on similarities between sequence homology and substrate 













in a delicate equilibrium propagating either pro-survival or pro-apoptotic signaling 
cascades (40).  The death receptor family includes CD95/Fas, TNF-related apoptosis-
inducing ligand receptor 1 (TRAILR1), TRAILR2, tumor necrosis factor receptor 1 
(TNFR1), DR3, DR6, ectodysplasin A receptor (EDAR) and nerve growth factor receptor 
(NGFR), which all contain cytoplasmic death domains (DDs).  Other members of the 
death receptor family include the decoy death receptors TRAILR3, TRAILR4, DcR3 and 
osteoprotegerin (OPG), which do not contain DDs (40–43).  
Apoptotic death receptor signaling culminates in the formation of a signaling 
complex on the cytosolic side of the plasma membrane that facilitates activation of 
initiator caspases-8 and -10.  For example, the CD95/Fas death receptors assemble into 
trimers within the plasma membrane.  Upon ligand binding, these trimers become 
stabilized and induce conformational changes that trigger the recruitment of death-
inducing signaling complexes (DISCs) (44, 45).  DISCs are composed of scaffold and 
signaling proteins including Fas-associated death domain (FADD; a scaffolding protein) 
(44, 46), cellular inhibitor of apoptosis (cIAP) (47, 48), cellular FLICE (FADD-like IL-
1β-converting enzyme)-inhibitory protein (c-FLIP) (49) and pro-caspases-8 (50–52) and -
10 (53, 54).  When pro-apoptotic signals overwhelm anti-apoptotic signals, death 
receptors facilitate proximity-induced dimerization and activation of caspase-8 (and -10) 
(27, 52).  Subsequently, activated caspase-8 (and -10) initiates apoptotic programming by 
catalyzing the direct cleavage and maturation of executioner caspase-3 (a phenomenon 
occurring in cells designated as type I) or by cleaving the BCL-2 homology 3 (BH3)-
interacting domain death agonist (BID) into truncated BID (tBID).  Truncated BID 
enables mitochondrial outer membrane permeabilization (MOMP) which triggers 
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apoptosome formation and caspase-9 activation followed by activation of caspase-3 
(occurs in cells designated as type II) (32, 55, 56).  Ultimately, activation of the 
executioner caspases-3 and -7 promotes the irreversible pro-apoptotic cleavage events 
that carry out programmed cell death. 
1.2.2 Caspase-dependent intrinsic apoptosis 
Intrinsic apoptosis is initiated by intracellular stresses including DNA damage or 
oxidative stress and is dependent on MOMP for the release of pro-apoptotic proteins 
from the intermembrane space (IMS) of the mitochondria (57, 58).  Permeabilization of 
the mitochondria is regulated by the B cell lymphoma 2 (BCL-2) family of proteins, 
which are recognized by the presence of one or more BCL-2 homology (BH) domains 
(59).  BCL-2 proteins can be classified as pro-apoptotic (e.g., BAK and BAX), anti-
apoptotic (e.g., BCL-2, and BCL-XL) or BH3-only (e.g., BID, BIM, BAD, BIK, BMF, 
BNIP3, HRK, NOXA, and PUMA) (57, 59, 60).  In order for MOMP to occur, pro-
apoptotic factors BAK and BAX undergo conformational changes that foster homo-
oligomerization and recruitment to the outer mitochondrial membrane (OMM) where 
they form proteolipid pores (61, 62).  These pores facilitate the release of soluble pro-
apoptotic proteins from the IMS into the cytosol including cytochrome c, second 
mitochondria-derived activator of caspase (SMAC/DIABLO), OMI and apoptosis-
inducing factor (AIF) (57, 58). 
The release of cytochrome c induces oligomerization of apoptotic protease-
activating factor 1 (APAF1) in the cytosol leading to the formation of the apoptosome 
and activation of initiator caspase-9 (63–66).  Subsequently, activated caspase-9 cleaves 
executioner caspases-3 and -7 thereby activating the irreversible cleavage of several 
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cellular components, which culminates in apoptotic execution.  The other members of the 
BCL-2 family serve to regulate activation of pro-apoptotic BAK and BAX (57).  
Ultimately, activation of intrinsic apoptosis requires the persistence of an intracellular 
stress that shifts the equilibrium of pro- and anti-apoptotic factors by disrupting the 
sequestration of BAK and BAX by anti-apoptotic BCL-2 and BH3-only proteins. 
Multicellular organisms rely on apoptosis during development and in the routine 
turnover of cells.  As a natural barrier to diseases, the balance between pro- and anti-
apoptotic signals must be tightly regulated to prevent excessive (atrophic) or insufficient 
(cancerous) apoptotic induction.  In summary, the proteolysis-triggered irreversible 
cascade of cellular events leading to cell death emphasizes the importance of regulating 
caspases to prevent unintentional initiation of apoptotic programming in cells.   
1.3 Functional crosstalk between protein kinases and 
caspases 
The overarching theme of this thesis centers around apoptotic regulation as it 
pertains to bidirectional crosstalk between caspases and protein kinases. Caspases 
catalyze irreversible proteolysis of key proteins that propagate apoptotic programming 
and, ultimately, commit the cell to death; therefore, characterizing mechanisms regulating 
caspase activity is important for elucidating thresholds between cell survival and cell 
death.  Moreover, accumulating evidence implicates protein kinases as modulators of 
caspase regulation as post-translational phosphorylation of both caspases and caspase 
substrates affects caspase-mediated cleavage while proteolysis of protein kinases by 








Figure 1.2 Functional consequences of interactions between protein kinases and 
apoptotic caspases. 
Bidirectional crosstalk between protein kinases and caspases has the capacity to transmit 
both pro-apoptotic and anti-apoptotic signals.  This figure highlights outcomes that can 
occur as a consequence of interactions between protein kinases and caspases including 
protein kinase-catalyzed phosphorylation of caspases and caspase cleavage of protein 













1.3.1 Direct phosphorylation of caspases by protein kinases 
The irreversibility of apoptosis is, in some measure, attributed to the activation of 
caspases.  Caspases are expressed as inert zymogens that require proteolysis for 
activation; however, since cells typically employ redundancies in critical regulatory 
mechanisms, caspase activity can also be modulated through protein interactions or by 
post-translational modifications.  Accumulating evidence suggests that protein kinases 
contribute to regulation of caspase activity, a phenomenon that was first revealed in a 
study by Cardone et al., (67), which demonstrated that caspase-9 activity is inhibited by 
Akt phosphorylation.  This finding indicates that, through phosphorylation, protein 
kinases can directly influence caspase activity by preventing activating proteolysis or by 
influencing interactions with caspase binding partners.  Several additional examples of 
caspase phosphorylation have now been identified and, in many cases, the consequences 
of these post-translational modifications have been delineated.  To highlight the 
prevalence and importance of phosphorylated caspases on apoptotic initiation and 
progression, select examples validated in the literature are described herein (Table 1.1). 
Initiator Caspases 
Generally, the activation of initiator caspases serves as the rate-determining step 
in apoptotic progression and cells employ a variety of mechanisms to ensure that 
activation of initiator caspases only occurs when a cell is committed to undergoing 
apoptosis.  The initiator caspase, caspase-8, is expressed in human cells as two 
predominant isoforms, ‘a’ and ‘b’, with variances located in the pro-domain region (68).  






Table 1.1 Select examples of caspases positively or negatively regulated by protein 
kinase-mediated phosphorylation. 
Adapted from (13, 14). 
 
  





















Caspase-9 PKA Unclear (81)
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phosphorylation occurs predominately at tyrosine residues rather than serine or threonine 
residues and, generally, phosphorylation of caspase-8 inhibits activation.  Caspase-8a 
(also known as α-4) and -8b (α-1) are phosphorylated by members of the Src family of 
protein kinases including Src, Fyn and Lyn at tyrosine 397 and tyrosine 380, respectively, 
to suppress caspase activity (69–71).  Jia et al., (70), discovered that Lyn protein kinase 
also phosphorylates caspases-8a and -8b at tyrosine 465 and tyrosine 448, respectively, 
and that the Src-homology domain 2 (SH2)-containing tyrosine phosphatase 1 (SHP1) 
can dephosphorylate these sites in addition to phosphorylated tyrosine 397 (caspase-8a) 
and tyrosine 380 (caspase-8b).  Caspase-8 activity is also suppressed by p38 mitogen-
activated protein kinase (p38 MAPK) phosphorylation of serine 364 (caspase-8a) and 
serine 347 (caspase-8b) (72).  More recently, Peng et al., (73), detected phosphorylation 
at threonine 263 (caspase-8b) catalyzed by protein kinase ribosomal S6 kinase 2 (RSK2). 
They also demonstrated that phosphorylation affects caspase-8 stability through EGF-
mediated ubiquitination and subsequent degradation.   
Numerous studies have also highlighted extensive phosphorylation of initiator 
caspase-9 and, similar to caspase-8, phosphorylation typically suppresses caspase-9 
activation.  As previously mentioned, human caspase-9 is phosphorylated by Akt at 
serine 196; however, this modification is not evolutionarily conserved (67).  Likewise, 
serine 348 is phosphorylated by CK2 in mice; however, this site is not conserved in 
human caspase-9 (74).  Phosphorylation of threonine 125 suppresses caspase-9 activation 
and can be catalyzed by a number of distinct kinases including the following: 
extracellular signal-regulated kinase 1/2 (Erk1/2) (75), dual-specificity tyrosine-
phosphorylation-regulated kinase A1 (DYRK1A) (76), p38 MAPK (77) and cyclin-
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dependent kinase 1 (CDK1) (78).  Moreover, it is hypothesized that phosphorylation of 
threonine 125 is an anti-apoptotic modification that protects cells from inadvertent cell 
death by preventing activation of caspase-9 in the event of mitochondrial release of 
cytochrome c.  In response to osmotic stress, PKCζ (79) phosphorylates serine 144 to 
suppress caspase-9 activity and, conversely, in response to DNA damage, c-Abl (80) 
phosphorylates tyrosine 153 to enhance caspase-9 activation.  Additionally, Martin et al., 
(81), identified three protein kinase A (PKA) phosphorylation sites (serine 99, serine 183, 
and serine 195) on caspase-9; however, the direct effects of these phosphorylation events 
remain uncharacterized.  Collectively, these examples illustrate the complex nature of the 
intersection of protein kinase pathways with regulation of the initiator caspases. 
Executioner Caspases 
In addition to the incidence of phosphorylation events regulating the activation of 
initiator caspases, executioner caspases can also be phosphorylated suggesting that a 
variety of checkpoints are in place to either prevent or expedite apoptotic progression.  
For example, activation of caspase-3 is suppressed by p38 MAPK phosphorylation of 
serine 150 (72).  CK2 phosphorylation of threonine 174 and serine 176 also suppresses 
caspase-3 activation (16) whereas phosphorylation by PKCδ (site unknown) enhances 
activation (82).  Furthermore, caspase-7 activation is suppressed by p21-activated kinase 
2 (PAK2) phosphorylation of serine 30, threonine 173 and serine 239 (83). 
Overall, caspases are at the precipice of irreversible apoptotic signaling; therefore, 
it is unsurprising that a variety of mechanisms regulate caspase activation. The 
aforementioned examples emphasize that protein kinases can directly contribute to 
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apoptotic regulation through direct phosphorylation of caspases and demonstrate that 
phosphorylation of caspases fine-tunes the threshold for caspase activation in cells. 
1.3.2 Cleavage of caspase substrates is positively and negatively 
regulated by protein kinase phosphorylation 
According to recent estimations, approximately 5% of the human proteome is 
targeted for caspase-mediated proteolysis; however, given the broad extent of cleavage, 
the impact of the majority of these events is poorly characterized (84, 85).  Mounting 
evidence reveals extensive intersection between protein kinase signaling pathways and 
the complex network of caspase substrates supporting the notion that phosphorylation 
exhibits both positive and negative effects on the cleavage of caspase substrates (15, 17, 
86).  
Extrinsic apoptosis in cells designated as type II relies on caspase-8 cleavage of 
the BCL-2 family protein known as BID (32, 56).  When BID is cleaved by active 
caspase-8, the truncated C-terminal fragment (tBID) is released and transported to the 
mitochondria where it facilitates cytochrome c release, which first triggers the activation 
of caspase-9 and, ultimately, the activation of executioner caspases-3 and -7 (56, 87).  
Interestingly, a study by Desagher et al., (88), revealed that caspase-8 cleavage of BID is 
negatively regulated by phosphorylation and previously, Wang et al., (89), observed that 
BID, overexpressed in mammalian cells, migrated as a doublet or triplet on Western 
blots.  This finding, confirmed by Desagher et al., (88), was presumably the result of 
post-translational modifications of the protein, namely phosphorylation.  Using metabolic 
[32P]-orthophosphate labeling, Desagher et al., (88), confirmed that BID is 
phosphorylated in cells and mapped the main phosphorylation sites to threonine 58, 
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serine 61 and serine 64.  Further analysis of BID phosphorylation site mutants suggested 
these events occur in a hierarchical manner and are catalyzed by protein kinases CK1 and 
CK2.  In terms of localization, these phosphorylation sites are found adjacent to the 
caspase-8 cleavage site within BID and phosphorylation reduces BID sensitivity to 
caspase-8 proteolysis considerably.  Collectively, the data suggests that protein kinases 
CK1 and CK2 influence apoptotic progression by preventing cleavage of BID into tBID 
by caspase-8.  
The serine/threonine protein kinase CK2 is of particular interest with respect to 
caspase cleavage because it recognizes highly acidic consensus sequences that often 
directly overlap with the aspartate-directed recognition sequences targeted by caspases-3 
and -7 (16, 90).  In fact, using a peptide-match program to examine systematic 
relationships between recognition motifs for protein kinases and caspases, Duncan et al., 
(16), identified CK2 as the protein kinase with the most prevalent overlap for caspase-3 
recognition sites. Protein kinase CK2 is a constitutively active enzyme implicated in the 
regulation of cell survival, suggesting that CK2 phosphorylation of caspase substrates 
could be a global mechanism to suppress apoptosis (90, 91).  For example, CK2-
catalyzed phosphorylation of the tumour suppressor phosphatase and tensin homolog 
(PTEN) negatively regulates its cleavage by caspase-3 during apoptosis (92).  Another 
CK2 substrate, hematopoietic lineage cell-specific protein 1 (HS1), expressed in 
hematopoietic and lymphoid cells, was reported to be phosphorylated extensively at 
tyrosine residues upon B-cell receptor cross-linking (93).  After identifying a physical 
interaction between CK2 (catalytic α subunit) and HS1 (94), Ruzzene et al., (95, 96), 
discovered that HS1 is phosphorylated at serine and threonine residues in intact platelets 
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and implicated CK2 as the protein kinase responsible. Yin et al., (97), demonstrated that 
CK2 phosphorylation of the gap junction protein Connexin 45.6 modulates its stability 
and degradation through the proteasome and, furthermore, prevents caspase-3-mediated 
cleavage at glutamic acid 367.  CK2 is also identified as the protein kinase that 
phosphorylates the caspase-inhibiting protein apoptosis repressor with caspase 
recruitment domain (ARC) (98, 99).  Phosphorylation of threonine 149 by CK2 enables 
ARC to localize to the mitochondria where it directly binds and inhibits caspase-8 
activation making this phosphorylation site essential for the anti-apoptotic role of ARC 
(99).  Another example of CK2 exerting cell survival functionality is through the 
transcription factor Yin Yang 1 (YY1), which is ubiquitously expressed and participates 
in the control of gene expression for processes such as proliferation, differentiation, 
embryogenesis, development, tumorigenesis and apoptosis (100–102).  In the 
transactivation domain of YY1, CK2 phosphorylates serine 118 and the presence of a 
phosphate at this position prevents caspase-7 degradation of YY1 during apoptosis (103).  
Taken together, these examples underscore the role of CK2 in promoting cell survival 
pathways and illustrate the convergence of CK2 on caspase cleavage recognition sites, 
which has the potential to modulate caspase signaling during apoptosis. 
While the examples highlighted above illustrate the potential for phosphorylation 
to block caspase substrate cleavage there are also instances where phosphorylation of 
caspase substrates can enhance substrate cleavage.  For example, protein kinase C δ 
(PKCδ), a major participant in the regulation of cell death, is cleaved during apoptosis in 
the hinge region by caspase-3 releasing a constitutively active kinase domain (104–106).  
In 2007, a study by Lu et al., (107), revealed that phosphorylation of tyrosine 332, 
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located at a position flanking the hinge region, is required for processing of PKCδ by 
caspase-3.  Furthermore, Src was identified as the protein kinase responsible for 
phosphorylation of PKCδ at tyrosine 332.  While studying golgin-160, a coiled-coil 
protein that participates in regulating the structure of the Golgi complex, Cha et al., 
(108), discovered another example of phosphorylation positively regulating caspase 
cleavage.  Golgin-160 is a phosphoprotein that undergoes caspase-dependent cleavage at 
aspartic acid residues 59, 139 and 311 by caspase-2, -3 and -7, respectively (109).  Cha et 
al., (108), subsequently identified mixed-lineage-kinase-3 (MLK3) as the kinase 
responsible for phosphorylating golgin-160 between residues 96 and 259 in the N-
terminal head region and also demonstrated that overexpression of MLK3 results in 
increased caspase-dependent proteolysis of golgin-160 at aspartic acid residue 139 (108, 
110).  More recently, global proteomics studies investigating the relationship between 
phosphorylation and caspase-cleavage have identified numerous instances in which 
phosphorylation positively regulates caspase cleavage (15, 17). Overall, phosphorylation 
can promote proteolysis and this mechanism further magnifies the already complex 
regulatory role of protein kinases in apoptotic signaling. 
In summary, the described examples illustrate the convergence of protein kinase 
signaling on the cleavage of caspase substrates.  Keeping in mind that the activity of 
several protein kinases is amplified during apoptosis and that protein kinase consensus 
sequences often overlap with caspase cleavage sites, it is evident that phosphorylation is 
an effective and dynamic mechanism for regulating proteolysis of caspase substrates.  
Furthermore, recent technological advancements in proteomics have enabled the 
17 
 
development of novel strategies for global investigation of relationships between the 
phosphoproteome and the caspase degradome.  
1.3.3 Caspase-mediated degradation of protein kinases and 
apoptotic progression  
It is evident that protein kinases play a central role in the regulation of caspase 
activation and caspase cleavage events; therefore, investigating how protein kinases are 
regulated to direct the fate of a cell is also an important consideration.  Protein kinases 
are controlled by a variety of mechanisms including activating phosphorylation catalyzed 
by auto-phosphorylation or other protein kinases, co-localizing with substrates, or 
interacting with regulatory partners.  In addition to these mechanisms, proteolytic 
processing of protein kinases during apoptosis is another major mechanism involved in 
modulating kinome signaling.  Consequences of proteolytic degradation of protein 
kinases during apoptosis include increased or constitutive activity, complete abrogation 
of activity, altered localization of the protein kinase or changes to the substrate preference 
of the protein kinase.  This section describes how caspase cleavage of select protein 
kinases contributes to apoptotic signaling (Table 1.2). 
Rho-associated coiled-coil containing protein 1 (ROCK1) 
The morphological features observed during apoptosis are a consequence of 
changes to the cytoskeleton.  At the initiation of apoptosis, the cell membrane begins to 
bleb as a result of actomyosin-mediated contractile forces regulated by Rho-family G 
proteins (111–113).  G proteins are GTPases that act as molecular switches converting 
between an active conformation when bound GDP is exchanged for GTP and an inactive 





Table 1.2 Select examples of protein kinases activated or inactivated by caspase-
mediated proteolysis. 
Protein kinases can be activated or inactivated by caspase-mediated cleavage and caspase 
cleavage sites for the listed protein kinases are indicated by a * following the residue 
directing caspase cleavage. Adapted from (13, 14). 
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RIP1 LQLD324*C (171, 182, 183)
+ denotes cleavage sites identified in vitro
m denotes cleavage sites identified in mice 
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GTPases propagate downstream signaling through effector proteins to regulate pathways 
including the intracellular actin network (111). For example, GTP-bound Rho binds and 
activates Rho-associated serine/threonine protein kinases ROCK1 and ROCK2 (isoforms 
encoded as separate genes on different chromosomes), which increases cell contractility 
by altering cytoskeletal actin dynamics (115–117). A major component of actin dynamics 
involves myosins and the distinctive myosin light chain (MLC) proteins that bind to and 
regulate myosins.  Regulation of MLCs is directly related to their phospho-occupancy, 
which is mediated by MLC kinase, Rho-associated kinases (ROCK1 and ROCK2) and 
myosin phosphatases.  With respect to apoptosis, concurrent studies conducted by 
Sebbagh et al., (118), and Coleman et al., (119), identified ROCK1 (but not ROCK2) as 
the enzyme responsible for the plasma membrane blebbing phenotype observed during 
apoptosis.  They demonstrated that upon activation of apoptosis, caspase-3 is responsible 
for cleaving ROCK1 at DETD1113.  Furthermore, pharmacological inhibition of ROCK1 
or expression of a dominant negative abolished the membrane blebbing phenotype (118, 
119).  Notably, the ROCK1 caspase-3 cleavage site is conserved in mice and rats while 
alignment of ROCK1 and ROCK2 sequences reveals that the caspase-3 recognition site is 
absent from ROCK2 (118).  Caspase-3 cleavage of ROCK1 at this site removes the 
autoinhibitory C-terminal domain and produces a constitutively active ROCK1 protein 
kinase fragment that phosphorylates MLC to promote membrane blebbing (118, 119).  To 
further understand the biochemical pathways involved in this phenomenon, Sebbagh et 
al., (118), monitored ROCK1 cleavage and membrane blebbing in Fas-triggered 
apoptotic Jurkat cells in the presence of a ROCK1 inhibitor (Y-27632), a caspase 
inhibitor (z-DEVD-fmk) and a Rho-inhibitor (TAT-C3) (120–122).  Treating cells with 
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the caspase inhibitor prevented increased phosphorylation of MLCs while treating cells 
with the Rho-inhibitor did not reduce phosphorylation of MLCs indicating that the 
increase in ROCK1 activity during apoptosis is caspase-dependent and Rho-independent.  
Taken together, these studies highlight ROCK1 as an example of a caspase cleavage 
event that alters the activity of a protein kinase through removal of a regulatory domain 
that liberates a constitutively active protein kinase fragment. With respect to protein 
kinase signaling, it is interesting that dysregulation of a single protein kinase can have 
such a profound influence on cellular processes and in this case, independently initiate 
morphological changes to cells during apoptosis. 
p21-activated Protein Kinase 2 (PAK2) 
In addition to ROCK1, which induces the formation of membrane protrusions 
during apoptosis when activated by caspase cleavage, another effector of Rho-family 
GTPases, p21-activated protein kinase 2 (PAK2), also participates in cytoskeletal 
reorganization during apoptosis (113, 123).  Similar to ROCK1, PAK2 is a 
serine/threonine protein kinase consisting of an N-terminal regulatory domain and a C-
terminal catalytic domain (reviewed in (124, 125)). Activation of full-length PAK2 
promotes cell survival; however, during apoptosis, PAK2 is proteolytically processed by 
caspases at SHVD212 to liberate the kinase domain, which is constitutively active and 
subsequently propagates apoptotic signaling (126, 127).  Unlike ROCK1, direct 
substrates and the consequences of the constitutively active PAK2 protein kinase 
fragment are poorly characterized.  Morphological features of apoptosis (e.g., cell 
rounding, chromatin condensation and membrane blebbing) are observed independent of 
cytochrome c release and caspase activation when the catalytic domain of PAK2 is 
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ectopically expressed or microinjected into cells (112, 128). In response to Fas-induced 
apoptosis, cells expressing catalytically inactive PAK2 fail to display the morphological 
manifestations of apoptosis (112, 113).  In contrast, caspase inhibition prevents 
membrane blebbing in apoptotic cells expressing a constitutively active PAK2 mutant 
(119).  Collectively, these results indicate that the PAK2 kinase domain is constitutively 
activated as a consequence of caspase-mediated degradation resulting in phosphorylation 
of PAK2 substrates, which contribute to the morphological changes observed during 
apoptosis.  Another interesting finding is that full-length PAK2, which promotes cell 
survival, is stable whereas the caspase-activated protein kinase fragment is typically 
degraded quickly by the 26S proteasome (129).  Stabilization of the protein kinase 
fragment during apoptosis may be attributed to the finding that caspase cleavage of 
PAK2 facilitates altered localization of the constitutively active kinase domain (129).  
Jakobi et al., (129), discovered that full-length PAK2 contains both a nuclear export 
signal (NES) and a nuclear localization signal (NLS) and under cell survival conditions, 
the NES overrides the NLS and PAK2 is localized to the cytoplasm.  Following caspase 
cleavage of PAK2 during apoptosis, the NES is disrupted and the NLS relocates the 
protein kinase fragment to the nucleus (129).  In contrast, a study by Vilas et al., (128), 
showed that the caspase-activated protein kinase fragment of PAK2 undergoes post-
translational myristoylation, which dispatches the protein kinase fragment to the plasma 
membrane.  Together, the data from these studies suggests that PAK2 signaling during 
apoptosis is multifaceted and future investigations will be required to fully evaluate the 
dual consequences (i.e., constitutive activity and altered localization) of PAK2 caspase 
cleavage and how subsequent signaling events influence apoptotic progression.  
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Focal Adhesion Kinase (FAK) 
The structure of many protein kinases consists of a regulatory domain and a 
catalytic kinase domain separated by a linker region.  Interestingly, a study by Dix et al., 
(86), revealed that caspase-cleavage events frequently occur within linker regions 
releasing two intact and often functional domains.  As described in the preceding section, 
ROCK1 and PAK2 are examples of kinases that are activated by caspase cleavage within 
the linker domain; however, there are also examples of kinase domains that are 
inactivated by caspase cleavage.  In these instances, the proteolytic fragments of 
inactivated protein kinases may not be catalytically functional; however, they may still be 
involved in the progression of apoptosis.  For example, focal adhesion kinase (FAK) is a 
non-receptor tyrosine kinase cleaved by caspases at the onset of apoptosis (130–135).  As 
the name suggests, FAK participates in cell adhesion and motility by regulating 
interactions between the cytoplasmic cytoskeleton and the extracellular matrix.  FAK was 
one of the first protein kinases identified as a caspase substrate and despite the fact that 
caspase cleavage of FAK inactivates kinase activity, fragments of FAK contribute to 
apoptosis indirectly by abolishing cell survival signals (133–135).  Specifically, upon 
initiation of apoptosis, FAK is cleaved at VSWD704 (preferentially by caspase-3) and 
DQTD772 (preferentially by caspase-6), which separates the focal adhesion targeting 
(FAT) domain from the tyrosine kinase domain and subsequently, interrupts transmission 
of survival signals from the extracellular matrix (134).  In addition, following caspase-
mediated cleavage the cleaved fragment containing the FAT domain suppresses 
activating phosphorylation of FAK as the FAT domains shares similar homology to an 
endogenous FAK inhibitor termed FAK-related nonkinase (FRNK) (134).   
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Protein kinase Akt 
Another example of caspase-mediated inactivation of a protein kinase that shifts 
signaling pathways from pro-survival to pro-apoptotic is caspase-3 catalyzed cleavage of 
Akt at TVAD108, EEMD119 and ECVD462 (136, 137).  Akt is a pro-survival kinase that 
undergoes caspase-cleavage to remove a C-terminal hydrophobic motif and a membrane-
targeting pleckstrin homology domain required for kinase activation (136, 137).  
Apoptotic cell death is delayed in cells overexpressing mutants of Akt resistant to caspase 
cleavage while overexpression of wildtype Akt has no effect on apoptotic induction (136, 
137).  In order for apoptosis to occur, pro-apoptotic signals must overcome signals 
promoting cell survival and as such, abolishing Akt signaling at the onset of apoptosis 
appears to be critical for apoptotic progression. 
Protein Kinase C δ (PKCδ) 
Another family of protein kinases targeted by caspases is the Protein Kinase C 
(PKC) family of lipid-activated serine/threonine protein kinases.  This family of protein 
kinases participates in a variety of different pathways including differentiation, cell 
survival and cell death (138).  PKC isoforms are subdivided into three groups based on 
their requirements for activation: conventional PKCs (cPKC), novel PKCs (nPKC) and 
atypical PKCs (138).  In terms of apoptotic signaling, Protein Kinase C δ (PKCδ) is the 
most extensively studied isoform and is classified as a novel PKC, meaning it adopts an 
active conformation upon binding of diacylglycerol or phorbol esters or by being 
phosphorylated (139).  In mammalian tissues, PKCδ is ubiquitously expressed and 
consists of an N-terminal regulatory domain separated from a C-terminal kinase domain 
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by a short hinge region (139).  This hinge region contains a recognition site for caspase-3 
(DMQD329) and, during apoptosis, this site is cleaved to constitutively activate the kinase 
fragment through release of the regulatory domain (105). Full-length PKCδ is localized to 
the cytoplasm during cell survival conditions and, similar to PAK2, PKCδ contains an 
NLS on the C-terminus, which facilitates localization of the kinase fragment to the 
nucleus following caspase cleavage (140).  Humphries et al., (141), showed that 
phosphorylation of tyrosine residues 64 and 155 on full-length PKCδ contributes to 
nuclear localization of PKCδ prior to caspase cleavage suggesting that phosphorylation of 
these sites may act as a switch to promote either cell survival or apoptosis.  Nuclear 
accumulation of PKCδ is required for apoptosis and evidence of PKCδ activity in the 
nucleus include phosphorylation of DNA dependent protein kinase (DNA-PK) (142), p53 
(143, 144), Rad9 (145) and lamin B (146).  Other studies have shown that the catalytic 
fragment of PKCδ is translocated to the mitochondria to enhance intrinsic apoptotic 
signaling by playing a role in promoting the release of cytochrome c and by facilitating 
proteolytic degradation of Mcl-1 (a BCL-2 family protein) (147, 148).  The catalytic 
fragment of PKCδ also complexes with c-Abl, which enhances intrinsic apoptotic 
signaling by establishing communication between the endoplasmic reticulum and the 
mitochondria (149).  Collectively, these results indicate that caspase-3 cleavage of PKCδ 
initiates a number of downstream signaling events that propagate apoptotic progression 
by not only constitutively activating the kinase domain of PKCδ but also by facilitating 
relocation of PKCδ activity. 
PKCδ exemplifies bidirectional crosstalk between protein kinases and caspases 
for propagating the apoptotic phenotype. At the onset of caspase-dependent apoptosis, 
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intrinsic or extrinsic, initiator caspases inevitably activate executioner caspases including 
caspase-3.  Recall, PKCδ is responsible for phosphorylating caspase-3 at a site that 
enhances its proteolytic activity and in turn, active caspase-3 cleaves PKCδ (82, 104–
106).  Caspase-3 cleavage of PKCδ is positively regulated by Src-mediated 
phosphorylation and caspase-3 cleavage of this site liberates the kinase domain of PKCδ 
in a constitutively active conformation allowing for increased phosphorylation and 
presumably enhanced caspase-3 activity (105, 107).  Overall, the evidence demonstrates a 
relationship between protein kinase PKCδ and caspase-3 and suggests that a positive 
feedback loop is triggered in order to propagate apoptotic signaling (Figure 1.3). 
From the examples presented, it is evident that protein kinase signaling plays a 
major role in biochemical pathways governing cellular fate and caspase-mediated 
cleavage of protein kinases is a fundamental regulatory mechanism required for 
apoptosis.  Overall, the consequences of protein kinase activation or inactivation act as a 
toggle between disabling pro-survival pathways and stimulating pro-apoptotic pathways. 
1.4 Strategies to investigate global crosstalk between 
protein kinases and caspases 
Thus far, examples provided highlight the complexity of interactions between 
protein kinases and caspases that facilitate the progression of apoptosis.  Numerous 
studies have focused on the pro-apoptotic consequences of specific kinase–caspase-
mediated signaling pathways; however, these findings reveal only a snapshot of the 
events contributing to programmed cell death.  In order to comprehensively understand 







Figure 1.3 Bidirectional crosstalk between PKCδ and caspase-3 during apoptosis. 
During apoptosis, PKCδ phosphorylation of caspase-3 enhances caspase-3 activity and in 
turn, activated caspase-3 cleaves Src-phosphorylated (tyrosine 332) PKCδ at DMQD329 
(82, 104–107).  Caspase-3 cleavage of PKCδ occurs in the hinge region that separates the 
regulatory domain from the catalytic domain; consequently, caspase-3 cleavage of PKCδ 
increases the activity of the kinase.  Increased PKCδ activity may increase 
phosphorylation of caspase-3 suggesting that caspase-3 cleavage of PKCδ initiates a 
positive feedback loop for enhanced caspase-3 activity via PKCδ phosphorylation during 
apoptosis.  Furthermore, the catalytic fragment of PKCδ translocates to the nucleus where 































strategies are required to systematically characterize the interplay between the apoptotic 
kinome and subsequent phosphoproteome, as well as the caspase degradome.  In this 
respect, the emergence of novel strategies involving proteomics, computational 
approaches, and techniques designed to monitor the spatial and temporal induction of 
apoptotic pathways within intact cells offer the promise of comprehensive new insights 
regarding protein kinase–caspase interactions. 
1.4.1 Computational approaches and bioinformatics investigating 
overlap between protein kinase consensus sites and 
caspase recognition motifs 
Based on initial findings suggesting that protein kinases influence caspase 
cleavage events during apoptosis, Duncan et al., (16), devised a peptide-based screen to 
systematically investigate the potential involvement of kinases in the global regulation of 
caspase signaling.  A peptide match program was used to search the human proteome for 
proteins with overlapping kinase and caspase consensus sequences.  This strategy 
revealed that an overwhelming number of caspase recognition motifs overlap with kinase 
recognition motifs with the most prevalent overlap involving the consensus sequence for 
protein kinase CK2, an acidophilic kinase with a consensus recognition motif exhibiting 
remarkable resemblance to many caspase recognition sequences.  Candidates identified 
by computational predictions were subsequently evaluated for CK2 phosphorylation 
using peptide arrays and an assay termed caspase substrate identification (CSI) was 
devised to detect caspase cleavage of peptide substrates.  Interestingly, these studies 
revealed that CK2 phosphorylates procaspase-3 at threonine 174 and serine 176, which 
flank the aspartic acid residue (IET174D⬇S176) directing cleavage for activation of caspase-
3.  These findings provided intriguing new insight into the potential for protein kinases to 
28 
 
modulate caspase pathways through phosphorylation of an extensive repertoire of caspase 
substrates and even direct phosphorylation of caspases. 
1.4.2 Proteomics-based strategies to investigate crosstalk within 
the phosphoproteome and the caspase degradome 
The aforementioned study by Duncan et al., (16), is a key example demonstrating 
how computational approaches linked to systematic biochemical workflows can be used 
to investigate crosstalk occurring between protein kinases and caspases.  Recent advances 
in proteomics have also expanded our knowledge of the phosphoproteome and the 
caspase degradome to extend our understanding of apoptotic signaling.   For example, to 
study the caspase degradome, Dix et al., (86), developed a systematic proteomic 
workflow termed Protein Topography and Migration Analysis Platform (PROTOMAP).  
PROTOMAP profiles proteolytic events occurring in natural biological systems using 
SDS-PAGE, reverse phase liquid chromatography (LC) and tandem mass spectrometry 
(MS/MS) analyses to assess global changes to protein size, topography and abundance.  
Comparative analyses employing PROTOMAP involve proteomes from control and 
experimental samples to be fractionated by SDS-PAGE followed by digestion with 
trypsin in preparation for LC-MS/MS analysis.  Control and experimental data are then 
assembled into “peptographs”, which plot sequence coverage (N- to C-terminal) left to 
right against SDS-PAGE migration (high to low molecular weight) top to bottom and 
also displays spectral counts in a chart corresponding to the data on the peptograph.  Dix 
et al., (86), applied this strategy to investigate cleavage events occurring in Jurkat T cells 
following induction of apoptosis with the broad specificity kinase inhibitor staurosporine.  
First, they confirmed that proteolytic markers of apoptosis (i.e., known substrates of 
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caspase cleavage) were included in their datasets and compared their findings to the 
Caspase Substrate Database Homepage (CASBAH) to confirm the presence of other 
known caspase substrates (150).  This technique enables analysis of both the magnitude 
and stability of cleaved protein fragments revealing that caspases do not necessarily 
facilitate complete degradation of substrates.  Instead caspase cleavage often generates 
stable protein fragments that can persist in the cell throughout the apoptotic program.  In 
addition, they also detected half-tryptic peptides containing an aspartic acid residue at 
one terminus, which resulted from caspase cleavage events allowing for explicit 
identification of caspase cleavage sites. Overall, Dix et al., (86), demonstrated that the 
PROTOMAP technique is a powerful approach for identifying the consequences of 
proteolytic events on the proteome in complex biological systems.  More recently, they 
introduced an advanced version of PROTOMAP termed quantitative phospho-
PROTOMAP (qP-PROTOMAP) that simultaneously and quantitatively analyzes both 
proteolysis and phosphorylation in the proteome (15).  The qP-PROTOMAP technique 
involves heavy and light SILAC (stable isotope labeling by amino acids in cell culture, 
(151)) labeling of control and experimental (i.e., staurosporine-treated) lysates 
respectively, which are subsequently combined and separated using SDS-PAGE.  As in 
the original PROTOMAP approach, the gel is cut into equal pieces and digested with 
trypsin, but prior to LC-MS/MS analysis, the sample is passed over immobilized metal-
affinity chromatography (IMAC) in order to enrich for the phosphoproteome.  The data is 
then summarized in a “qPeptograph” which, in addition to displaying the same 
information as peptographs, also includes the quantification data for each peptide and 
indicates which peptides are phosphorylated.  Using this strategy, Dix et al., (15), 
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concluded that during apoptosis, proteolytic digestion rewires regulatory phosphorylation 
networks to facilitate apoptotic signaling.  The qPROTOMAP dataset showed that 
proteolysis of various proteins exposes additional phosphorylation sites and revealed a 
number of apoptosis-specific phosphorylation events.  Interestingly, the data suggests 
that, in addition to inhibition of cleavage, phosphorylation can also directly promote 
caspase substrate cleavage, primarily when a phosphate is transferred to a phospho-
acceptor in the P3 position of caspase recognition motifs.  Overall, PROTOMAP and 
qPROTOMAP are extremely useful approaches for directly investigating both caspase 
cleavage and phosphorylation events in apoptosis.   
As a logical extension of the abovementioned studies by Duncan et al., (16), and 
complementary to the approaches of Dix et al., (15, 86), we (17) devised another 
unbiased proteomic strategy based on the TAILS (terminal amino isotopic labeling of 
substrates) N-terminomics approach (152) to identify caspase substrates regulated by 
phosphorylation in order to analyze the caspase degradome in the context of the native 
phosphoproteome.  Using this approach, caspase degradomes from heavy- and light-
labeled phosphorylated and dephosphorylated lysates were analyzed to identify 
phosphorylated and non-phosphorylated proteins digested by caspases.  In agreement 
with conclusions drawn by Dix et al., (15, 86), these studies identified a number of 
substrates negatively regulated by phosphorylation and also a number of caspase 
substrates that appeared to be positively regulated by phosphorylation (17).  Candidate 
caspase substrates identified in the proteomic screen showing positive regulation (MST3) 
or negative regulation (Yap1 and Golgin-160) by phosphorylation were validated in cells 
using Western blots.  In contrast to results for MST3 obtained from lysates in the 
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proteomic screen, caspase cleavage of model synthetic peptides based on the MST3 
sequence showed negative regulation by phosphorylation similar to model peptides for 
Yap1 and Golgin-160 suggesting that positive regulation by phosphorylation resides in 
determinants outside the primary amino acid sequence. In addition, the influence of 
serine and phosphoserine throughout the entirety of an expanded caspase cleavage motif 
for caspase-3, -7 and -8 synthetic peptides were tested revealing that phosphorylation 
generally has an overall inhibitory effect on caspase cleavage. Again, these observations 
suggest that alterations in the tertiary structure of the protein may be required for 
phosphorylation to have a positive effect on regulation of caspase cleavage events. 
Overall, this work extends knowledge of the role of phosphorylation in regulating 
caspase cleavage revealing novel regulatory positions across the entirety of the caspase 
cleavage motif. In addition, this study demonstrates that N-terminomics strategies can be 
adapted to study crosstalk between phosphorylation and proteolysis. 
1.4.3 Reporters to monitor the spatial and temporal dynamics of 
caspase cleavage in living cells 
In addition to proteomic workflows that enable systematic evaluation of the entire 
phosphoproteome and caspase degradome, strategies to validate the spatial and temporal 
incidence of events revealed in high-throughput studies are essential for deciphering the 
intricacies of apoptotic signaling networks.  A number of strategies devised to monitor 
caspase activation in living cells include using fluorescent tags and live-cell imaging.  For 
example, Hellwig et al., (153), monitored caspase-8 cleavage by developing a FRET 
(Förster resonance energy transfer) probe consisting of cyan fluorescent protein and 
yellow fluorescent protein separated by a linker encoding either an IETD caspase-8 
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recognition site or the full-length sequence of BID.  Caspase-8 cleavage of these FRET 
probes produces a quantifiable loss of FRET signal that can be monitored in real-time in 
mammalian cells to assess caspase-8 activation.   
In summary, the development of systematic strategies to evaluate the 
phosphoproteome in the context of the caspase degradome offers comprehensive new 
insights with respect to bidirectional crosstalk occurring between protein kinases and 
caspases during apoptosis.  
1.5 Scope of Thesis 
In this thesis, we employ diverse strategies to study the amplitude of 
phosphorylation and proteolysis in apoptotic cells.  First, in chapter 2, we investigated the 
influence of apoptotic-driven proteolysis on phosphotransferase signaling by 
interrogating the DegraBase repository generated by Crawford et al., (154).  Our 
evaluation revealed that a considerable proportion of both the human kinome and 
phosphatome are subjected to proteolytic processing in response to various apoptotic 
stimuli across distinct cell types.  As a logical extension of these findings, we used two 
complementary quantitative proteomics strategies to explore both the apoptotic kinome 
and the apoptotic phosphoproteome of HeLa cells treated with doxorubicin, a clinically 
relevant cytotoxic chemotherapy.  Consistent with observations from our kinome profile 
suggesting distinct variations within protein kinases, we observed extensive hypo- and 
hyper-phosphorylation of identified phosphorylation sites suggesting that apoptotic 
phosphoproteome dynamics involve intricate regulatory mechanisms. 
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Next, in chapter 3, we explored the context-specific apoptotic degradome of HeLa 
cells treated with doxorubicin using a quantitative N-terminomics strategy known as 
TAILS (terminal amine isotope labeling of substrates) (155).  Following validation of the 
TAILS method we analyzed our HeLa N-terminome enrichment by characterizing 
peptides identified both quantitatively and qualitatively.  Collectively, we identified a 
number of previously validated protease cleavage products and indexed numerous novel 
neo-N-termini.  Overall, our study provides an unbiased surveillance of proteolytic 
processing in HeLa cells treated with doxorubicin and illustrates the diversity and 
complexity of signaling within protease webs. 
Finally, in chapter 4, we systematically investigated the impact of serine and 
phosphoserine determinants within caspase cleavage motifs. Using a peptide-centric 
approach, we demonstrated that phosphoserine negatively regulates caspase cleavage 
both within and beyond the canonical boundaries of documented caspase motifs.  With 
this notion, we developed a number of prospective FRET biosensors to monitor the 
relationship between protein kinase CK2 phosphorylation and caspase-mediated 
proteolysis to expand the biochemical toolbox for defining the spatial and temporal 
evolution of kinase–caspase networks during apoptosis in live cells. 
In summary, using both peptide- and process-centric strategies, we have 
investigated the functional relationship between post-translational phosphorylation and 
proteolysis; ultimately, this thesis provides insights into the bidirectional interplay 
between protein kinase and protease signaling during apoptosis.  
34 
 
1.6 References  
1.  Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) 
The protein kinase complement of the human genome. Science 298, 1912–1934
 
2.  Hunter, T. (2000) Signaling--2000 and beyond. Cell 100, 113–127
 
3.  Franklin, R. A., and McCubrey, J. A. (2000) Kinases: positive and negative 
regulators of apoptosis. Leukemia 14, 2019–2034
 
4.  Pawson, T. (2004) Specificity in signal transduction: from phosphotyrosine-SH2 
domain interactions to complex cellular systems. Cell 116, 191–203
 
5.  Huse, M., and Kuriyan, J. (2002) The conformational plasticity of protein kinases. 
Cell 109, 275–282
 
6.  Karin, M., and Hunter, T. (1995) Transcriptional control by protein 
phosphorylation: signal transmission from the cell surface to the nucleus. Curr 
Biol 5, 747–757
 
7.  Bah, A., Vernon, R. M., Siddiqui, Z., Krzeminski, M., Muhandiram, R., Zhao, C., 
Sonenberg, N., Kay, L. E., and Forman-Kay, J. D. (2015) Folding of an 
intrinsically disordered protein by phosphorylation as a regulatory switch. Nature 
519, 106–109
 
8.  Bah, A., and Forman-Kay, J. D. (2016) Modulation of Intrinsically Disordered 
Protein Function by Post-translational Modifications. J Biol Chem 291, 6696–
6705
 
9.  Ubersax, J. A., and Ferrell, J. E. (2007) Mechanisms of specificity in protein 
phosphorylation. Nat Rev Mol Cell Biol 8, 530–541
 
10.  Lahiry, P., Torkamani, A., Schork, N. J., and Hegele, R. A. (2010) Kinase 
mutations in human disease: interpreting genotype-phenotype relationships. Nat 
Rev Genet 11, 60–74
 
11.  Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57–
70
 
12.  Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: the next 
generation. Cell 144, 646–674
 
13.  Kurokawa, M., and Kornbluth, S. (2009) Caspases and kinases in a death grip. 
Cell 138, 838–854
 
14.  Parrish, A. B., Freel, C. D., and Kornbluth, S. (2013) Cellular mechanisms 
35 
 
controlling caspase activation and function. Cold Spring Harb Perspect Biol 5, 
  
15.  Dix, M. M., Simon, G. M., Wang, C., Okerberg, E., Patricelli, M. P., and Cravatt, 
B. F. (2012) Functional interplay between caspase cleavage and phosphorylation 
sculpts the apoptotic proteome. Cell 150, 426–440
 
16.  Duncan, J. S., Turowec, J. P., Duncan, K. E., Vilk, G., Wu, C., Lüscher, B., Li, S. 
S.-C., Gloor, G. B., and Litchfield, D. W. (2011) A peptide-based target screen 
implicates the protein kinase CK2 in the global regulation of caspase signaling. 
Sci Signal 4, ra30 
 
17.  Turowec, J. P., Zukowski, S. A., Knight, J. D. R., Smalley, D. M., Graves, L. M., 
Johnson, G. L., Li, S. S. C., Lajoie, G. A., and Litchfield, D. W. (2014) An 
unbiased proteomic screen reveals caspase cleavage is positively and negatively 
regulated by substrate phosphorylation. Mol Cell Proteomics 13, 1184–1197
 
18.  Hopkins, A. L., and Groom, C. R. (2002) The druggable genome. Nat Rev Drug 
Discov 1, 727–730
 
19.  Cohen, P. (2002) Protein kinases--the major drug targets of the twenty-first 
century? Nat Rev Drug Discov 1, 309–315
 
20.  Volkamer, A., Eid, S., Turk, S., Jaeger, S., Rippmann, F., and Fulle, S. (2015) 
Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped 
protein kinases for drug discovery. J Chem Inf Model 55, 538–549
 
21.  Burgoyne, L. A. (1999) The mechanisms of pyknosis: hypercondensation and 
death. Exp Cell Res 248, 214–222
 
22.  Kerr, J. F., Wyllie, A. H., and Currie, A. R. (1972) Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26, 
239–257
 
23.  Nagata, S. (2000) Apoptotic DNA fragmentation. Exp Cell Res 256, 12–18
 
24.  Liu, X., Zou, H., Slaughter, C., and Wang, X. (1997) DFF, a heterodimeric protein 
that functions downstream of caspase-3 to trigger DNA fragmentation during 
apoptosis. Cell 89, 175–184
 
25.  Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. 
(1998) A caspase-activated DNase that degrades DNA during apoptosis, and its 
inhibitor ICAD. Nature 391, 43–50
 
26.  Sakahira, H., Enari, M., and Nagata, S. (1998) Cleavage of CAD inhibitor in CAD 




27.  Pop, C., and Salvesen, G. S. (2009) Human caspases: activation, specificity, and 
regulation. J Biol Chem 284, 21777–21781
 
28.  Timmer, J. C., Zhu, W., Pop, C., Regan, T., Snipas, S. J., Eroshkin, A. M., Riedl, 
S. J., and Salvesen, G. S. (2009) Structural and kinetic determinants of protease 
substrates. Nat Struct Mol Biol 16, 1101–1108
 
29.  Timmer, J. C., and Salvesen, G. S. (2007) Caspase substrates. Cell Death Differ 
14, 66–72
 
30.  McStay, G. P., Salvesen, G. S., and Green, D. R. (2008) Overlapping cleavage 
motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell 
Death Differ 15, 322–331
 
31.  Tözsér, J., Bagossi, P., Zahuczky, G., Specht, S. I., Majerova, E., and Copeland, 
T. D. (2003) Effect of caspase cleavage-site phosphorylation on proteolysis. 
Biochem J 372, 137–143
 
32.  Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., 
Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., 
Gottlieb, E., Green, D. R., Hengartner, M. O., Kepp, O., Knight, R. A., Kumar, S., 
Lipton, S. A., Lu, X., Madeo, F., Malorni, W., Mehlen, P., Nuñez, G., Peter, M. 
E., Piacentini, M., Rubinsztein, D. C., Shi, Y., Simon, H. U., Vandenabeele, P., 
White, E., Yuan, J., Zhivotovsky, B., Melino, G., and Kroemer, G. (2012) 
Molecular definitions of cell death subroutines: recommendations of the 
Nomenclature Committee on Cell Death 2012. Cell Death Differ 19, 107–120
 
33.  Wajant, H. (2002) The Fas signaling pathway: more than a paradigm. Science 296, 
1635–1636
 
34.  Schütze, S., Tchikov, V., and Schneider-Brachert, W. (2008) Regulation of 
TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell 
Biol 9, 655–662
 
35.  Mehlen, P., and Bredesen, D. E. (2011) Dependence receptors: from basic 
research to drug development. Sci Signal 4, mr2 
 
36.  Bredesen, D. E., Mehlen, P., and Rabizadeh, S. (2005) Receptors that mediate 
cellular dependence. Cell Death Differ 12, 1031–1043
 
37.  Guenebeaud, C., Goldschneider, D., Castets, M., Guix, C., Chazot, G., Delloye-
Bourgeois, C., Eisenberg-Lerner, A., Shohat, G., Zhang, M., Laudet, V., Kimchi, 
A., Bernet, A., and Mehlen, P. (2010) The dependence receptor UNC5H2/B 





38.  Mille, F., Thibert, C., Fombonne, J., Rama, N., Guix, C., Hayashi, H., Corset, V., 
Reed, J. C., and Mehlen, P. (2009) The Patched dependence receptor triggers 
apoptosis through a DRAL-caspase-9 complex. Nat Cell Biol 11, 739–746
 
39.  Forcet, C., Ye, X., Granger, L., Corset, V., Shin, H., Bredesen, D. E., and Mehlen, 
P. (2001) The dependence receptor DCC (deleted in colorectal cancer) defines an 
alternative mechanism for caspase activation. Proc Natl Acad Sci U S A 98, 3416–
3421
 
40.  Lavrik, I., Golks, A., and Krammer, P. H. (2005) Death receptor signaling. J Cell 
Sci 118, 265–267
 
41.  Ashkenazi, A., and Dixit, V. M. (1999) Apoptosis control by death and decoy 
receptors. Curr Opin Cell Biol 11, 255–260
 
42.  Ashkenazi, A., and Dixit, V. M. (1998) Death receptors: signaling and 
modulation. Science 281, 1305–1308
 
43.  French, L. E., and Tschopp, J. (2003) Protein-based therapeutic approaches 
targeting death receptors. Cell Death Differ 10, 117–123
 
44.  Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, 
P. H., and Peter, M. E. (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-
associated proteins form a death-inducing signaling complex (DISC) with the 
receptor. EMBO J 14, 5579–5588
 
45.  Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O’Rourke, K., Shevchenko, A., 
Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., 
Peter, M. E., and Dixit, V. M. (1996) FLICE, a novel FADD-homologous 
ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing 
signaling complex. Cell 85, 817–827
 
46.  Chinnaiyan, A. M., Tepper, C. G., Seldin, M. F., O’Rourke, K., Kischkel, F. C., 
Hellbardt, S., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) 
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis 
factor receptor-induced apoptosis. J Biol Chem 271, 4961–4965
 
47.  Deveraux, Q. L., Roy, N., Stennicke, H. R., Van Arsdale, T., Zhou, Q., 
Srinivasula, S. M., Alnemri, E. S., Salvesen, G. S., and Reed, J. C. (1998) IAPs 
block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition 
of distinct caspases. EMBO J 17, 2215–2223
 
48.  Bertrand, M. J. M., Milutinovic, S., Dickson, K. M., Ho, W. C., Boudreault, A., 
Durkin, J., Gillard, J. W., Jaquith, J. B., Morris, S. J., and Barker, P. A. (2008) 
cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that 




49.  Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., 
Bodmer, J. L., Schröter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., 
and Tschopp, J. (1997) Inhibition of death receptor signals by cellular FLIP. 
Nature 388, 190–195
 
50.  Martin, D. A., Siegel, R. M., Zheng, L., and Lenardo, M. J. (1998) Membrane 
oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) 
death signal. J Biol Chem 273, 4345–4349
 
51.  Salvesen, G. S., and Dixit, V. M. (1999) Caspase activation: the induced-
proximity model. Proc Natl Acad Sci U S A 96, 10964–10967
 
52.  Muzio, M., Stockwell, B. R., Stennicke, H. R., Salvesen, G. S., and Dixit, V. M. 
(1998) An induced proximity model for caspase-8 activation. J Biol Chem 273, 
2926–2930
 
53.  Wang, J., Chun, H. J., Wong, W., Spencer, D. M., and Lenardo, M. J. (2001) 
Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci 
U S A 98, 13884–13888
 
54.  Sprick, M. R., Rieser, E., Stahl, H., Grosse-Wilde, A., Weigand, M. A., and 
Walczak, H. (2002) Caspase-10 is recruited to and activated at the native TRAIL 
and CD95 death-inducing signalling complexes in a FADD-dependent manner but 
can not functionally substitute caspase-8. EMBO J 21, 4520–4530
 
55.  Barnhart, B. C., Alappat, E. C., and Peter, M. E. (2003) The CD95 Type I/Type II 
model. Seminars in immunology 15, 185–193
 
56.  Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998) Cleavage of BID by caspase 8 
mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491–
501
 
57.  Tait, S. W. G., and Green, D. R. (2010) Mitochondria and cell death: outer 
membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11, 621–632
 
58.  Kroemer, G., Galluzzi, L., and Brenner, C. (2007) Mitochondrial membrane 
permeabilization in cell death. Physiol Rev 87, 99–163
 
59.  Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., and Green, D. R. (2010) 
The BCL-2 family reunion. Mol Cell 37, 299–310
 
60.  Ren, D., Tu, H.-C., Kim, H., Wang, G. X., Bean, G. R., Takeuchi, O., Jeffers, J. 
R., Zambetti, G. P., Hsieh, J. J.-D., and Cheng, E. H.-Y. (2010) BID, BIM, and 
PUMA are essential for activation of the BAX- and BAK-dependent cell death 




61.  Renault, T. T., Floros, K. V., and Chipuk, J. E. (2013) BAK/BAX activation and 
cytochrome c release assays using isolated mitochondria. Methods 61, 146–155
 
62.  Westphal, D., Dewson, G., Czabotar, P. E., and Kluck, R. M. (2011) Molecular 
biology of Bax and Bak activation and action. Biochim Biophys Acta 1813, 521–
531
 
63.  Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. (1997) Apaf-1, a 
human protein homologous to C. elegans CED-4, participates in cytochrome c-
dependent activation of caspase-3. Cell 90, 405–413
 
64.  Acehan, D., Jiang, X., Morgan, D. G., Heuser, J. E., Wang, X., and Akey, C. W. 
(2002) Three-dimensional structure of the apoptosome: implications for assembly, 
procaspase-9 binding, and activation. Mol Cell 9, 423–432
 
65.  Kuida, K., Haydar, T. F., Kuan, C. Y., Gu, Y., Taya, C., Karasuyama, H., Su, M. 
S., Rakic, P., and Flavell, R. A. (1998) Reduced apoptosis and cytochrome c-
mediated caspase activation in mice lacking caspase 9. Cell 94, 325–337
 
66.  Malladi, S., Challa-Malladi, M., Fearnhead, H. O., and Bratton, S. B. (2009) The 
Apaf-1*procaspase-9 apoptosome complex functions as a proteolytic-based 
molecular timer. EMBO J 28, 1916–1925
 
67.  Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., 
Stanbridge, E., Frisch, S., and Reed, J. C. (1998) Regulation of cell death protease 
caspase-9 by phosphorylation. Science 282, 1318–1321
 
68.  Scaffidi, C., Medema, J. P., Krammer, P. H., and Peter, M. E. (1997) FLICE is 
predominantly expressed as two functionally active isoforms, caspase-8/a and 
caspase-8/b. J Biol Chem 272, 26953–26958
 
69.  Senft, J., Helfer, B., and Frisch, S. M. (2007) Caspase-8 interacts with the p85 
subunit of phosphatidylinositol 3-kinase to regulate cell adhesion and motility. 
Cancer Res 67, 11505–11509
 
70.  Jia, S. H., Parodo, J., Kapus, A., Rotstein, O. D., and Marshall, J. C. (2008) 
Dynamic regulation of neutrophil survival through tyrosine phosphorylation or 
dephosphorylation of caspase-8. J Biol Chem 283, 5402–5413
 
71.  Cursi, S., Rufini, A., Stagni, V., Condò, I., Matafora, V., Bachi, A., Bonifazi, A. 
P., Coppola, L., Superti-Furga, G., Testi, R., and Barilà, D. (2006) Src kinase 
phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis 
suppression. EMBO J 25, 1895–1905
 
72.  Alvarado-Kristensson, M., Melander, F., Leandersson, K., Rönnstrand, L., 
40 
 
Wernstedt, C., and Andersson, T. (2004) p38-MAPK signals survival by 
phosphorylation of caspase-8 and caspase-3 in human neutrophils. J Exp Med 199, 
449–458
 
73.  Peng, C., Cho, Y.-Y., Zhu, F., Zhang, J., Wen, W., Xu, Y., Yao, K., Ma, W.-Y., 
Bode, A. M., and Dong, Z. (2011) Phosphorylation of caspase-8 (Thr-263) by 
ribosomal S6 kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability. J 
Biol Chem 286, 6946–6954
 
74.  McDonnell, M. A., Abedin, M. J., Melendez, M., Platikanova, T. N., Ecklund, J. 
R., Ahmed, K., and Kelekar, A. (2008) Phosphorylation of murine caspase-9 by 
the protein kinase casein kinase 2 regulates its cleavage by caspase-8. J Biol Chem 
283, 20149–20158
 
75.  Allan, L. A., Morrice, N., Brady, S., Magee, G., Pathak, S., and Clarke, P. R. 
(2003) Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK 
MAPK. Nat Cell Biol 5, 647–654
 
76.  Seifert, A., Allan, L. A., and Clarke, P. R. (2008) DYRK1A phosphorylates 
caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine. 
FEBS J 275, 6268–6280
 
77.  Seifert, A., and Clarke, P. R. (2009) p38alpha- and DYRK1A-dependent 
phosphorylation of caspase-9 at an inhibitory site in response to hyperosmotic 
stress. Cell Signal 21, 1626–1633
 
78.  Allan, L. A., and Clarke, P. R. (2007) Phosphorylation of caspase-9 by 
CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell 26, 301–310
 
79.  Brady, S. C., Allan, L. A., and Clarke, P. R. (2005) Regulation of caspase 9 
through phosphorylation by protein kinase C zeta in response to hyperosmotic 
stress. Mol Cell Biol 25, 10543–10555
 
80.  Raina, D., Pandey, P., Ahmad, R., Bharti, A., Ren, J., Kharbanda, S., 
Weichselbaum, R., and Kufe, D. (2005) c-Abl tyrosine kinase regulates caspase-9 
autocleavage in the apoptotic response to DNA damage. J Biol Chem 280, 11147–
11151
 
81.  Martin, M. C., Allan, L. A., Lickrish, M., Sampson, C., Morrice, N., and Clarke, 
P. R. (2005) Protein kinase A regulates caspase-9 activation by Apaf-1 
downstream of cytochrome c. J Biol Chem 280, 15449–15455
 
82.  Voss, O. H., Kim, S., Wewers, M. D., and Doseff, A. I. (2005) Regulation of 
monocyte apoptosis by the protein kinase Cdelta-dependent phosphorylation of 




83.  Li, X., Wen, W., Liu, K., Zhu, F., Malakhova, M., Peng, C., Li, T., Kim, H.-G., 
Ma, W., Cho, Y. Y., Bode, A. M., Dong, Z., and Dong, Z. (2011) Phosphorylation 
of caspase-7 by p21-activated protein kinase (PAK) 2 inhibits chemotherapeutic 
drug-induced apoptosis of breast cancer cell lines. J Biol Chem 286, 22291–22299
 
84.  Arntzen, M. Ø., and Thiede, B. (2012) ApoptoProteomics, an integrated database 
for analysis of proteomics data obtained from apoptotic cells. Mol Cell Proteomics 
11, M111.010447 
 
85.  Crawford, E. D., and Wells, J. A. (2011) Caspase substrates and cellular 
remodeling. Annu Rev Biochem 80, 1055–1087
 
86.  Dix, M. M., Simon, G. M., and Cravatt, B. F. (2008) Global mapping of the 
topography and magnitude of proteolytic events in apoptosis. Cell 134, 679–691
 
87.  Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. (1998) Bid, a Bcl2 
interacting protein, mediates cytochrome c release from mitochondria in response 
to activation of cell surface death receptors. Cell 94, 481–490
 
88.  Desagher, S., Osen-Sand, A., Montessuit, S., Magnenat, E., Vilbois, F., 
Hochmann, A., Journot, L., Antonsson, B., and Martinou, J. C. (2001) 
Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 
8. Mol Cell 8, 601–611
 
89.  Wang, K., Yin, X. M., Chao, D. T., Milliman, C. L., and Korsmeyer, S. J. (1996) 
BID: a novel BH3 domain-only death agonist. Genes Dev 10, 2859–2869
 
90.  Turowec, J. P., Duncan, J. S., Gloor, G. B., and Litchfield, D. W. (2011) 
Regulation of caspase pathways by protein kinase CK2: identification of proteins 
with overlapping CK2 and caspase consensus motifs. Mol Cell Biochem 356, 159–
167
 
91.  Litchfield, D. W. (2003) Protein kinase CK2: structure, regulation and role in 
cellular decisions of life and death. Biochem J 369, 1–15
 
92.  Torres, J., Rodriguez, J., Myers, M. P., Valiente, M., Graves, J. D., Tonks, N. K., 
and Pulido, R. (2003) Phosphorylation-regulated cleavage of the tumor suppressor 
PTEN by caspase-3: implications for the control of protein stability and PTEN-
protein interactions. J Biol Chem 278, 30652–30660
 
93.  Kitamura, D., Kaneko, H., Miyagoe, Y., Ariyasu, T., and Watanabe, T. (1989) 
Isolation and characterization of a novel human gene expressed specifically in the 
cells of hematopoietic lineage. Nucleic Acids Res 17, 9367–9379
 
94.  Ruzzene, M., Brunati, A. M., Sarno, S., Donella-Deana, A., and Pinna, L. A. 
(1999) Hematopoietic lineage cell specific protein 1 associates with and down-
42 
 
regulates protein kinase CK2. FEBS Lett 461, 32–36
 
95.  Ruzzene, M., Brunati, A. M., Sarno, S., Marin, O., Donella-Deana, A., and Pinna, 
L. A. (2000) Ser/Thr phosphorylation of hematopoietic specific protein 1 (HS1): 
implication of protein kinase CK2. Eur J Biochem 267, 3065–3072
 
96.  Ruzzene, M., Penzo, D., and Pinna, L. A. (2002) Protein kinase CK2 inhibitor 
4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent 
degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. 
Biochem J 364, 41–47
 
97.  Yin, X., Gu, S., and Jiang, J. X. (2001) The development-associated cleavage of 
lens connexin 45.6 by caspase-3-like protease is regulated by casein kinase II-
mediated phosphorylation. J Biol Chem 276, 34567–34572
 
98.  Koseki, T., Inohara, N., Chen, S., and Núñez, G. (1998) ARC, an inhibitor of 
apoptosis expressed in skeletal muscle and heart that interacts selectively with 
caspases. Proc Natl Acad Sci U S A 95, 5156–5160
 
99.  Li, P.-F., Li, J., Müller, E.-C., Otto, A., Dietz, R., and Harsdorf, R. von (2002) 
Phosphorylation by protein kinase CK2: a signaling switch for the caspase-
inhibiting protein ARC. Mol Cell 10, 247–258
 
100.  Austen, M., Luscher, B., and Luscher-Firzlaff, J. M. (1997) Characterization of 
the Transcriptional Regulator YY1: the bipartite transactivation domain is 
independent of interaction with the TATA box-binding protein, transcription 
factor IIB, TAFII55, or cAMP-responsive element-binding protein (CBP)-binding 
protein. Journal of Biological Chemistry 272, 1709–1717
 
101.  Gordon, S., Akopyan, G., Garban, H., and Bonavida, B. (2006) Transcription 
factor YY1: structure, function, and therapeutic implications in cancer biology. 
Oncogene 25, 1125–1142
 
102.  Shi, Y., Lee, J. S., and Galvin, K. M. (1997) Everything you have ever wanted to 
know about Yin Yang 1...... Biochim Biophys Acta 1332, F49–66
 
103.  Riman, S., Rizkallah, R., Kassardjian, A., Alexander, K. E., Lüscher, B., and Hurt, 
M. M. (2012) Phosphorylation of the transcription factor YY1 by CK2α prevents 
cleavage by caspase 7 during apoptosis. Mol Cell Biol 32, 797–807
 
104.  Griner, E. M., and Kazanietz, M. G. (2007) Protein kinase C and other 
diacylglycerol effectors in cancer. Nat Rev Cancer 7, 281–294
 
105.  Emoto, Y., Manome, Y., Meinhardt, G., Kisaki, H., Kharbanda, S., Robertson, M., 
Ghayur, T., Wong, W. W., Kamen, R., and Weichselbaum, R. (1995) Proteolytic 
activation of protein kinase C delta by an ICE-like protease in apoptotic cells. 
43 
 
EMBO J 14, 6148–6156
 
106.  Ghayur, T., Hugunin, M., Talanian, R. V., Ratnofsky, S., Quinlan, C., Emoto, Y., 
Pandey, P., Datta, R., Huang, Y., Kharbanda, S., Allen, H., Kamen, R., Wong, W., 
and Kufe, D. (1996) Proteolytic activation of protein kinase C delta by an 
ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med 184, 
2399–2404
 
107.  Lu, W., Lee, H.-K., Xiang, C., Finniss, S., and Brodie, C. (2007) The 
phosphorylation of tyrosine 332 is necessary for the caspase 3-dependent cleavage 
of PKCdelta and the regulation of cell apoptosis. Cell Signal 19, 2165–2173
 
108.  Cha, H., Smith, B. L., Gallo, K., Machamer, C. E., and Shapiro, P. (2004) 
Phosphorylation of golgin-160 by mixed lineage kinase 3. J Cell Sci 117, 751–760
 
109.  Mancini, M., Machamer, C. E., Roy, S., Nicholson, D. W., Thornberry, N. A., 
Casciola-Rosen, L. A., and Rosen, A. (2000) Caspase-2 is localized at the Golgi 
complex and cleaves golgin-160 during apoptosis. J Cell Biol 149, 603–612
 
110.  Hicks, S. W., and Machamer, C. E. (2002) The NH2-terminal domain of Golgin-
160 contains both Golgi and nuclear targeting information. J Biol Chem 277, 
35833–35839
 
111.  Hall, A. (1998) Rho GTPases and the Actin Cytoskeleton. Science 279, 509–514
 
112.  Lee, N., MacDonald, H., Reinhard, C., Halenbeck, R., Roulston, A., Shi, T., and 
Williams, L. T. (1997) Activation of hPAK65 by caspase cleavage induces some 
of the morphological and biochemical changes of apoptosis. Proc Natl Acad Sci U 
S A 94, 13642–13647
 
113.  Rudel, T., and Bokoch, G. M. (1997) Membrane and morphological changes in 
apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276, 
1571–1574
 
114.  Neves, S. R., Ram, P. T., and Iyengar, R. (2002) G protein pathways. Science 296, 
1636–1639
 
115.  Matsui, T., Amano, M., Yamamoto, T., Chihara, K., Nakafuku, M., Ito, M., 
Nakano, T., Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996) Rho-associated 
kinase, a novel serine/threonine kinase, as a putative target for small GTP binding 
protein Rho. EMBO J 15, 2208–2216
 
116.  Leung, T., Chen, X. Q., Manser, E., and Lim, L. (1996) The p160 RhoA-binding 
kinase ROK alpha is a member of a kinase family and is involved in the 




117.  Ishizaki, T., Maekawa, M., Fujisawa, K., Okawa, K., Iwamatsu, A., Fujita, A., 
Watanabe, N., Saito, Y., Kakizuka, A., Morii, N., and Narumiya, S. (1996) The 
small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein 
kinase homologous to myotonic dystrophy kinase. EMBO J 15, 1885–1893
 
118.  Sebbagh, M., Renvoizé, C., Hamelin, J., Riché, N., Bertoglio, J., and Bréard, J. 
(2001) Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation 
and apoptotic membrane blebbing. Nat Cell Biol 3, 346–352
 
119.  Coleman, M. L., Sahai, E. A., Yeo, M., Bosch, M., Dewar, A., and Olson, M. F. 
(2001) Membrane blebbing during apoptosis results from caspase-mediated 
activation of ROCK I. Nat Cell Biol 3, 339–345
 
120.  Sekine, A., Fujiwara, M., and Narumiya, S. (1989) Asparagine residue in the rho 
gene product is the modification site for botulinum ADP-ribosyltransferase. J Biol 
Chem 264, 8602–8605
 
121.  Ridley, A. J., and Hall, A. (1992) The small GTP-binding protein rho regulates the 
assembly of focal adhesions and actin stress fibers in response to growth factors. 
Cell 70, 389–399
 
122.  Nagahara, H., Vocero-Akbani, A. M., Snyder, E. L., Ho, A., Latham, D. G., Lissy, 
N. A., Becker-Hapak, M., Ezhevsky, S. A., and Dowdy, S. F. (1998) Transduction 
of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces 
cell migration. Nat Med 4, 1449–1452
 
123.  Walter, B. N., Huang, Z., Jakobi, R., Tuazon, P. T., Alnemri, E. S., Litwack, G., 
and Traugh, J. A. (1998) Cleavage and activation of p21-activated protein kinase 
gamma-PAK by CPP32 (caspase 3). Effects of autophosphorylation on activity. J 
Biol Chem 273, 28733–28739
 
124.  Lim, L., Manser, E., Leung, T., and Hall, C. (1996) Regulation of phosphorylation 
pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in 
phosphorylation signalling pathways. Eur J Biochem 242, 171–185
 
125.  Sells, M. A., and Chernoff, J. (1997) Emerging from the Pak: the p21-activated 
protein kinase family. Trends Cell Biol 7, 162–167
 
126.  Jakobi, R., Moertl, E., and Koeppel, M. A. (2001) p21-activated protein kinase 
gamma-PAK suppresses programmed cell death of BALB3T3 fibroblasts. J Biol 
Chem 276, 16624–16634
 
127.  Tang, T. K., Chang, W. C., Chan, W. H., Yang, S. D., Ni, M. H., and Yu, J. S. 
(1998) Proteolytic cleavage and activation of PAK2 during UV irradiation-




128.  Vilas, G. L., Corvi, M. M., Plummer, G. J., Seime, A. M., Lambkin, G. R., and 
Berthiaume, L. G. (2006) Posttranslational myristoylation of caspase-activated 
p21-activated protein kinase 2 (PAK2) potentiates late apoptotic events. Proc Natl 
Acad Sci U S A 103, 6542–6547
 
129.  Jakobi, R., McCarthy, C. C., Koeppel, M. A., and Stringer, D. K. (2003) Caspase-
activated PAK-2 is regulated by subcellular targeting and proteasomal 
degradation. J Biol Chem 278, 38675–38685
 
130.  Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., and 
Parsons, J. T. (1992) pp125FAK a structurally distinctive protein-tyrosine kinase 
associated with focal adhesions. Proc Natl Acad Sci U S A 89, 5192–5196
 
131.  Schaller, M. D., Borgman, C. A., and Parsons, J. T. (1993) Autonomous 
expression of a noncatalytic domain of the focal adhesion-associated protein 
tyrosine kinase pp125FAK. Mol Cell Biol 13, 785–791
 
132.  Schaller, M. D., Hildebrand, J. D., and Parsons, J. T. (1999) Complex formation 
with focal adhesion kinase: A mechanism to regulate activity and subcellular 
localization of Src kinases. Mol Biol Cell 10, 3489–3505
 
133.  Wen, L. P., Fahrni, J. A., Troie, S., Guan, J. L., Orth, K., and Rosen, G. D. (1997) 
Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem 272, 
26056–26061
 
134.  Gervais, F. G., Thornberry, N. A., Ruffolo, S. C., Nicholson, D. W., and Roy, S. 
(1998) Caspases cleave focal adhesion kinase during apoptosis to generate a 
FRNK-like polypeptide. J Biol Chem 273, 17102–17108
 
135.  Levkau, B., Herren, B., Koyama, H., Ross, R., and Raines, E. W. (1998) Caspase-
mediated cleavage of focal adhesion kinase pp125FAK and disassembly of focal 
adhesions in human endothelial cell apoptosis. J Exp Med 187, 579–586
 
136.  Bachelder, R. E., Wendt, M. A., Fujita, N., Tsuruo, T., and Mercurio, A. M. 
(2001) The cleavage of Akt/protein kinase B by death receptor signaling is an 
important event in detachment-induced apoptosis. J Biol Chem 276, 34702–34707
 
137.  Xu, J., Liu, D., and Songyang, Z. (2002) The role of Asp-462 in regulating Akt 
activity. J Biol Chem 277, 35561–35566
 
138.  Mellor, H., and Parker, P. J. (1998) The extended protein kinase C superfamily. 
Biochem J 332 ( Pt 2), 281–292
 
139.  Zhao, M., Xia, L., and Chen, G.-Q. (2012) Protein kinase cδ in apoptosis: a brief 




140.  DeVries, T. A., Neville, M. C., and Reyland, M. E. (2002) Nuclear import of 
PKCdelta is required for apoptosis: identification of a novel nuclear import 
sequence. EMBO J 21, 6050–6060
 
141.  Humphries, M. J., Ohm, A. M., Schaack, J., Adwan, T. S., and Reyland, M. E. 
(2008) Tyrosine phosphorylation regulates nuclear translocation of PKCdelta. 
Oncogene 27, 3045–3053
 
142.  Bharti, A., Kraeft, S. K., Gounder, M., Pandey, P., Jin, S., Yuan, Z. M., Lees-
Miller, S. P., Weichselbaum, R., Weaver, D., Chen, L. B., Kufe, D., and 
Kharbanda, S. (1998) Inactivation of DNA-dependent protein kinase by protein 
kinase Cdelta: implications for apoptosis. Mol Cell Biol 18, 6719–6728
 
143.  Lee, S.-J., Kim, D.-C., Choi, B.-H., Ha, H., and Kim, K.-T. (2006) Regulation of 
p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic 
cell death. J Biol Chem 281, 2215–2224
 
144.  Yoshida, K., Liu, H., and Miki, Y. (2006) Protein kinase C delta regulates Ser46 
phosphorylation of p53 tumor suppressor in the apoptotic response to DNA 
damage. J Biol Chem 281, 5734–5740
 
145.  Yoshida, K., Wang, H.-G., Miki, Y., and Kufe, D. (2003) Protein kinase Cdelta is 
responsible for constitutive and DNA damage-induced phosphorylation of Rad9. 
EMBO J 22, 1431–1441
 
146.  Cross, T., Griffiths, G., Deacon, E., Sallis, R., Gough, M., Watters, D., and Lord, 
J. M. (2000) PKC-delta is an apoptotic lamin kinase. Oncogene 19, 2331–2337
 
147.  Costa, A. M. D’, and Denning, M. F. (2005) A caspase-resistant mutant of PKC-
delta protects keratinocytes from UV-induced apoptosis. Cell Death Differ 12, 
224–232
 
148.  Sitailo, L. A., Tibudan, S. S., and Denning, M. F. (2006) The protein kinase C 
delta catalytic fragment targets Mcl-1 for degradation to trigger apoptosis. J Biol 
Chem 281, 29703–29710
 
149.  Qi, X., and Mochly-Rosen, D. (2008) The PKCdelta -Abl complex communicates 
ER stress to the mitochondria - an essential step in subsequent apoptosis. J Cell 
Sci 121, 804–813
 
150.  Lüthi, A. U., and Martin, S. J. (2007) The CASBAH: a searchable database of 
caspase substrates. Cell Death Differ 14, 641–650
 
151.  Ong, S.-E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, 
A., and Mann, M. (2002) Stable isotope labeling by amino acids in cell culture, 





152.  Kleifeld, O., Doucet, A., auf dem Keller, U., Prudova, A., Schilling, O., Kainthan, 
R. K., Starr, A. E., Foster, L. J., Kizhakkedathu, J. N., and Overall, C. M. (2010) 
Isotopic labeling of terminal amines in complex samples identifies protein N-
termini and protease cleavage products. Nat Biotechnol 28, 281–288
 
153.  Hellwig, C. T., Ludwig-Galezowska, A. H., Concannon, C. G., Litchfield, D. W., 
Prehn, J. H. M., and Rehm, M. (2010) Activity of protein kinase CK2 uncouples 
Bid cleavage from caspase-8 activation. J Cell Sci 123, 1401–1406
 
154.  Crawford, E. D., Seaman, J. E., Agard, N., Hsu, G. W., Julien, O., Mahrus, S., 
Nguyen, H., Shimbo, K., Yoshihara, H. A. I., Zhuang, M., Chalkley, R. J., and 
Wells, J. A. (2013) The DegraBase: a database of proteolysis in healthy and 
apoptotic human cells. Mol Cell Proteomics 12, 813–824
 
155.  Kleifeld, O., Doucet, A., Prudova, A., auf dem Keller, U., Gioia, M., 
Kizhakkedathu, J. N., and Overall, C. M. (2011) Identifying and quantifying 
proteolytic events and the natural N terminome by terminal amine isotopic 
labeling of substrates. Nat Protoc 6, 1578–1611
 
156.  Salvesen, G. S., and Ashkenazi, A. (2011) Snapshot: caspases. Cell 147, 476–
476.e1
 
157.  Fuentes-Prior, P., and Salvesen, G. S. (2004) The protein structures that shape 
caspase activity, specificity, activation and inhibition. Biochem J 384, 201–232
 
158.  Roschitzki-Voser, H., Schroeder, T., Lenherr, E. D., Frölich, F., Schweizer, A., 
Donepudi, M., Ganesan, R., Mittl, P. R. E., Baici, A., and Grütter, M. G. (2012) 
Human caspases in vitro: expression, purification and kinetic characterization. 
Protein Expr Purif 84, 236–246
 
159.  López-Otín, C., and Hunter, T. (2010) The regulatory crosstalk between kinases 
and proteases in cancer. Nat Rev Cancer 10, 278–292
 
160.  DeVries-Seimon, T. A., Ohm, A. M., Humphries, M. J., and Reyland, M. E. 
(2007) Induction of apoptosis is driven by nuclear retention of protein kinase C 
delta. J Biol Chem 282, 22307–22314
 
161.  Di Bacco, A. M. A., and Cotter, T. G. (2002) p53 expression in K562 cells is 
associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein 
kinases. Br J Haematol 117, 588–597
 
162.  Barilà, D., Rufini, A., Condò, I., Ventura, N., Dorey, K., Superti-Furga, G., and 
Testi, R. (2003) Caspase-dependent cleavage of c-Abl contributes to apoptosis. 




163.  Machuy, N., Rajalingam, K., and Rudel, T. (2004) Requirement of caspase-
mediated cleavage of c-Abl during stress-induced apoptosis. Cell Death Differ 11, 
290–300
 
164.  Okita, N., Kudo, Y., and Tanuma, S. (2007) Checkpoint kinase 1 is cleaved in a 
caspase-dependent pathway during genotoxic stress-induced apoptosis. Biol 
Pharm Bull 30, 359–362
 
165.  Matsuura, K., Wakasugi, M., Yamashita, K., and Matsunaga, T. (2008) Cleavage-
mediated activation of Chk1 during apoptosis. J Biol Chem 283, 25485–25491
 
166.  Graves, J. D., Gotoh, Y., Draves, K. E., Ambrose, D., Han, D. K., Wright, M., 
Chernoff, J., Clark, E. A., and Krebs, E. G. (1998) Caspase-mediated activation 
and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J 
17, 2224–2234
 
167.  Kakeya, H., Onose, R., and Osada, H. (1998) Caspase-mediated activation of a 36-
kDa myelin basic protein kinase during anticancer drug-induced apoptosis. Cancer 
Res 58, 4888–4894
 
168.  Lee, K. K., Murakawa, M., Nishida, E., Tsubuki, S., Kawashima, S., Sakamaki, 
K., and Yonehara, S. (1998) Proteolytic activation of MST/Krs, STE20-related 
protein kinase, by caspase during apoptosis. Oncogene 16, 3029–3037
 
169.  Lee, K. K., Ohyama, T., Yajima, N., Tsubuki, S., and Yonehara, S. (2001) MST, a 
physiological caspase substrate, highly sensitizes apoptosis both upstream and 
downstream of caspase activation. J Biol Chem 276, 19276–19285
 
170.  Song, J. J., and Lee, Y. J. (2008) Differential cleavage of Mst1 by caspase-7/-3 is 
responsible for TRAIL-induced activation of the MAPK superfamily. Cell Signal 
20, 892–906
 
171.  Fischer, U., Stroh, C., and Schulze-Osthoff, K. (2006) Unique and overlapping 
substrate specificities of caspase-8 and caspase-10. Oncogene 25, 152–159
 
172.  Panaretakis, T., Laane, E., Pokrovskaja, K., Björklund, A.-C., Moustakas, A., 
Zhivotovsky, B., Heyman, M., Shoshan, M. C., and Grandér, D. (2005) 
Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, 
and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell 16, 3821–3831
 
173.  Widmann, C., Gerwins, P., Johnson, N. L., Jarpe, M. B., and Johnson, G. L. 
(1998) MEK kinase 1, a substrate for DEVD-directed caspases, is involved in 
genotoxin-induced apoptosis. Mol Cell Biol 18, 2416–2429
 
174.  Bachelder, R. E., Ribick, M. J., Marchetti, A., Falcioni, R., Soddu, S., Davis, K. 
49 
 
R., and Mercurio, A. M. (1999) p53 inhibits alpha 6 beta 4 integrin survival 
signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell 
Biol 147, 1063–1072
 
175.  Asselin, E., Mills, G. B., and Tsang, B. K. (2001) XIAP regulates Akt activity and 
caspase-3-dependent cleavage during cisplatin-induced apoptosis in human 
ovarian epithelial cancer cells. Cancer Res 61, 1862–1868
 
176.  Jahani-Asl, A., Basak, A., and Tsang, B. K. (2007) Caspase-3-mediated cleavage 
of Akt: involvement of non-consensus sites and influence of phosphorylation. 
FEBS Lett 581, 2883–2888
 
177.  Tikhomirov, O., and Carpenter, G. (2001) Caspase-dependent cleavage of ErbB-2 
by geldanamycin and staurosporin. J Biol Chem 276, 33675–33680
 
178.  Tikhomirov, O., Dikov, M., and Carpenter, G. (2005) Identification of proteolytic 
fragments from ErbB-2 that induce apoptosis. Oncogene 24, 3906–3913
 
179.  Benoit, V., Chariot, A., Delacroix, L., Deregowski, V., Jacobs, N., Merville, M.-
P., and Bours, V. (2004) Caspase-8-dependent HER-2 cleavage in response to 
tumor necrosis factor alpha stimulation is counteracted by nuclear factor kappaB 
through c-FLIP-L expression. Cancer Res 64, 2684–2691
 
180.  Strohecker, A. M., Yehiely, F., Chen, F., and Cryns, V. L. (2008) Caspase 
cleavage of HER-2 releases a Bad-like cell death effector. J Biol Chem 283, 
18269–18282
 
181.  Crouch, D. H., Fincham, V. J., and Frame, M. C. (1996) Targeted proteolysis of 
the focal adhesion kinase pp125 FAK during c-MYC-induced apoptosis is 
suppressed by integrin signalling. Oncogene 12, 2689–2696
 
182.  Lin, Y., Devin, A., Rodriguez, Y., and Liu, Z. G. (1999) Cleavage of the death 
domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 13, 
2514–2526
 
183.  Kim, J. W., Choi, E. J., and Joe, C. O. (2000) Activation of death-inducing 
signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP. 
Oncogene 19, 4491–4499
 
184.  Matthess, Y., Raab, M., Sanhaji, M., Lavrik, I. N., and Strebhardt, K. (2010) 
Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. 




Chapter 2  
2 Examining the apoptotic kinome and mapping the 
phosphorylation landscape in HeLa cells treated with 
doxorubicin 
2.1 Introduction 
The completion of the human genome project, and succeeding revisions, revealed 
a surprisingly modest approximation of only 20,000 protein-coding genes when 
juxtaposed with the millions of proteins currently estimated in the human proteome (1–
6).  While modifications at the transcript level contribute to expansion of proteomic 
diversity, post-translational modifications exponentially increase the complexity of the 
human proteome and facilitate dynamic regulation of cellular activity (2, 5, 7–10).  One 
of the most prevalent and well-studied post-translational modifications is the reversible 
phosphorylation of proteins.  Serving as a mechanism for the transmission of intracellular 
signals, phosphorylation and its counterpart, dephosphorylation, are independently 
regulated by protein kinases and protein phosphatases, respectively (11–13).  With 
700,000 potentially phosphorylatable residues in the human proteome and given the 
importance of phosphorylation in the regulation of critical cell signaling pathways, it is 
unsurprising that perturbations to the stoichiometry of protein phosphorylation are an 
underlying cause or consequence of many diseases (14–16).  Pathophysiological 
alterations within the phosphorylation landscape, typically attributed to aberrant signaling 
by protein kinases or phosphatases, have motivated efforts to target these 
phosphotransferases with small-molecule inhibitors to combat disease and restore healthy 
phosphoproteome signaling (17–22).  
51 
 
Abnormal regulation of protein kinase signaling networks is considered a 
hallmark phenotype in cancer biology and frequently serves as a driver of tumorigenic 
progression (15, 21, 23).  Moreover, a prominent feature of cancer cells is the ability to 
bypass natural barriers to cancer development and inappropriately persist by evading 
apoptotic programming (24, 25).  Apoptosis, a tightly regulated cellular process essential 
for normal development and tissue homeostasis, relies on protein kinase signaling to 
mediate responses to both internal and external apoptotic stimuli (26–28).  Mounting 
evidence suggests that functional crosstalk between protein kinases and the family of 
proteases responsible for executing cellular degradation, termed caspases (cysteine-
dependent aspartate-directed proteases), serves to fine-tune the equilibrium between cell 
survival and cell death (reviewed in (29)).  Caspases, which catalyze irreversible post-
translational proteolytic processing of proteins, can be activated or inactivated by 
phosphorylation and, likewise, phosphorylation of caspase substrates can promote or 
inhibit caspase-mediated proteolysis (30–33).  Additionally, caspase cleavage of protein 
kinases can rewire signaling pathways maintaining cell survival into pathways that 
govern cell death (29, 34).  Considering the influence of phosphorylation in the upstream 
induction and downstream execution of apoptosis, novel strategies in proteomics and 
systems biology offer opportunities to gain comprehensive insights regarding the role of 
protein kinases as regulatory participants in apoptosis (35–37). 
In an effort to systematically investigate rewiring of the phosphoproteome during 
apoptosis, we used a bioinformatics approach to evaluate proteolytic processing of 
phosphotransferases in apoptosis and applied complementary quantitative proteomics 





Figure 2.1 Investigational workflow for evaluating phosphorylation signaling in 
apoptosis. 
To characterize the impact of protease–kinome signaling in apoptosis, we interrogated the 
DegraBase dataset, generated by Crawford et al., (38), to identify human protein kinases 
and human phosphatases cleaved by proteases during apoptosis.  To complement our 
bioinformatics analysis and illustrate the influence of phosphorylation signaling in 
apoptotic cells, we employed parallel approaches using quantitative mass spectrometry to 
evaluate both the active kinome (chemoproteomic kinome profiling) and the 
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Our bioinformatics analysis entailed a computational interrogation of the DegraBase 
dataset, generated by Crawford et al., (38), to identify protein kinases and protein 
phosphatases cleaved by proteases in response to apoptotic stimuli.  Our findings suggest 
that during apoptosis an extensive proportion of the human kinome and phosphatome are 
substrates of proteases, which emphasizes the direct impact of apoptotic-driven 
proteolysis on the phosphotransferases responsible for regulating phosphoproteome 
signaling.   
Historically, the biological significance of protein phosphorylation was 
investigated using small-scale approaches focused on characterizing the functional role of 
individual phosphorylation sites and validating corresponding protein kinases (35).  
Technological advances in mass spectrometry and the contemporary emergence of 
quantitative high-throughput proteomics approaches provides innovative opportunities to 
globally profile both the apoptotic protein kinome and the corresponding 
phosphoproteome (36, 37, 39–41).  To enrich for an apoptotic human kinome, we 
processed the proteomes of SILAC-labeled HeLa cells, treated with DMSO (control) or 
doxorubicin (apoptotic), using multiplexed inhibitor beads (MIBs) composed of broad 
specificity ATP-competitive protein kinase inhibitors.  Coupled with LC-MS/MS 
identification and subsequent relative quantification, we identified protein kinases 
upregulated and downregulated in the doxorubicin-induced apoptotic proteome.  As the 
activity of many protein kinases is regulated by auto- or trans-phosphorylation, we also 
searched our kinome profiling dataset for phosphorylation sites on the identified protein 
kinases.  Complementary to our evaluation of the human kinome, we performed 
quantitative profiling of the doxorubicin-induced apoptotic phosphoproteome using the 
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EasyPhos strategy, established by Humphrey et al., (41), and LC-MS/MS analysis.  We 
observed both up- and down-regulation of specific phosphosites and using 
PHOXTRACK, an open-source software developed by Weidner et al., (42), we defined 
experimentally validated hypo- and hyper-phosphorylation of kinase-specific 
phosphosites. 
Collectively, this work emphasizes the influence of apoptotic-driven proteolysis 
on phosphotransferase signaling and highlights the emergence of global strategies to 
systematically investigate the activity of protein kinases and consequent topography of 
the phosphorylation landscape in doxorubicin-induced apoptosis. 
2.2 Materials and Methods 
2.2.1 Bioinformatics: exploring the DegraBase dataset 
We interrogated the DegraBase dataset (version 1.0, downloaded March 3, 2015), 
generated by Crawford et al., (38), using corresponding UniprotKB (www.uniprot.org) 
accession numbers for human protein kinases, catalogued by Manning et al., (11), to 
identify protein kinases processed by proteolysis during apoptosis.  The illustration of the 
phylogenetic tree of the human kinome was reproduced courtesy of Cell Signaling 
Technology, Inc. (www.cellsignal.com) and annotation mapping was rendered using 
KinMap (43).  Subsequently, we searched the DegraBase using UniprotKB accession 
numbers for human phosphatases, catalogued by Sacco et al., (12), to identify catalytic 
and regulatory phosphatase subunits cleaved during apoptosis. 
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2.2.2 Western blot validation of apoptotic induction in HeLa cells 
treated with doxorubicin 
HeLa cells were cultured in DMEM containing 10% fetal bovine serum (FBS), 
100 U/mL penicillin (Life Technologies) and 100 µg/mL streptomycin (Life 
Technologies) at 37˚C in an atmosphere supplemented with 5% CO2.  Cells were treated 
with DMSO (12 hours, negative control (Fisher Scientific)) or 5 µM doxorubicin (12-
hour timecourse (LC laboratories)), harvested and lysed in 50 mM Tris-HCl pH 7.5 
(Bioshop), 150 mM NaCl (Bioshop), 1% NP-40 (Bioshop) supplemented with protease 
inhibitors (0.1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), 10 µg/mL 
pepstatin A (Bioshop), 5 µg/mL aprotinin (Bioshop) and 10 µg/mL leupeptin (Sigma-
Aldrich)).  Lysates were sonicated with three, 10 second pulses on ice and subsequently 
cleared by centrifugation at 16,000 × g for 15 minutes at 4˚C.  The supernatant was 
retained and protein concentrations were determined by BCA assay (Thermo Scientific) 
using bovine serum albumin (BSA) (Thermo Scientific) as a protein standard.  Lysate 
samples diluted in 2× Laemmli buffer and boiled for 5 minutes were loaded equally (25 
µg) and separated by SDS-PAGE.  A broad range pre-stained protein marker (BLUeye, 
FroggaBio) was used as an indicator of molecular weight.  Proteins were transferred to a 
PVDF membrane (Millipore) using a wet electroblotting system (Bio-Rad) at 400 mA for 
one hour at 4˚C.  Membranes were blocked for one hour at ambient room temperature in 
5% BSA/TBST and subsequently probed with primary anti-caspase-3 (Cell Signaling 
Technology, #9662), anti-PARP (Cell Signaling Technology, #9542), or anti-GAPDH 
(Millipore, MAB374) antibodies diluted in 5% BSA/TBST for 16 hours at 4˚C.  IRDye® 
secondary antibodies GAR-800 (LI-COR, #926-32211) and GAM-680 (LI-COR, #925-
68070) diluted in 1% BSA/TBST were incubated for 45 minutes at ambient room 
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temperature.  Membranes were imaged using an Odyssey® Classic Imager (LI-COR) at 
700 nm and 800 nm wavelengths and densitometric analysis was performed using 
Odyssey® software (v3.0). 
2.2.3 SILAC-labeling in HeLa cells: media formulation, 
incorporation and validation by LC-MS/MS 
Preparation of “light” and “heavy” SILAC media was achieved using custom 
SILAC-dropout DMEM media (DMEM formulated with 4.5 g/L D-glucose, 2 mM L-
glutamine and excluding L-lysine, L-arginine, L-proline and sodium pyruvate) 
supplemented with unlabeled L-lysine (0.274 mM, (Cambridge Isotope Laboratories 
Inc.)) and unlabeled L-arginine (0.398 mM, (Cambridge Isotope Laboratories Inc.)) or 
isotope-encoded L-lysine-4,4,5,5-D4 (0.274 mM, (Silantes)) and L-arginine-13C6 (0.398 
mM, (Silantes)).  Both “light” and “heavy” SILAC formulations were also supplemented 
with 400 mg/L proline (to prevent arginine to proline conversion (44, 45)), 10% 10kDa-
dialyzed FBS (Corning), 100 U/mL penicillin (Life Technologies) and 100 µg/mL 
streptomycin (Life Technologies).  Media was filter-sterilized prior to use for cell culture 
using a sterile Nalgene® Rapid-Flow™ bottle top 0.2 µm PES membrane filter (VWR).  
HeLa cells were adapted in “light” or “heavy” SILAC media over a period of 20 days 
with 5 sub-passages.  A plate of “heavy” SILAC-labeled HeLa cells was harvested and 
lysed in 6 M guanidine hydrochloride (EMD Millipore), 100 mM Tris pH 8.5 (Bioshop), 
10 mM TCEP (tris(2-carboxyethyl)phosphine) (Sigma-Aldrich) and 40 mM 2-
chloroacetamide (Sigma-Aldrich).  Lysate was boiled for 5 minutes at 95˚C, cooled on 
ice for 15 minutes, sonicated on ice for 20 seconds (three times) and boiled again for 5 
minutes at 95˚C.  Lysate was centrifuged at 3,500 × g for 30 minutes at 4˚C and protein 
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concentration was determined by Bradford assay (Bio-Rad) using bovine serum albumin 
(BSA) (Thermo Scientific) as a protein standard. Using 50 µg of lysate, proteins were 
precipitated by chloroform (Sigma-Aldrich) and methanol (Fisher) extraction methods 
using methanol, chloroform and water at ratios of 4:1, 1:1 and 3:1 with respect to sample 
volume (46).  Protein pellets were resuspended and digested in 50 mM Tris pH 8.5 
(Bioshop), 0.01 µg/µL Trypsin/Lys-C (Promega) and 1% ProteaseMAX™ Surfactant 
(Promega) for 16 hours at 37˚C with gentle agitation.  Subsequently, an additional 1 µg 
of trypsin (Pierce) was added and the sample was incubated at 37˚C for 4 hours with 
gentle agitation.  The digested peptides were then desalted using a C18 StageTip (3M 
Empore) (47) and 0.7 µg (estimated using a NanoDrop™ (Thermo Scientific)) was 
injected for LC-MS/MS analysis using the method for long gradient acquisition (see 
section 2.2.10).  
Raw mass spectra were analyzed using MaxQuant (v1.5.3.8) and searched against 
the Swissprot-Uniprot sequence database (homo sapiens taxon, accessed December 26, 
2015).  Group-specific parameters were set using a Multiplicity of 2, with “heavy” labels 
designated as ‘Lys4’ and ‘Arg6’.  Protease selectivity was set to trypsin/P with a 
maximum of 3 missed cleavages.  The minimum number of amino acids in a peptide was 
set to 7, with a 1% FDR for peptide spectrum matches and protein matches.  The re-
quantify option was selected and the decoy-database was set to “Revert”. Cysteine 
carbamidomethylation (+57.0215 Da) was set as a fixed modification while methionine 
oxidation (+15.9949 Da), N-terminal protein acetylation (+42.0105 Da) and asparagine 
and glutamine deamidation (+0.9840 Da) were set as variable modifications (with the 
number of variable modifications per peptide set to 5 and minimum score for modified 
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peptides set to 40).  For quantification, unmodified peptides and those with cysteine 
carbamidomethylation, methionine oxidation, protein N-terminus acetylation or 
asparagine and glutamine deamidation were included.  Mass tolerances for parent ion 
mass (MS) and fragment ion mass (MS/MS) were set to 4.5 ppm and 0.5 Da, 
respectively.  Following peptide identification and quantification using MaxQuant 
(v1.5.3.8), the “evidence.txt” output file, containing a non-redundant list of identified 
peptides, was loaded into Perseus software (v1.5.3.0).  Peptides matched to the reverse 
decoy database or identified as potential contaminants were removed from the list.  To 
estimate percent incorporation for “heavy”-labeled peptides, we calculated the H/L ratio 
using heavy and light intensity values and applied two formulae: ((H/L > 1) × 100) and 
(100 – (1/(H/L < 1) × 100).  Incorporation efficiency was estimated by the median 
percent incorporation for isotopically-labeled peptides. 
2.2.4 Kinome Profiling: cell culture, lysis, kinome enrichment and 
sample preparation for mass spectrometry analysis 
SILAC media supplemented with “light” and “heavy” isotope-encoded L-lysine 
and L-arginine was prepared as previously described (section 2.2.3).  Three biological 
replicates (i.e., individual culture plates) of SILAC-labeled HeLa cells were treated with 
DMSO (“light”, negative control (Fisher Scientific)) or 5 µM doxorubicin (“heavy”, 
treatment (LC laboratories)) for six hours at 37˚C in an atmosphere of 5% CO2.  A “label-
swap” replicate was also prepared by inversely treating “heavy”-labeled HeLa cells with 
DMSO and “light”-labeled HeLa cells with 5 µM doxorubicin.  Cells were harvested and 
lysed in buffer containing 50 mM HEPES pH 7.5 (Bioshop), 150 mM NaCl (Bioshop), 
0.5% Triton X-100 (Sigma), 1 mM EDTA (Sigma), 1 mM EGTA (Sigma), 10 mM 
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sodium fluoride (NaF) (Sigma), 2.5 mM sodium orthovanadate (Na3VO4) (Aldrich), 0.2 
mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), 2 µg/mL pepstatin A 
(Bioshop), 4 µg/mL aprotinin (Bioshop), 20 µg/mL leupeptin (Sigma-Aldrich), 1× 
phosphatase inhibitor cocktail 2 (Sigma, #P0044) and 1× phosphatase inhibitor cocktail 3 
(Sigma, #P5726).  Next, samples were sonicated for 10 seconds, three times, on ice and 
centrifuged at 16,000 × g for 15 minutes at 4˚C.  The supernatant was filtered using an 
0.45 µm Acrodisc® Syringe Filter with HT Tuffryn® Membrane (VWR) and protein 
concentrations were determined by BCA assay (Thermo Scientific) using bovine serum 
albumin (BSA) (Thermo Scientific) as a protein standard.  Kinome enrichment was 
performed as previously described in Kurimchak et al., (36) using Multiplexed Inhibitor 
Beads (MIBs) generously provided by Dr. James S. Duncan at the Fox Chase Cancer 
Center (Philadelphia, PA). Briefly, to isolate protein kinases, equal volumes of “light” 
(4.5 mg) and “heavy” (4.5 mg) lysates were mixed and passed over a Poly-Prep® 
chromatography column (Bio-Rad) containing kinase inhibitor-conjugated Sepharose 
beads (VI16832 (39), purvalanol-B (48), PP58 (49, 50)) followed by passage over a 
second column containing kinase inhibitor CTx-0294885-conjugated Sepharose beads 
(51).  Each column was washed 2×10 mL in high-salt buffer and 1×10 mL in low-salt 
buffer (containing 50 mM HEPES pH 7.5 (Bioshop), 0.5% Triton X-100 (Sigma), 1 mM 
EDTA (Sigma), 1 mM EGTA (Sigma), and 1 M NaCl or 150 mM NaCl (Bioshop), 
respectively) and captured protein kinases were eluted by boiling the beads at 95˚C in 
2×250 µL elution buffer (0.1 M Tris-HCl pH 6.8 (Bioshop), 0.5% SDS (Bioshop) and 1% 
β-mercaptoethanol (VWR)) for 10 (first eluent) and 20 (second eluent) minutes.  Eluents 
for each biological replicate were pooled, reduced using 5 mM DTT at 60˚C for 5 
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minutes and alkylated with 20 mM iodoacetamide at room temperature for 30 minutes in 
the dark.  Alkylation was quenched with 10 mM DTT and samples were concentrated 
using a 0.5 mL 10 kDa-cutoff spin filter (Millipore) to a volume of ~50 µL.  Proteins 
were then precipitated by chloroform (Sigma-Aldrich) and methanol (Fisher) extraction 
methods using methanol, chloroform and water at ratios of 4:1, 1:1 and 3:1 with respect 
to sample volume (46).  Protein pellets were resuspended and digested in 50 mM 
ammonium bicarbonate pH 8.5 (FLUKA) and 0.05 µg/µL Trypsin/Lys-C (Promega) for 
16 hours at 37˚C with gentle agitation. The digested peptides were then desalted using a 
C18 StageTip (3M Empore) (47) and 1 µg (estimated using a NanoDrop™ (Thermo 
Scientific)) was injected for LC-MS/MS analysis using the method for long gradient 
acquisition (see section 2.2.10). 
2.2.5 Kinome Profiling: data analysis of raw mass spectra 
Raw mass spectra were analyzed using MaxQuant (v1.5.3.8) and searched against 
the Swissprot-Uniprot sequence database (homo sapiens taxon, accessed December 26, 
2015).  Group-specific parameters were set using a Multiplicity of 2, with “heavy” labels 
designated as ‘Lys4’ and ‘Arg6’.  Protease selectivity was set to trypsin/P with a 
maximum of 3 missed cleavages.  The minimum number of amino acids in a peptide was 
set to 7, with a 1% FDR for peptide spectrum matches and protein matches.  The re-
quantify option was selected and the decoy-database was set to “Revert”. Cysteine 
carbamidomethylation (+57.0215 Da) was set as a fixed modification while methionine 
oxidation (+15.9949 Da), N-terminal protein acetylation (+42.0105 Da), asparagine and 
glutamine deamidation (+0.9840 Da) and serine, threonine and tyrosine phosphorylation 
(+79.9663 Da) were set as variable modifications (with the number of variable 
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modifications per peptide set to 5 and minimum score for modified peptides set to 40).  
For quantification, unmodified peptides and those with cysteine carbamidomethylation, 
methionine oxidation, N-terminal protein acetylation or asparagine and glutamine 
deamidation were included.  Mass tolerances for parent ion mass (MS) and fragment ion 
mass (MS/MS) were set to 4.5 ppm and 0.5 Da, respectively.  The option for second 
peptide search was selected, as was the use of “Match Between Runs”, using default 
matching parameters for respective pairs of samples between biological replicates.  
Peptides without a quantified corresponding “light” or “heavy” modified peptide were 
excluded from the protein group quantification.   
To analyze the captured kinome data searched by MaxQuant (v1.5.3.8), the 
“ProteinGroups.txt” output file, containing a list of all protein groups identified at the 
specified FDR cutoff, was loaded into Perseus software (v1.5.3.0).  Peptides matched to 
the reverse decoy database, identified as potential contaminants or protein identifications 
only matched to modified peptides were removed from the list.  The mean 
log2(‘normalized H/L’, calculated by MaxQuant) was considered for each protein 
identified in at least two biological replicates.  Likewise, to analyze phosphorylation data 
searched by MaxQuant (v1.5.3.8) for the captured kinome, the “Phospho(STY)Sites.txt” 
output file, containing a list of all phosphorylation sites identified at the specified FDR 
cutoff, was loaded into Perseus software (v1.5.3.0).  Peptides matched to the reverse 
decoy database, identified as potential contaminants or unquantified were removed from 
the list.  Phosphorylation sites were indicated as singly-, doubly- or triply-phosphorylated 
and considered if the localization probability was ≥ 0.75.  The mean log2(‘normalized 
62 
 
H/L’, calculated by MaxQuant) was considered for each phosphopeptide identified in at 
least two biological replicates. 
2.2.6 Kinome Profiling: comparative interrogation of the 
DegraBase 
We interrogated the DegraBase dataset (version 1.0, downloaded March 3, 2015), 
generated by Crawford et al., (38), using corresponding UniprotKB (www.uniprot.org) 
accession numbers for human protein kinases identified in our kinome profiling dataset 
for HeLa cells treated with doxorubicin.  We mapped the protein kinases identified in our 
kinome profiling dataset, the DegraBase dataset and those identified in both 
investigations on a phylogenetic tree of the human kinome (reproduced courtesy of Cell 
Signaling Technology, Inc. (www.cellsignal.com)) using KinMap (43). 
2.2.7 Phosphoproteome Profiling: cell culture, lysis, 
phosphopeptide enrichment and sample preparation for 
mass spectrometry analysis 
SILAC media supplemented with “light” and “heavy” isotope-encoded L-lysine 
and L-arginine was prepared as previously described (section 2.2.3).  Three biological 
replicates (i.e., individual culture plates) of SILAC-labeled HeLa cells were treated with 
DMSO (“light”, negative control (Fisher Scientific)) or 5 µM doxorubicin (“heavy”, 
treatment (LC laboratories)) for six hours at 37˚C in an atmosphere of 5% CO2.  Cells 
were harvested and lysed in buffer containing 6 M guanidine hydrochloride (EMD 
Millipore), 100 mM Tris pH 8.5 (Bioshop), 10 mM TCEP (tris(2-
carboxyethyl)phosphine) (Sigma-Aldrich) and 40 mM 2-chloroacetamide (Sigma-
Aldrich).  Lysates were boiled for 5 minutes at 95˚C, cooled on ice for 15 minutes, 
sonicated on ice for 30 seconds (three times) and boiled again for 5 minutes at 95˚C.  
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Lysates were centrifuged at 3,500 × g for 30 minutes at 4˚C and protein concentrations 
were determined by Bradford assay (Bio-Rad) using bovine serum albumin (BSA) 
(Thermo Scientific) as a protein standard.  Using 1 mg of “light” lysate mixed with 1 mg 
of “heavy” lysate, proteins were precipitated by chloroform (Sigma-Aldrich) and 
methanol (Fisher) extraction methods using methanol, chloroform and water at ratios of 
4:1, 1:1 and 3:1 with respect to sample volume (46).  Protein pellets were resuspended in 
500 µL TFE buffer (5% 2,2,2-trifluoroethanol (TFE) (Aldrich) in 100 mM ammonium 
bicarbonate (FLUKA)) with 0.04 µg/µL Trypsin/Lys-C (Promega) and incubated for 4 
hours at 37˚C with gentle agitation.  Subsequently, an additional 20 µg of trypsin (Pierce) 
was added and the sample was incubated at 37˚C for 16 hours with gentle agitation.  For 
whole proteome analysis, 50 µg of the digested peptides were desalted using a C18 
StageTip (3M Empore) (47) and subsequently, 0.7 µg (estimated using a NanoDrop™ 
(Thermo Scientific)) was injected for LC-MS/MS analysis using the method for long 
gradient acquisition (see section 2.2.10).  For analysis of the phosphoproteome, 
phosphopeptide enrichment was performed largely as described in Humphrey et al., (41).  
Briefly, to the remaining volume of digested peptides in TFE buffer (pre-C18 StageTip) 
KCl (Sigma), potassium phosphate monobasic (KH2PO4) (Sigma), acetonitrile (ACN) 
(Fisher) and trifluoroacetic acid (TFA) (Sigma) were added to final concentrations of 300 
mM, 5 mM, 50% and 6%, respectively.  Peptide solutions were vortexed for 1 minute, 
cleared at 16,000 × g for 15 minutes at room temperature and supernatants were 
transferred to clean, low-retention microcentrifuge tubes.  Titanium dioxide (TiO2) beads 
resuspended in 80% ACN and 6% TFA (10 µm Titansphere phos-TiO, Canadian Life 
Science) were added to peptide solutions at a ratio of 10:1 (beads/peptides) and vortexed 
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for 5 minutes at room temperature.  Beads were then pelleted by centrifugation at 3,500 × 
g for 1 minute at room temperature.  The supernatant, representing the “non-
phosphopeptides”, was removed and stored at –80˚C.  Non-specifically bound peptides 
were washed from the TiO2 beads using Wash Buffer (60% ACN, 1% TFA) and 
transferred to a clean low-retention microcentrifuge tube before being washed four 
additional times with Wash Buffer.  The TiO2 beads were then resuspended in 100 µL 
80% ACN with 0.5% formic acid, transferred to a single layer C18 StageTip and 
centrifuged at 500 × g to remove all liquid.  Bound phosphopeptides were eluted in 100 
µL 40% ACN, 15% ammonium hydroxide (25% NH4OH, HPLC grade (Sigma)).  Eluted 
samples were concentrated in a SpeedVac for 15 minutes at 45˚C to ~30 µL and acidified 
with 10 µL of 10% TFA (Sigma).  Peptides were loaded onto styrenedivinylbenzene–
reversed phase sulfonated (SDB-RPS; 3M Empore) StageTips and centrifuged at 500 × g 
until ≤ 5 µL remained.  StageTips were washed with 200 µL SDB-RPS wash buffer 
(0.2% TFA), centrifuged at 2,000 × g until all liquid passed through and phosphopeptides 
were eluted with 100 µL SDB-RPS elution buffer (80% ACN (Fisher), 5% NH4OH 
(25%, HPLC grade (Sigma))) into low-retention microcentrifuge tubes by centrifugation 
at 500 × g for ~3-5 minutes. Samples were immediately concentrated in a SpeedVac at 
45˚C until ~2 µL remained and then were acidified with 15 µL of 0.1% formic acid (FA) 
(Fisher).  Finally, 0.7 µg (estimated using a NanoDrop™ (Thermo Scientific)) was 




2.2.8 Phosphoproteome Profiling: data analysis of raw mass 
spectra 
Raw mass spectra were analyzed using MaxQuant (v1.5.3.8) and searched against 
the Swissprot-Uniprot sequence database (homo sapiens taxon, accessed December 26, 
2015).  Group-specific parameters were set using a Multiplicity of 2, with “heavy” labels 
designated as ‘Lys4’ and ‘Arg6’.  Protease selectivity was set to trypsin/P with a 
maximum of 3 missed cleavages.  The minimum number of amino acids in a peptide was 
set to 7, with a 1% FDR for peptide spectrum matches and protein matches.  The re-
quantify option was selected and the decoy-database was set to “Revert”. Cysteine 
carbamidomethylation (+57.0215 Da) was set as a fixed modification while methionine 
oxidation (+15.9949 Da), N-terminal protein acetylation (+42.0105 Da), asparagine and 
glutamine deamidation (+0.9840 Da) were set as variable modifications for both whole 
proteome and phosphoproteome searches (with the number of variable modifications per 
peptide set to 5 and minimum score for modified peptides set to 40).  For the 
phosphoproteome search, serine, threonine and tyrosine phosphorylation (+79.9663 Da) 
were also included as variable modifications.  For quantification, unmodified peptides 
and those with cysteine carbamidomethylation, methionine oxidation, N-terminal protein 
acetylation or asparagine and glutamine deamidation were included.  Mass tolerances for 
parent ion mass (MS) and fragment ion mass (MS/MS) were set to 4.5 ppm and 0.5 Da, 
respectively.  The option for second peptide search was selected, as was the use of 
“Match Between Runs”, using default matching parameters, for respective pairs of 
samples between biological replicates.  Peptides without a quantified corresponding 
“light” or “heavy” modified peptide were excluded from the protein group quantification. 
66 
 
To analyze the whole proteome data searched by MaxQuant (v1.5.3.8), the 
“ProteinGroups.txt” output file, containing a list of all protein groups identified at the 
specified FDR cutoff, was loaded into Perseus software (v1.5.3.0).  Peptides matched to 
the reverse decoy database, identified as potential contaminants or protein identifications 
only matched to modified peptides were removed from the list.  The mean 
log2(‘normalized H/L’, calculated by MaxQuant) was calculated for each protein 
identified in all three biological replicates.  Likewise, to analyze the phosphoproteome 
data generated by MaxQuant (v1.5.3.8), the “Phospho(STY)Sites.txt” output file, 
containing a list of all phosphorylation sites identified at the specified FDR cutoff, was 
loaded into Perseus software (v1.5.3.0).  Peptides matched to the reverse decoy database, 
identified as potential contaminants or unquantified were removed from the list.  
Phosphorylation sites were indicated as singly-, doubly- or triply-phosphorylated and 
considered if the localization probability was ≥ 0.75.  The mean log2(‘normalized H/L’, 
calculated by MaxQuant) was calculated for each phosphopeptide identified in three 
biological replicates.  Using a one-sample Student’s t-test with multiple hypothesis 
correction (Benjamini-Hochberg, FDR = 0.05), statistically significant mean 
log2(‘normalized H/L’) ratios were identified. 
2.2.9 Phosphoproteome Profiling: PHOXTRACK data analysis 
To decipher kinase–substrate relationships in the phosphoproteome of 
doxorubicin-treated HeLa cells, we used PHOXTRACK (PHOsphosite-X-TRacing 
Analysis of Causal Kinases), an open-source software developed by Weidner et al., (42), 
at the Max Planck Institute for Molecular Genetics.  PHOXTRACK applies non-
parametric Kolmogorov-Smirnov enrichment statistics (52, 53) to significantly define 
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hypo- and hyper-phosphorylation of experimentally validated kinase-specific 
phosphosites.  Using the PHOXTRACK settings recommended by Weidner et al., (42), 
(unweighted Kolmogorov-Smirnov statistics, 10,000 permutations, 3 phosphosites/kinase 
and FDR < 0.25), we queried the PhosphoSitePlus database (54, 55) with uploaded mean 
log2(normalized H/L) ratios of phosphorylation sites identified in our doxorubicin-
treatment phosphoproteomic dataset.   
2.2.10 Long gradient LC-MS/MS acquisition 
Peptide samples were loaded onto an ACQUITY UPLC Symmetry C18 
NanoAcquity, 10K, 2G V/M, 180 µm x 20 mm, 100A, 5 µm trapping column (Waters 
Corporation, Milford, MA) via a Waters NanoAcquity UPLC, at a flow rate of 10 µL/min 
for 4 minutes using 99% buffer A (0.1% formic acid) and 1% buffer B (acetonitrile, 0.1% 
formic acid).  After trapping, peptides were eluted onto the analytical column for 
separation using a 290-minute run time. Flow was established at 300 nL/min for the 
ACQUITY UPLC Peptide BEH C18 NanoAcquity Column 10K psi, 130Am 1.7 µm x 25 
mm which was held at 35˚C. The gradient initial condition was 5% buffer B. Buffer B 
then increased to 7.5% over 1 minute, 25% over 179 minutes, 32.5% over 40 minutes, 
60% over 20 minutes, 98% over 5 minutes, then held at 98% for 5 minutes, reduced to 
2% over 5 minutes, then held at 2% for 5 minutes, increased to 98% over 5 minutes, then 
held at 98% for 5 minutes, reduced to 5% over 5 minutes and finally held at 5% for 15 
minutes for re-equilibration to the initial condition. This gradient builds in a saw-tooth 
washing stage to clean the column. The LC system was directly connected to a NanoFlex 
(Thermo Electron Corp., Waltham, MA) nanospray ionization source with a source 
voltage of 2.4 KV and was interfaced to an Orbitrap Elite, VelosPro mass spectrometer. 
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The mass spectrometer was controlled by Xcalibur software (Thermo, v2.7.0) and 
operated in the data-dependent mode using an FT/IT/CID Top 20 scheme.  The MS scan 
recorded the mass-to-charge ratios (m/z) of ions over the range of 400–1450 in FT 
(resolution of 120,000 at m/z 400), positive ion, profile, full MS mode using a lock mass 
(445.120025 m/z). The 20 most abundant multiply charged ions were automatically 
selected for subsequent collisional induced dissociation in ion trap mode (IT/CID) with 
an isolation width of 2.00 Da, rapid scan rate, centroid mode, with charge state filtering 
allowing only ions of +2, +3 and +4 charged states.  Normalized collision energy was 35 
and precursor ions were then excluded from further CID for 30 seconds. 
2.2.11 Short gradient LC-MS/MS acquisition 
Peptide samples were loaded onto an ACQUITY UPLC Symmetry C18 
NanoAcquity, 10K, 2G V/M, 180 µm x 20 mm, 100A, 5 µm trapping column (Waters 
Corporation, Milford, MA) via a Waters NanoAcquity UPLC, at a flow rate of 10 µL/min 
for 5 minutes using 99% buffer A (0.1% formic acid) and 1% buffer B (acetonitrile, 0.1% 
formic acid).  After trapping, peptides were eluted onto the analytical column for 
separation, using a 130-minute run time. Flow was established at 300 nL/min for the 
ACQUITY UPLC Peptide BEH C18 NanoAcquity Column 10K psi, 130Am 1.7 µm x 25 
mm which was held at 35˚C. The gradient initial condition was 5% buffer B. Buffer B 
then increased to 7.5% over 1 minute, 25% over 59 minutes, 32.5% over 14 minutes, 
60% over 6 minutes, 98% over 5 minutes, then held at 98% for 5 minutes, reduced to 2% 
over 5 minutes, then held at 2% for 5 minutes, increased to 98% over 5 minutes, then 
held at 98% for 5 minutes, then reduced to 5% over 5 minutes, and finally held at 5% for 
15 minutes for re-equilibration to the initial condition. This gradient builds in a saw-tooth 
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washing stage to clean the column. The LC system was directly connected to a NanoFlex 
(Thermo Electron Corp., Waltham, MA) nanospray ionization source with a source 
voltage of 2.4 KV and was interfaced to an Orbitrap Elite, VelosPro mass spectrometer. 
The mass spectrometer was controlled by Xcalibur software (Thermo, v2.7.0) and 
operated in the data-dependent mode using an FT/IT/CID Top 20 scheme.  The MS scan 
recorded the mass-to-charge ratios (m/z) of ions over the range of 400–1450 in FT 
(resolution of 120,000 at m/z 400), positive ion, profile, full MS mode using a lock mass 
(445.120025 m/z). The 20 most abundant multiply charged ions were automatically 
selected for subsequent collisional induced dissociation in ion trap mode (IT/CID) with 
an isolation width of 2.00 Da, rapid scan rate, centroid mode, with charge state filtering 
allowing only ions of +2, +3 and +4 charged states.  Normalized collision energy was 35 
and precursor ions were then excluded from further CID for 30 seconds. 
2.3 Results 
2.3.1 Bioinformatics analysis reveals extensive proteolysis of 
phosphotransferases in apoptosis 
In an effort to investigate the global impact of proteolytic processing of 
phosphotransferases in apoptosis, we systematically interrogated the DegraBase dataset, 
published by Crawford et al., (38), for apoptotic proteolysis of human kinases and 
phosphatases.  Briefly, the DegraBase is an open-source dataset generated using a 
subtiligase-based, positive enrichment mass spectrometry strategy for comparison of N-
terminomes from healthy and apoptotic cells.  Encompassing a diverse complement of 
human cells lines (Jurkat, THP-1, DB, RPMI 8226, MM1-S and U266) together with 
various apoptotic stimuli (doxorubicin, etoposide, bortezomib, FasL, CD95, 
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staurosporine or TRAIL), the DegraBase dataset contains >8,000 unique N-termini from 
~3,200 proteins and serves as a comprehensive resource of post-translational proteolysis 
sites in both healthy and apoptotic human cells (38). 
Using UniprotKB accession numbers for 523 human protein kinases, we 
interrogated the DegraBase dataset and illustrated our findings on a phylogenetic map of 
the human kinome (11, 43) (Figure 2.2, Supplementary Table 2.1).  Examination of the 
DegraBase revealed 89 protein kinases (18% of the human kinome) modified by 
proteolysis in response to chemically induced apoptosis, with 55% of those cleavage 
events occurring when, in terms of classic protease cleavage nomenclature, aspartic acid 
is the P1 residue (56) (Figure 2.3).  With the notion that post-translational 
phosphorylation is a reversible signaling mechanism, we complemented our work 
investigating proteolysis of the human kinome by also interrogating the DegraBase for 
proteolysis of the phosphotransferases responsible for removing phosphates from 
proteins.  Using UniprotKB accession numbers for human phosphatases (198 catalytic 
subunits and 54 regulatory subunits), we interrogated the DegraBase dataset and 
categorized our findings based on familial phosphatase classifications catalogued by 
Sacco et al., (12) (Figure 2.4, Supplementary Table 2.2).  We identified 32 catalytic 
phosphatase subunits (representing 16% of the human phosphatome) cleaved in response 
to chemically induced apoptosis, with 31% of those cleavage events occurring when the 
P1 residue is aspartic acid or glutamic acid (Figure 2.5A-B).  Moreover, we identified 14 
regulatory phosphatase subunits (corresponding to 26% of phosphatase regulatory 
subunits) in the DegraBase dataset, with 64% of those cleavage events occurring when 




Figure 2.2 Human protein kinases identified in the DegraBase. 
To examine the interplay between proteases and protein kinases in apoptosis, we 
interrogated the DegraBase for all human protein kinases.  Protein kinases identified in 
the DegraBase are highlighted with orange circles on the phylogenetic tree of the human 
kinome (illustration reproduced courtesy of Cell Signaling Technology, Inc. 















Figure 2.3 Percentage of human protein kinases identified in the DegraBase. 
A) Approximately 18% of the human kinome was identified in the DegraBase dataset and 
B) within those identified, 55% had an aspartic acid residue (D) in the P1 position (where 
‘X’ represents any amino acid).  
















Figure 2.4 Human protein phosphatases identified in the DegraBase. 
To complement our work investigating cleavage of protein kinases during apoptosis, we 
interrogated the DegraBase to identify the catalytic and regulatory subunits of 
phosphatases that undergo cleavage.  The catalytic and regulatory subunits of 
phosphatases are arranged in families based on catalytic domain sequence similarity (12) 
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Figure 2.5 Percentage of catalytic and regulatory phosphatase subunits identified in 
the DegraBase. 
A)  Approximately 16% of catalytic phosphatase subunits were identified in the 
DegraBase dataset set and B) within those identified, 31% had an aspartic (D) or 
glutamic (E) acid residue in the P1 position (where ‘X’ represents any amino acid).  C) 
Approximately 26% of regulatory phosphatase subunits were identified in the DegraBase 
dataset and D) within those identified, 64% had an aspartic (D) or glutamic (E) acid 
residue in the P1 position (where ‘X’ represents any amino acid).  
Cleaved Uncleaved P1 = D/E P1 = X






















reveals that both the kinome and phosphatome undergo extensive proteolytic processing 
in response to apoptotic stimuli. 
2.3.2 Validating apoptotic induction in HeLa cells treated with 
doxorubicin 
The extensive proportion of protein kinases and phosphatases identified in the 
DegraBase motivated our interest in understanding the relationship between the apoptotic 
kinome and the corresponding phosphoproteome.  Taking into consideration the notion 
that the most commonly used laboratory cell lines share ubiquitous proteome expression, 
we performed our experiments using HeLa cells treated with doxorubicin to induce 
apoptosis (57).  Originally isolated from Streptomyces peucetius, doxorubicin is used 
clinically to treat a variety of cancers (58, 59).  Classified as a nonselective class I 
anthracycline, doxorubicin comprises an aromatic aglycon chromophore conjugated to an 
amino sugar (i.e., daunosamine) by a glycosidic bond (60) (Figure 2.6A).  
Mechanistically, doxorubicin promotes DNA damage through inhibition of the enzyme 
topoisomerase II and intercalation with DNA.  During DNA replication and RNA 
transcription topoisomerase II inhibition prevents uncoiling and introduces breaks while 
DNA intercalation stalls polymerases (58, 61).  As occurrences of DNA damage 
accumulate and proliferation stalls, the inability to efficiently repair breaks and restore 
replicative activity ultimately triggers apoptosis in cells treated with doxorubicin (58, 61, 
62).  In accordance with Crawford et al., (38), we treated HeLa cells with a 5 µM dose of 
doxorubicin and to confirm the temporal induction of apoptosis in HeLa cells, we used 





Figure 2.6 Doxorubicin treatment induces caspase-3 and PARP cleavage in HeLa 
cells. 
Lysates from HeLa cells treated with DMSO (12 hours, negative control) or A) 5 µM 
doxorubicin (12-hour timecourse) were separated using SDS-PAGE and analyzed by 
Western Blot for B) caspase-3 cleavage and C) PARP cleavage. GAPDH was used as a 





































Caspase-3 (35 kDa), a critical executioner of apoptosis, is proteolytically activated during 
apoptosis by upstream caspases into activated fragments (17 kDa and 12kDa) (63).  As a 
consequence of caspase-3 activation and subsequent apoptotic progression, PARP (116 
kDa), a nuclear poly (ADP-ribose) polymerase, is proteolytically digested by activated 
caspase-3 to separate its N-terminal DNA binding domain (24 kDa) from its C-terminal 
catalytic domain (89 kDa) (63).  Cleavage of both caspase-3 and PARP is observed 6 
hours after treatment of HeLa cells with 5 µM doxorubicin indicating that the apoptotic 
program was initiated (Figure 2.6B-C).  Based on these observations, in subsequent 
experiments using HeLa cells, induction of apoptosis was achieved by treatment with 5 
µM doxorubicin for 6 hours.  
2.3.3 Exploring variations within the kinome of HeLa cells treated 
with doxorubicin 
To profile the active kinome of apoptotic HeLa cells using quantitative 
proteomics, we employed a kinome enrichment strategy using multiplexed inhibitor 
beads (MIBs) composed of a mixture of broad specificity ATP-competitive protein 
kinase inhibitors.  As a prelude to our kinome profiling workflow, we adapted a HeLa 
cell line into “light” (K0, R0) or “heavy” (K4, R6) SILAC medium over 20 days with 5 
sub-passages.  To calculate the median efficiency for the incorporation of labelled amino 
acids, a “heavy”-labeled sample was processed for whole proteome LC-MS/MS 
acquisition and analyzed using MaxQuant (v1.5.3.8).  The distribution of incorporated 
peptides detected and identified for our SILAC-labeled HeLa cell line was negatively 
skewed with a median incorporation efficiency of >95% demonstrating that our SILAC-
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labeled HeLa cell line can be used for quantitative comparisons in SILAC experiments 
(64, 65) (Supplementary Figure 2.1).   
After verifying SILAC incorporation in our HeLa cell line, three biological 
replicates (i.e., individual culture plates) were treated with DMSO (“light”, negative 
control) or 5 µM doxorubicin (“heavy”, treatment) for six hours.  Light and heavy 
proteomes were mixed and passed over a chromatography column containing kinase 
inhibitor-conjugated Sepharose beads (VI16832 (39), purvalanol-B (48), PP58 (49, 50)) 
followed by passage over a second column containing kinase inhibitor CTx-0294885-
conjugated Sepharose beads (51).  Following tryptic digestion, raw spectra for the 
kinome enriched samples were acquired using LC-MS/MS and analyzed using MaxQuant 
software (v1.5.3.8) (Figure 2.7).  We also processed a control “label-swap” replicate by 
inversely treating “heavy”-labeled HeLa cells with DMSO and “light”-labeled HeLa cells 
with 5 µM doxorubicin.  Within our kinome enrichment dataset, we identified 161 
protein kinases, representing approximately 30% of the human kinome (Figure 2.8A).  
Furthermore, our kinome profiling strategy enriched for protein kinases across all major 
kinase groups and, with the exception of protein kinases classified as atypical, the relative 
distribution of protein kinase groups in our kinome enrichment dataset is comparable to 
the representation of kinase groups within the entire complement of the human kinome 
(Figure 2.8B-C).   
Quantification of the kinome enrichment dataset revealed distinct variations 
within the kinome in response to apoptotic-inducing doxorubicin treatment in HeLa cells.  
We observed 9 down-regulated (log2 ratio < –0.5) and 8 up-regulated (log2 ratio > 0.5) 




Figure 2.7 Experimental workflow for chemoproteomic kinome profiling using 
Multiplexed Inhibitor Beads. 
Three biological replicates of SILAC-labeled HeLa cells were treated with DMSO 
(“light”, control) or 5 µM doxorubicin (“heavy”, treatment) for six hours. DMSO control 
(“light”) and doxorubicin-treated (“heavy”) lysates were mixed 1:1 (w/w) and enrichment 
of the active kinome was achieved by processing lysate mixtures over Multiplexed 
Inhibitor Beads conjugated to VI16832 (39), purvalanol-B (48), PP58 (49, 50) and CTx-
0294885 (51).  Captured protein kinases were digested using trypsin and resultant 
peptides were analyzed by LC-MS/MS.  Peptide identification and relative quantification 

































Figure 2.8 Kinome enrichment profiling summary. 
A) Number of protein kinases identified in the kinome enrichment profile of doxorubicin-
treated HeLa cells (purple) within the kinome (blue).  B) Pie chart showing the number of 
protein kinases identified as representatives of respective kinase groups.  C) Relative 
enrichment of protein kinases identified in 9 major kinase groups in the kinome 

























































Figure 2.9 Identification and quantification of protein kinases identified in the 
kinome enrichment dataset. 
SILAC-labeled HeLa cells treated with DMSO (“light”, control) or 5 µM doxorubicin 
(“heavy”, treatment) for six hours were harvested and processed using Multiplexed 
Inhibitor Beads to enrich for the active kinome.  Raw mass spectra were acquired by LC-
MS/MS and peptides were identified and quantified using MaxQuant (v1.5.3.8).  The 
mean log2(Doxorubicin/DMSO) ratio for protein kinases identified in at least 2/3 
biological replicates are shown.  Error bars depicting standard deviations are included for 
identifications where quantitative information was acquired in three biological replicates.  
Protein kinases with a mean log2(Doxorubicin/DMSO) ratio less than –0.5 or greater than 
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As the activity of many protein kinases is regulated by auto- or trans-phosphorylation, we 
also examined our kinome profiling dataset for phosphorylation sites on the identified 
protein kinases (Figure 2.10, Supplementary Figure 2.3).  Furthermore, we cross-
referenced the protein kinases identified in our kinome enrichment dataset with protein 
kinases that were previously identified in the DegraBase.  In total, approximately 25% of 
our kinome enrichment dataset overlaps with protein kinases identified in the DegraBase 
(Figure 2.11). 
2.3.4 Systematic phosphoproteome evaluation of HeLa cells 
treated with doxorubicin 
To complement evaluation of the human kinome, we performed quantitative 
profiling of the doxorubicin-induced apoptotic phosphoproteome using the EasyPhos 
strategy established by Humphrey et al., (41).  Briefly, three biological replicates (i.e., 
individual culture plates) of SILAC-labeled HeLa cells were treated with DMSO (“light”, 
negative control) or 5 µM doxorubicin (“heavy”, treatment) for six hours.  Light and 
heavy proteomes were mixed and digested using trypsin and Lys-C proteases.  
Phosphopeptide enrichment was achieved using titanium dioxide beads and, using an 
aliquot retained from each digested sample prior to titanium dioxide enrichment, we 
processed complementary whole proteome samples for comparative analysis.  Raw 
spectra for both proteome and phosphoproteome samples were acquired using LC-
MS/MS and quantified using MaxQuant (v1.5.3.8) (Figure 2.12).  A total of 1,807 
phosphorylation sites (serine, threonine or tyrosine residues) and 2,205 protein groups 
were identified and quantified across all biological replicates (Figure 2.13). Surveying the 




Figure 2.10 Quantification of protein kinase phosphorylation sites in the kinome 
enrichment dataset. 
Protein kinases identified in the kinome enrichment dataset containing quantified 
phosphorylation sites, with a phosphosite localization probability exceeding 0.75 on 
serine, threonine or tyrosine residues, are illustrated by heatmap for each biological 


































































Figure 2.11 Comparative analysis of protein kinases identified in the DegraBase and 
kinome enrichment dataset. 
Protein kinases identified in the DegraBase (green circles), the kinome enrichment 
dataset (blue circles) or both (pink circles) are annotated on the phylogenetic tree of the 
human kinome (illustration reproduced courtesy of Cell Signaling Technology, Inc. 









Figure 2.12 Experimental workflow for quantitative phosphoproteomics. 
Three biological replicates of SILAC-labeled HeLa cells were treated with DMSO 
(“light”, control) or 5 µM doxorubicin (“heavy”, treatment) for six hours. DMSO control 
(“light”) and doxorubicin-treated (“heavy”) lysates were mixed 1:1 (w/w), digested using 
trypsin and processed for whole proteome analysis or enriched for phosphopeptides using 
titanium dioxide beads prior to phosphoproteome analysis.  Resultant peptides were 
analyzed by LC-MS/MS and subsequent peptide identification and relative quantification 


















































Figure 2.13 Quantitative phosphoproteomics summary. 
Parallel preparations of whole proteome and phosphoproteome samples from SILAC-
labelled HeLa cells treated with DMSO (“light”, control) or 5 µM doxorubicin (“heavy”, 
treatment) were processed for LC-MS/MS analysis followed by peptide identification and 
quantification using MaxQuant (v1.5.3.8).  This figure summarizes the total number of 
MS1 and MS2 spectra acquired and the number of protein groups and phosphorylation 
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log2 ratios centred tightly around zero in comparison to a broader distribution of 
phosphopeptide mean log2 ratios centered slightly below zero (Supplementary Figure 2.4-
2.5).  This data demonstrates that doxorubicin treatment in HeLa cells influences the 
occupancy of phosphorylation sites both positively and negatively.  Each phosphorylation 
site was evaluated based on magnitude of change and, using a one-sample Student’s t-test 
with multiple hypothesis correction (Benjamini-Hochberg, FDR = 0.05), we observed 
166 phosphosites with increased occupancy (mean log2 ratio > 1) and 194 phosphosites 
with decreased occupancy (mean log2 ratio < –1) (Supplementary Table 2.3-2.4).  
Plotting the phosphoproteomic data on a volcano plot illustrates the broad impact of 
doxorubicin-treatment in HeLa cells and highlights apoptotic phosphoproteome dynamics 
(Figure 2.14).  To confirm that changes within the phosphoproteome are independent of 
protein abundance, we plotted statistically significant phosphorylation site mean log2 
ratios against corresponding protein group mean log2 ratios (Figure 2.15).   
2.3.5 PHOXTRACK analysis of phosphoproteomics dataset 
reveals perturbations to protein kinases ATR, ATM and CK2 
To decipher kinase–substrate relationships in the phosphoproteome of 
doxorubicin-treated HeLa cells we used PHOXTRACK (PHOsphosite-X-TRacing 
Analysis of Causal Kinases), an open-source software developed by Weidner et al., (42), 
that applies non-parametric Kolmogorov-Smirnov enrichment statistics (52, 53) to 
significantly define hypo- and hyper-phosphorylation of experimentally validated kinase-
specific phosphosites.  Essentially, PHOXTRACK infers up- or down-regulation of 
protein kinases in a phosphoproteomics dataset by evaluating the stoichiometric 






Figure 2.14 Volcano plot of quantified phosphorylation sites from HeLa cells treated 
with doxorubicin. 
Phosphoproteome samples from SILAC-labelled HeLa cells treated with DMSO (“light”, 
control) or 5 µM doxorubicin (“heavy”, treatment) were processed for LC-MS/MS 
analysis followed by peptide identification and quantification using MaxQuant (v1.5.3.8).  
Volcano plot depicts entire phosphoproteome dataset (3/3 biological replicates, 
phosphosite localization probability ≥ 0.75) and illustrates the mean 
log2(Doxorubicin/DMSO) ratios against the significance of the changes as –log10(p-value, 
one-sample Student’s t-test, FDR < 0.05). Vertical red lines at –1 and +1 highlight log2 























Figure 2.15 Comparative analysis of quantified proteome and phosphoproteome 
samples from HeLa cells treated with doxorubicin. 
Parallel preparations of whole proteome and phosphoproteome samples from SILAC-
labelled HeLa cells treated with DMSO (“light”, control) or 5 µM doxorubicin (“heavy”, 
treatment) were processed for LC-MS/MS analysis followed by peptide identification and 
quantification using MaxQuant (v1.5.3.8).  The mean log2(Doxorubicin/DMSO) ratio for 
statistically significant (one-sample Student’s t-test, FDR < 0.05) quantified 
phosphorylation sites (with phosphosite localization probability ≥ 0.75) were plotted 
against the mean log2(Doxorubicin/DMSO) ratio for respective protein abundance 






























Using the recommended settings for PHOXTRACK analysis, we queried the 
PhosphoSitePlus database (54, 55) with uploaded mean log2 ratios of phosphorylation 
sites identified in our doxorubicin-treatment phosphoproteomic dataset.  Our 
PHOXTRACK analysis (FDR < 0.25) revealed increased phosphorylation on substrates 
corresponding to protein kinases ATM and ATR while substrates of protein kinase CK2 
exhibited bidirectional alterations in phosphorylation site occupancy (Figure 2.16).   
2.4 Discussion 
Numerous studies detailing bidirectional signaling between protein kinases and 
caspases as a key mechanism of apoptotic regulation, highlights the convergence of two 
fundamentally distinct post-translational modifications, namely phosphorylation and 
proteolysis (reviewed in (29)).  Protein kinases are typically regulated by reversible 
mechanisms including trans- or auto-phosphorylation, substrate co-localization or by 
interacting with activating or inhibitory proteins (66).  Regarding irreversible apoptotic 
proteolysis of protein kinases, potential regulatory consequences include increased or 
constitutive activity, complete abrogation of activity, altered localization or changes to 
substrate preference (34).  Mounting evidence informs that the global balance of 
phosphorylation is critical for transmitting signals rather than the antiquated notion that 
pathways are simply switched on and off by protein kinases or phosphatases (13).  As 
such, crosstalk among caspases and phosphatases, though not currently well-
characterized, is also an integral component of deciphering the global interplay between 
apoptotic phosphorylation and proteolysis.  Furthermore, given the breadth and diversity 
of the degradome, it is intriguing that nearly 5% of the human proteome is reportedly 





Figure 2.16 PHOXTRACK analysis of quantified phosphorylation sites. 
Phosphoproteome samples from SILAC-labelled HeLa cells treated with DMSO (“light”, 
control) or 5 µM doxorubicin (“heavy”, treatment) were processed for LC-MS/MS 
analysis followed by peptide identification and quantification using MaxQuant (v1.5.3.8).  
PHOXTRACK analysis (42), revealed A) hyper-phosphorylation of substrates for protein 
kinase ATR, B) hyper-phosphorylation of substrates for protein kinase ATM and C) both 



















































































we used to mine the DegraBase provides an unbiased, global assessment of apoptotic 
phosphotransferase proteolysis (38).   
2.4.1 Exploring proteolytic processing of phosphotransferases in 
apoptosis 
Our analysis revealed that a sizeable fraction of the human kinome, approximately 
one-fifth, is subject to proteolysis in response to various apoptotic stimuli. Furthermore, a 
phylogenetic map of our findings illustrated that apoptotic proteolysis of the human 
kinome is widespread, involving protein kinases from all major groups in addition to 
highlighting extensive proteolysis of protein kinases classified as atypical.  Overall, the 
validity of our strategy is demonstrated by the identification of several protein kinases 
previously characterized as caspase substrates.  For example, the DegraBase dataset 
includes three serine/threonine MST (mammalian Ste20-related) kinases (i.e., MST1, 
MST3 and MST4).  Members of the MST family of protein kinases are ubiquitously 
expressed and participate in signaling pathways involving morphogenesis including 
proliferation, cell migration and, relevant to our investigation, apoptosis (69).  In healthy 
cells, MST kinases are regulated by activating phosphorylation and dimerization; 
however, MST1, MST2 and MST3 contain documented caspase cleavage sites located in 
the linker region separating the N-terminal kinase domain from the C-terminal regulatory 
domain (69–71).  During apoptosis, caspase-mediated cleavage liberates the kinase 
domain, which becomes constitutively active and, in the absence of NES motifs found in 
the regulatory domain, translocates to the nucleus (72).  Remarkably, the activity of 
cleaved MST1 is reportedly 9-fold higher than the full-length kinase and overexpression 
of cleaved MST kinase fragments is sufficient to induce morphological features 
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associated with apoptosis (73).  Collectively, the detection of protein kinases in the 
DegraBase previously characterized as caspase substrates, including the MST kinases 
described above and others (e.g., Abl (74–76), Chk1 (77, 78), Lyn (79), Fyn (79, 80), 
RIPK1 (81–83), etc.), reinforces the impact of investigating apoptotic degradation in the 
kinome. 
Analogous to our assessment of the kinome, we observed a slightly lower 
incidence of cleaved catalytic phosphatase subunits identified across various superfamily 
classifications.  With roughly 700,000 potentially phosphorylatable residues in the human 
proteome, it is intriguing that the human genome encodes substantially fewer 
phosphatases (~200) than protein kinases (~520) (12, 14).  Moreover, broad in vitro 
substrate specificity prompted the historical viewpoint that unlike protein kinases, which 
typically target distinct consensus sequences, phosphatases were considered poorly-
regulated, promiscuous enzymes (12).  On the contrary, more recent studies unveiled a 
variety of mechanisms conferring remarkable phosphatase substrate specificity through 
accessory domains, short linear motifs or by acting in concert with regulatory subunits 
(12, 84).  These mechanisms exponentially expand the variability of substrates targeted 
by individual phosphatases and compensate for the genomic disparity regarding cognate 
protein kinases (84).  As such, cursory comparison of the catalytic phosphatase subunits 
and protein kinases identified in our analysis of the DegraBase, implies that apoptotic 
proteolysis impacts the kinome and phosphatome comparably.  However, coupled with 
the finding that 30% of regulatory phosphatase subunits are also identified in the 
DegraBase suggests that the phosphatome, albeit in this context largely unexplored, may 
be more substantially impacted by apoptotic proteolysis than the kinome. 
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Interestingly, roughly half of the protein kinases, one-third of the catalytic 
phosphatase subunits and two-thirds of the regulatory phosphatase subunits identified in 
the DegraBase contain an aspartic acid (or glutamic acid) residue in the P1 position.  In 
terms of apoptotic signaling, we predict that these cleavage events are a consequence of 
caspase activation, which have a dominant specificity for protein substrates containing an 
aspartic acid residue amino-terminal to the scissile bond (85).  Furthermore, Mahrus et 
al., (86), showed that in untreated Jurkat cells, less than 5% of protein N-termini contain 
an aspartic acid in the P1 position, reinforcing our estimate that phosphotransferases 
identified containing P1 aspartic acid residues are likely putative substrates of caspases 
activated in response to apoptotic stimuli.  Interestingly, recent studies observed 
alternative P1 site specificities and demonstrated that a salient feature of caspases is that 
proteolytic cleavage is contingent on the target site being preferentially located in 
extended loop conformations rather than α-helices or β-sheets (33, 87, 88).  For example, 
Seaman et al., (89), demonstrated that caspase-3 can cleave amino-terminal of 
phosphoserine and they revealed that the catalytic efficiency of caspase-3 and -7 cleaving 
a substrate with a P1 aspartic acid residue is only two-fold greater than the catalytic 
efficiency for cleaving a corresponding substrate with a P1 glutamic acid residue.  
Consequently, phosphotransferases in our analysis with P1 glutamic acid residues may 
also, in some measure, be attributed to caspase-mediated cleavage.  To account for 
proteolysis occurring after residues not associated with caspase cleavage, we speculate 
that non-caspase proteases activated as a consequence of apoptotic programming, such as 
calpains, serine proteases or lysosomal proteases, are responsible and serve to amplify the 
apoptotic phenotype by acting in parallel with caspases as the cell is degraded (90, 91).  
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Overall, our comprehensive analysis of the DegraBase suggests that apoptotic proteolysis 
of phosphotransferases facilitates extensive rewiring within the apoptotic 
phosphoproteome and this finding motivated our interest in further evaluating both the 
apoptotic kinome and phosphoproteome using global mass spectrometry strategies. 
2.4.2 Evaluating variations within the kinome of HeLa cells treated 
with doxorubicin 
To enrich for the apoptotic human kinome, we processed healthy and apoptotic 
proteomes using MIBs composed of broad specificity ATP-competitive protein kinase 
inhibitors (36).  We observed capture of ~30% of the human kinome, which is only 
marginally lower than previously reported values obtained using related enrichment 
procedures and comparable MIB mixtures (36, 37, 51).  We attribute differences in 
enrichment to the apoptotic proteolysis of protein kinases, which may disrupt active site 
specificity and interfere with binding to ATP-competitive protein kinase inhibitors.  
Overall, the broad coverage of the kinome in our dataset, as demonstrated by the 
representation of each kinase family in our kinome profile, offers insights concerning the 
impact of doxorubicin on various kinase families.  Within our kinome profile we 
observed distinct variations in response to apoptotic doxorubicin treatment in HeLa cells.  
Notable protein kinases that were up-regulated (log2 ratio > 0.5) or down-regulated (log2 
ratio < –0.5) in our kinome profile include Bub1 and Fyn, respectively.  The former, 
Bub1, is a serine/threonine protein kinase essential in the formation of the mitotic spindle 
checkpoint and in the establishment of chromosome congression (92); the latter, Fyn, is 
classified as a Src family non-receptor tyrosine kinase and, as a regulator of many 
biological processes related to cell growth and proliferation, is often exploited by cancer 
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cells to support progression and metastasis (93).  Perera et al., (94), demonstrated that 
Bub1 is susceptible to cleavage by caspases-3, -6 and -7 and provided evidence 
suggesting that cleavage deregulates Bub1 activity.  Additionally, Bub1 is implicated as a 
component of apoptotic cell death pathways associated with spindle-damaging agents and 
topoisomerase poisons, including doxorubicin (95).  Intriguingly, Fyn is a well-
documented example of apoptotic kinase–caspase crosstalk.  Together with Src and Lyn, 
Fyn mediates anti-apoptotic signaling by suppressing caspase-8 activation through 
phosphorylation of tyrosine 397 (‘a’ isoform) or 380 (‘b’ isoform).  Furthermore, 
consequent to apoptotic induction, Fyn is proteolytically processed by caspase-3, which 
induces enhanced kinase activity and subcellular translocation to the cytoplasm (79, 80, 
96–98).   
In parallel with our assessment of kinome remodeling during apoptosis, we also 
examined phosphorylation sites on the protein kinases within our dataset as many protein 
kinases are activated by trans- or auto-phosphorylation.  Specifically, we observed 
marked increases in activating phosphorylation sites on MAPK1 (threonine 185 and 
tyrosine 187) suggesting up-regulation of the MAPK pathway; while, increased 
phosphorylation of MAPK14 (p38α) on tyrosine 182, in the absence of phosphorylated 
threonine 180, suggests down-regulation of p38 MAPK pathways (99, 100).  
Additionally, inactivating phosphorylation of tyrosine 15 on a variety of closely related 
CDKs indicates downregulation of cell cycle progression (101).  Finally, we also 
observed striking down-regulation of phosphorylation on serine 350 of RIOK2.  
Although this site on RIOK2 is frequently documented in high-throughput studies, the 
biological relevance is currently unknown (55).  Considering our kinome samples were 
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not specifically enriched for comprehensive phosphoproteome analysis, our evaluations 
of these phosphorylation sites are interpreted qualitatively.  Regardless, these findings 
pose intriguing questions with respect to the activity and regulation of protein kinases in 
response to apoptotic doxorubicin treatment.  
2.4.3 Assessing the phosphorylation landscape of HeLa cells 
treated with doxorubicin 
Consistent with observations from our profile suggesting distinct variations within 
the kinome, we observed extensive hypo- and hyper-phosphorylation of numerous 
phosphosites in our quantitative evaluation of the doxorubicin-induced apoptotic 
phosphoproteome. As previously mentioned, doxorubicin is a DNA damaging agent 
acting through inhibition of the enzyme topoisomerase II and by intercalation with DNA 
(58, 61).  Unable to efficiently repair DNA breaks, cells accumulate occurrences of DNA 
damage, which stalls proliferation and ultimately triggers apoptotic cell death (58, 61, 
62).  Analysis of our phosphoproteomics data using PHOXTRACK revealed increased 
activity of both ATR and ATM protein kinases.  ATR and ATM are serine/threonine 
protein kinases belonging to the phosphatidylinositol-3-kinase-like kinase (PIKK) family 
and, as both are involved in DNA damage sensing signaling pathways, it is unsurprising 
that we observed hyper-phosphorylation of ATR and ATM substrates (102).  With 
respect to both ATR and ATM up-regulation, we observed hyper-phosphorylation of 
COP9 signalosome complex subunit 1 (COPS1) on serine 474, which is involved in the 
DNA damage response and apoptotic induction (103).  Furthermore, our data revealed 
increased phosphorylation of serine 314 on Bub1, a protein kinase up-regulated in our 
kinome profiling dataset.  ATM-mediated phosphorylation of this site is required for 
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Bub1 activity and considering Bub1 is a validated substrate of caspases, hyper-
phosphorylation at this site supports the notion that Bub1 activity is deregulated in 
response to doxorubicin treatment (94, 104).   
Lastly, our PHOXTRACK analysis revealed bidirectional alterations in 
phosphorylation site occupancies for substrates attributed to protein kinase CK2.  Protein 
kinase CK2 is ubiquitously expressed and distinguished from other protein kinases 
because it is a constitutively active serine/threonine protein kinase.  Despite unclear 
regulatory mechanisms, CK2 participates in a number of vital, highly-regulated signaling 
pathways, with an extensive body of literature implicating CK2 as a participant in the 
DNA damage response, DNA damage repair pathways and as an important regulator of 
apoptosis (105).  From the substrates identified in our analysis, we observed both hypo- 
and hyper-phosphorylation suggesting that CK2 activity is coordinated by mechanisms 
that facilitate distinct phosphorylation events.  For example, we observed differential 
phosphorylation of two separate CK2 phosphorylation sites, serine 2 and serine 67, 
previously validated in experimental studies on eukaryotic translation initiation factor 2 
subunit 2 (EIF2S2) (106, 107).  Our data revealed hypo-phosphorylation of serine 2 and 
hyper-phosphorylation of serine 67.  Interestingly, serine 2 is specifically characterized as 
a CK2 holoenzyme phosphorylation site, indicating that phosphorylation is CK2β-
dependent and raising intriguing considerations regarding independent roles for 
holoenzyme CK2 (CK2α2β2, CK2α’2β2, or CK2αα’β2) and free CK2 catalytic subunits 
(CK2α or CK2α’) in pathways related to DNA damage and apoptosis (108).  
Furthermore, both serine 2 and serine 67 are dephosphorylated by protein phosphatase-1, 
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which brings to light the activity of phosphatases in the regulation of phosphosite 
occupancy and as a potential dimension of CK2 regulation (109).   
Overall, investigation of doxorubicin treatment in HeLa cells using kinome 
profiling and phosphoproteomics revealed distinct variations within the kinome coupled 
with significant changes observed within the phosphoproteome.  Collectively, our study 
demonstrates the influence of apoptotic-driven proteolysis on phosphotransferase 
signaling and highlights the emergence of global strategies for systematically 
investigating protein kinase activity and phosphorylation in response to doxorubicin.   
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Supplementary Table 2.1 List of protein kinases identified in the DegraBase. 
Experimental details from the DegraBase dataset (38) for identified protein kinases. 
 
Protein 




AAK1 Other NAK Q2M2I8 Jurkat bortezomib F 
ABL TK Abl P00519 RPMI 8226 Myeloma Doxorubicin D 
ADCK3 Atypical ABC1 Q8NI60 MM1S, DB, Jurkat Staurosporine, Bortezomib, Doxorubicin F 
ADCK4 Atypical ABC1 Q96D53 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined K 
AKT1 AGC Akt P31749 MM1S, DB, Jurkat Staurosporine, Bortezomib, Doxorubicin D 
ATM Atypical PIKK Q13315 MM1-S bortezomib D 
BARK1 AGC GRK P25098 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
BAZ1A Atypical BAZ Q9NRL2 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
BAZ1B Atypical BAZ Q9UIG0 MM1-S bortezomib D 
BCKDK Atypical PDHK O14874 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined R 
BCR Atypical BCR P11274 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined R 
BIKE Other NAK Q9NSY1 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined H 
BMPR1B TKL STKR O00238 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined K 
BRAF TKL RAF P15056 MM1-S bortezomib D 
BRD2 Atypical BRD P25440 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined - 
BRD4 Atypical BRD O60885 Jurkat Etoposide D 
BUB1 Other BUB O43683 MM1-S bortezomib D 
BUBR1 Other BUB O60566 Jurkat bortezomib M 
CaMK4 CAMK CAMK1 Q16566 Jurkat bortezomib A 
CaMKK2 Other CAMKK Q96RR4 MM1-S bortezomib C 
CCK4 TK CCK4 Q13308 Jurkat bortezomib T 
CDK4 CMGC CDK P11802 U266 bortezomib K 
CDK6 CMGC CDK Q00534 Jurkat bortezomib D 
CHED CMGC CDK Q14004 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
CHK1 CAMK CAMKL O14757 U266 bortezomib D 
CHK2 CAMK RAD53 O96017 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined Y 
CK1d CK1 CK1 P48730 Jurkat bortezomib R 
CK2a2 CMGC CK2 P19784 Jurkat Etoposide L 
Col4A3BP Atypical Col4A3BP Q9Y5P4 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined E 
CRK7 CMGC CDK Q9NYV4 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined T 








DRAK1 CAMK DAPK Q9UEE5 Jurkat Etoposide - 
FRAP Atypical PIKK P42345 DB Lymphoma Doxorubicin D 
FYN TK Src P06241 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
GAK Other NAK O14976 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined C 
GPRK6 AGC GRK P43250 MM1S, DB, Jurkat Staurosporine, Bortezomib, Doxorubicin D 
HPK1 STE STE20 Q92918 DB Lymphoma Doxorubicin P 
KSR1 TKL RAF Q8IVT5 MM1-S bortezomib P 
LCK TK Src P06239 Jurkat bortezomib N 
LMR2 TK Lmr Q8IWU2 U266 bortezomib D 
LOK STE STE20 O94804 MM1S, DB, Jurkat Staurosporine, Bortezomib, Doxorubicin D 
LYN TK Src P07948 U266 bortezomib T 
MAP2K1 STE STE7 Q02750 MM1S, DB, Jurkat Staurosporine, Bortezomib, Doxorubicin D 
MAP2K2 STE STE7 P36507 MM1-S bortezomib L 
MAP2K3 STE STE7 P46734 U266 bortezomib M 
MAP3K5 STE STE11 Q99683 U266 bortezomib D 
MARK1 CAMK CAMKL Q9P0L2 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
MARK2 CAMK CAMKL Q7KZI7 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined N 
MNK1 CAMK MAPKAPK Q9BUB5 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined M 
MSK2 AGC RSK O75676 MM1-S bortezomib D 
MST1 STE STE20 Q13043 MM1S, DB, Jurkat Staurosporine, Bortezomib, Doxorubicin T 
MST3 STE STE20 Q9Y6E0 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
MST4 STE STE20 Q9P289 RPMI 8226 Myeloma Doxorubicin K 
NEK1 Other NEK Q96PY6 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
NEK4 Other NEK P51957 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
NEK9 Other NEK Q8TD19 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined L 
OSR1 STE STE20 O95747 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined L 
p38a CMGC MAPK Q16539 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined Y 
PAK1 STE STE20 Q13153 MM1-S bortezomib R 
PAK2 STE STE20 Q13177 DB Lymphoma Doxorubicin D 
PAN3 Other PAN3 Q58A45 MM1-S bortezomib D 
PBK Other TOPK Q96KB5 Jurkat bortezomib C 
PCTAIRE1 CMGC CDK Q00536 MM1S, DB, Jurkat Staurosporine, Bortezomib, Doxorubicin S 
PDHK1 Atypical PDHK Q15118 DB Lymphoma Doxorubicin F 
PDK1 AGC PDK1 O15530 Jurkat bortezomib L 
PFTAIRE1 CMGC CDK O94921 MM1-S bortezomib Q 








PIM2 CAMK PIM Q9P1W9 MM1-S bortezomib - 
PITSLRE CMGC CDK P21127 Jurkat Etoposide D 
PKCi AGC PKC P41743 U266 bortezomib D 
PKD3 CAMK PKD O94806 MM1-S bortezomib R 
PRPK Other Bud32 Q96S44 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined R 
PYK2 TK FAK Q14289 MM1-S bortezomib D 
QSK CAMK CAMKL Q9Y2K2 MM1-S bortezomib D 
RAF1 TKL RAF P04049 U266 bortezomib H 
RIOK1 Atypical RIO Q9BRS2 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
RIOK2 Atypical RIO Q9BVS4 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined N 
RIPK1 TKL RIPK Q13546 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
RIPK3 TKL RIPK Q9Y572 MM1-S bortezomib D 
ROCK2 AGC DMPK O75116 MM1S, DB, Jurkat Staurosporine, Bortezomib, Doxorubicin D 
SLK STE STE20 Q9H2G2 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
SRC TK Src P12931 Jurkat Etoposide D 
SRPK1 CMGC SRPK Q96SB4 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined Q 
SRPK2 CMGC SRPK P78362 DB Lymphoma Doxorubicin L 
STLK3 STE STE20 Q9UEW8 DB Lymphoma Doxorubicin D 
TAK1 TKL MLK O43318 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined R 
TIF1a Atypical TIF1 O15164 U266 bortezomib A 
TIF1b Atypical TIF1 Q13263 DB Lymphoma Doxorubicin D 
TIF1g Atypical TIF1 Q9UPN9 DB Lymphoma Doxorubicin D 
TLK2 Other TLK Q86UE8 MM1S, DB, Jurkat Staurosporine, Bortezomib, Doxorubicin D 
VACAMK
L CAMK CAMK-Unique Q8NCB2 Jurkat 
Staurosporine (2uM) or TRAIL 
(2nM), extracts combined D 
VRK1 CK1 VRK Q99986 DB Lymphoma Doxorubicin D 
Wnk1 Other WNK Q9H4A3 DB Lymphoma Doxorubicin D 
ZAP70 TK Syk P43403 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined N 
ZC2/TNIK STE STE20 Q9UKE5 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 




Supplementary Table 2.2 List of catalytic and regulatory phosphatase subunits 
identified in the DegraBase. 
Experimental details from the DegraBase dataset (38) for identified catalytic and 
regulatory phosphatase subunits. 
 
 Gene Name Class Sub-class 
Uniprot 





ACP1 PTP LMW-PTP P24666 MM1-S bortezomib D 
CDC25B PTP CDC25 P30305 MM1S, DB, Jurkat 
Staurosporine, Bortezomib, 
Doxorubicin R 
DUSP12 PTP Atypical DSP Q9UNI6 Jurkat bortezomib Q 
DUSP23 PTP Atypical DSP Q9BVJ7 U266 bortezomib M 





DUSP6 PTP MKP Q16828 U266 bortezomib - 
GAK PTP PTEN O14976 Jurkat Etoposide A 
ILKAP PPM PPM Q9H0C8 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
INPP5D LP INPP5 Q92835 U266 bortezomib S 
INPP5F LP INPP5 Q9Y2H2 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined F 
LOC28387
1 HAD HAD A6NDG6 Jurkat 
Staurosporine (2uM) or TRAIL 
(2nM), extracts combined L 
MINPP1 LP INPP5 Q9UNW1 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined C 
MTMR2 PTP MTMR Q13614 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
MTMR3 PTP MTMR Q13615 U266 bortezomib D 
MTMR4 PTP MTMR Q9NYA4 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined S 
NUDT3 NUDT NUDT O95989 Jurkat bortezomib Y 
PPA1 LP INPP5 Q15181 MM1-S bortezomib R 
PPA2 LP INPP5 Q9H2U2 MM1-S bortezomib F 
PPM1G PPM PPM O15355 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined N 
PPM1N PPM PPM Q8N819 MM1S, DB, Jurkat 
Staurosporine, Bortezomib, 
Doxorubicin S 
PPP1CA PPP PPP P62136 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined K 
PPP1CC PPP PPP P36873 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined K 
PPP6C PPP PPP O00743 Jurkat bortezomib M 
PSPH HAD HAD P78330 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined C 
PSPH PPM PPM Q8NI37 MM1S, DB, Jurkat 
Staurosporine, Bortezomib, 
Doxorubicin R 
PTPN1 PTP NRPTP P18031 Jurkat bortezomib N 
PTPN12 PTP NRPTP Q05209 MM1-S bortezomib V 
PTPN3 PTP NRPTP P26045 MM1-S bortezomib D 
PTPRC-1 PTP RPTP P08575 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined L 
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 Gene Name Class Sub-class 
Uniprot 




PTPRZ1-1 PTP RPTP P23471 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined N 
SSH2 PTP SSH Q76I76 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
TNS3 PTP PTEN Q68CZ2 MM1-S bortezomib L 
Regulatory 
ANP32D RS PP1 RS O95626 Jurkat Etoposide I 
CABIN1 RS PPP3CA RS Q9Y6J0 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
PHACTR2 RS PP2A RS O75167 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined A 
PHACTR4 RS PP2A RS Q8IZ21 MM1-S bortezomib D 
PPP1R12A RS PP1 RS O14974 Jurkat bortezomib D 
PPP1R14B RS PP1 RS Q96C90 MM1-S bortezomib D 
PPP1R2 RS PP1 RS P41236 Jurkat bortezomib S 
PPP1R8 RS PP1 RS Q12972 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined V 
PPP2R1A RS PP2A RS P30153 U266 bortezomib R 
PPP2R5C RS PP2A RS Q13362 Jurkat Etoposide D 
PPP4R1 RS PPP4 RS Q8TF05 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined D 
PPTC7 RS PPP6 RS Q9UPN7 Jurkat Etoposide D 
SAPS3 RS PPP6 RS Q5H9R7 Jurkat Staurosporine (2uM) or TRAIL (2nM), extracts combined F 








Supplementary Figure 2.1 Frequency distribution of L-lysine (4,4,5,5-D4) and L-
arginine (13C6) amino acid incorporation in HeLa cells. 
HeLa cells were adapted in “light” (K0, R0) or “heavy” (K4, R6) DMEM medium over 
20 days with 5 sub-passages.  A sample of the “heavy” incorporated cells was processed 
for LC-MS/MS analysis and peptides were quantified using MaxQuant (v1.5.3.8).  
Distribution is representative of all quantified lysine (K4) and arginine (R6) peptides 
















Supplementary Figure 2.2 Identification and quantification of protein kinases 
identified in the label-swap control kinome enrichment dataset. 
SILAC-labeled HeLa cells treated with DMSO (“heavy”, control) or 5 µM doxorubicin 
(“light”, treatment) for six hours were harvested and processed using Multiplexed 
Inhibitor Beads to enrich for the active kinome.  Raw mass spectra were acquired by LC-
MS/MS and peptides were identified and quantified using MaxQuant (v1.5.3.8).  The 
log2(Doxorubicin/DMSO) ratio for identified protein kinases is shown. Protein kinases 
with log2(Doxorubicin/DMSO) ratios less than –0.5 or greater than 0.5 are labeled in blue 





























































































































































































































Supplementary Figure 2.3 Quantification of protein kinase phosphorylation sites in 
the label-swap control kinome enrichment dataset. 
Protein kinases identified in the label-swap kinome enrichment dataset containing 
quantified phosphorylation sites with a phosphosite localization probability exceeding 



















































































Supplementary Figure 2.4 Frequency distribution of protein groups in HeLa cells 
treated with doxorubicin. 
Whole proteome samples from SILAC-labelled HeLa cells treated with DMSO (“light”, 
control) or 5 µM doxorubicin (“heavy”, treatment) for six hours were processed for LC-
MS/MS analysis followed by peptide identification and quantification using MaxQuant 
(v1.5.3.8).  The mean log2(Doxorubicin/DMSO) ratio of three biological replicates for 






















Supplementary Figure 2.5 Frequency distribution of phosphorylation sites in HeLa 
cells treated with doxorubicin. 
Phosphoproteomics samples from SILAC-labelled HeLa cells treated with DMSO 
(“light”, control) or 5 µM doxorubicin (“heavy”, treatment) for six hours were processed 
for LC-MS/MS analysis followed by peptide identification and quantification using 
MaxQuant (v1.5.3.8).  The mean log2(Doxorubicin/DMSO) ratio of three biological 














Supplementary Table 2.3 List of increasing phosphorylation sites in HeLa cells 
treated with doxorubicin. 
Phosphoproteomics samples from SILAC-labelled HeLa cells treated with DMSO 
(“light”, control) or 5 µM doxorubicin (“heavy”, treatment) for six hours were processed 
for LC-MS/MS analysis followed by peptide identification and quantification using 
MaxQuant (v1.5.3.8).  Phosphopeptides with a phosphosite localization probability ≥ 
0.75 and mean log2(Doxorubicin/DMSO) ratio (3/3 biological replicates) > 1 (one-sample 
Student’s t-test, FDR < 0.05) are interpreted as significantly increased. 
 
Gene Name Uniprot ID Mean log2(Doxorubicin/DMSO) –10log(p-value) 
Phosphosite 
Position Multiplicity 
ACIN1 Q9UKV3-5 3.445122719 2.053724344 328 ___1 
ACIN1 Q9UKV3-5 1.849106312 2.054535645 240 ___2 
ACIN1 Q9UKV3-5 1.849106312 2.054535645 243 ___2 
ADNP Q9H2P0 2.092873295 2.138182602 738 ___1 
AHNAK Q09666 1.359293063 3.684800469 5110 ___1 
AHNAK Q09666 2.033385436 2.61972666 4425 ___1 
AHNAK Q09666 2.691774845 3.076217096 210 ___1 
ANLN Q9NQW6-2 2.253450712 2.952087116 755 ___1 
ANXA2;ANXA2P2 P07355 1.200777411 2.654472728 12 ___1 
ARHGEF2 Q92974-3 1.867540479 1.893472195 617 ___1 
ATXN10 Q9UBB4 2.68168354 2.097759563 430 ___1 
BCLAF1 Q9NYF8-2 1.833978136 2.338125946 181 ___1 
BCLAF1 Q9NYF8-2 1.483162522 5.082457245 283 ___1 
BRAT1 Q6PJG6 1.787764072 2.686704137 742 ___1 
BUB1 O43683-2 2.920916637 2.046918192 314 ___1 
CCDC6 Q16204 1.772054871 2.37883044 323 ___1 
CCDC82 Q8N4S0-2 1.537871281 2.481294597 131 ___1 
CCDC86 Q9H6F5 2.628060897 2.541073355 128 ___1 
CD3EAP O15446 1.258915305 1.775077662 309 ___1 
CD97 P48960-2 1.860266765 2.354240834 738 ___1 
CDC42EP4 Q9H3Q1 1.543392857 2.439745827 174 ___1 
CENPF P49454 1.47436444 1.890574321 1822 ___1 
CEP131 Q9UPN4-3 2.038653215 2.55540328 47 ___1 
CHD4 Q14839 3.814865828 2.893407513 1570 ___1 
CIC Q96RK0 1.008316139 2.403245102 173 ___1 
CLTA P09496-2 2.319726706 4.701785721 105 ___1 
CTTN Q14247-3 2.947229226 2.123993311 410 ___1 
DDX47 Q9H0S4-2 3.177045981 2.460283373 9 ___2 
DDX47 Q9H0S4-2 3.177045981 2.460283373 14 ___2 
DIDO1 Q9BTC0 1.46298333 2.706483827 1456 ___1 
DSN1 Q9H410-4 1.820591847 2.112982861 12 ___2 
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Gene Name Uniprot ID Mean log2(Doxorubicin/DMSO) –10log(p-value) 
Phosphosite 
Position Multiplicity 
DSN1 Q9H410-4 1.820591847 2.112982861 14 ___2 
DYNC1LI1 Q9Y6G9 1.023534377 2.670034971 516 ___1 
EGFR P00533 1.59991312 2.037862547 693 ___1 
EIF5B O60841 2.280592044 1.867345833 186 ___1 
EIF5B O60841 3.003089666 2.932199459 137 ___1 
EPPK1 P58107 1.367553552 2.569937449 2716 ___1 
FKBP5 Q13451 3.486485322 3.497958523 445 ___1 
FLNB O75369-8 2.300028642 3.094303692 2509 ___1 
GPS1 Q13098-5 1.909246325 1.700377175 470 ___1 
GTF3C4 Q9UKN8 3.077618837 2.989537454 652 ___1 
H1FX Q92522 2.984336853 3.450655503 2 ___1 
HDGF P51858 3.473169883 2.399194888 239 ___1 
HMGA1 P17096 1.533545931 2.9746437 102 ___1 
HNRNPA2B1 P22626 2.84132274 1.818142265 176 ___1 
HNRNPC P07910-2 2.237655878 2.073579719 108 ___1 
HNRNPH1;HNRNPH2 P31943 1.212483803 2.438300326 104 ___1 
HNRNPK P61978-3 2.321893295 3.469609074 355 ___1 
HNRNPU Q00839-2 4.270847241 2.55971781 59 ___1 
HP1BP3 Q5SSJ5 1.940969745 1.914139913 249 ___1 
HSPA4 P34932 1.807398518 2.923031677 538 ___1 
HSPB1 P04792 1.630172571 2.154865705 199 ___1 
HSPB1 P04792 3.438264688 3.388293481 15 ___1 
HSPB1 P04792 2.238997539 3.687957387 82 ___1 
HTT P42858 1.814516465 2.311439673 1874 ___1 
IQGAP2 Q13576 2.151476423 2.217772153 16 ___1 
LARP7 Q4G0J3 1.132984718 3.322659496 337 ___2 
LARP7 Q4G0J3 1.132984718 3.322659496 338 ___2 
LIMCH1 Q9UPQ0-10 2.790920258 2.32101528 493 ___1 
LMNA P02545 4.790351232 2.84633683 636 ___1 
LMNB1 P20700 2.363891681 2.726770206 23 ___1 
LMO7 Q8WWI1-3 2.271204313 2.578673445 471 ___1 
LUC7L3 O95232 3.229273717 2.637447705 148 ___1 
MAGED2 Q9UNF1 2.595431725 2.004977984 265 ___1 
MAP1B P46821 1.866456389 2.733979585 1156 ___1 
MAP1B P46821 1.140639981 2.87054159 832 ___1 
MAP1B P46821 1.184281548 2.151581391 1443 ___1 
MAPK1 P28482 2.419950088 2.068076361 185 ___2 
MAPK1 P28482 2.419950088 2.068076361 187 ___2 
MAPK14 Q16539-2 3.604261001 3.037793715 180 ___2 
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Phosphosite 
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MAPK14 Q16539-2 3.604261001 3.037793715 182 ___2 
MARCKS P29966 2.006989797 2.43452785 101 ___1 
MATR3 P43243 1.888286869 2.662039308 195 ___1 
MCM2 P49736 1.607850671 3.0355092 170 ___1 
MCM3 P25205 2.89384373 2.117658636 535 ___1 
MCM6 Q14566 3.009020487 1.796202902 762 ___1 
MCM6 Q14566 2.056039055 2.305590859 13 ___1 
MDN1 Q9NU22 1.079865992 2.33246296 4538 ___1 
MTDH Q86UE4 2.272860448 3.43196881 298 ___1 
MYBBP1A Q9BQG0 1.803384701 1.881810167 1310 ___1 
NASP P49321 3.311777512 2.780510093 421 ___1 
NCL P19338 1.538537423 3.305761695 496 ___1 
NELFE P18615 2.470294158 2.424544526 115 ___1 
NES P48681 1.423469265 1.914615639 680 ___1 
NIFK Q9BYG3 1.733186483 3.041315237 247 ___1 
NKTR P30414 1.116930048 2.99244701 463 ___1 
NUFIP2 Q7Z417 1.001739065 1.761089191 652 ___1 
NUMA1 Q14980-2 5.037610849 3.262304779 395 ___1 
NUP50 Q9UKX7-2 2.345238765 3.330977725 193 ___1 
NUP98 P52948-2 1.162121058 2.201744652 606 ___1 
OSBP P22059 1.32197845 2.539573234 193 ___1 
PAFAH1B2 P68402 3.492326578 2.792416952 2 ___1 
PALLD Q8WX93-3 3.085998694 4.139342699 511 ___1 
PDAP1 Q13442 2.629610538 2.71434938 63 ___1 
PDHA1;PDHA2 P08559 1.685111602 2.427351281 293 ___1 
PHF14 O94880 2.574981769 2.288673721 84 ___1 
PKN2 Q16513-3 1.266283393 2.875260866 535 ___1 
PNN Q9H307 2.027449886 2.70165643 381 ___1 
PPP1R2;PPP1R2P3 P41236 1.094212294 3.524151147 121 ___1 
PRKAR2A P13861-2 2.698093017 2.38698534 78 ___1 
PRKDC P78527 3.271025101 3.302276375 3205 ___1 
PSMD1 Q99460 1.383040826 3.042827032 273 ___1 
PTGES3 Q15185-4 1.933492859 2.114696865 130 ___1 
PTMA P06454-2 1.199629088 1.943201531 2 ___1 
PTRF Q6NZI2 2.895672242 2.71133615 300 ___1 
PTRF Q6NZI2 1.930823525 2.133349819 387 ___2 
PTRF Q6NZI2 1.930823525 2.133349819 389 ___2 
RABL6 Q3YEC7 2.352152268 2.51542609 599 ___1 
RAD50 Q92878 1.681531866 1.787839604 690 ___1 
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Phosphosite 
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RAD51AP1 Q96B01-3 2.203378836 1.992145733 120 ___1 
RBBP7 Q16576 3.901673476 2.244498847 3 ___1 
RBM7 Q9Y580 2.888344924 2.416748082 136 ___1 
REEP4 Q9H6H4 1.066849351 1.995338791 152 ___1 
RIF1 Q5UIP0-2 1.366450826 2.760922549 1688 ___1 
RPLP0;RPLP0P6 P05388 1.591945966 1.799296188 307 ___1 
RPLP1 P05386 2.475651105 3.276074485 104 ___1 
RPLP2;RPLP1 P05387 2.475651105 3.276074485 105 ___1 
RRP15 Q9Y3B9 1.010428031 2.167332063 11 ___1 
SART1 O43290 1.336225152 2.231765612 448 ___1 
SCAF11 Q99590-2 4.104987383 2.32108717 218 ___1 
SET Q01105-2 2.100420396 2.602814685 50 ___1 
SF3A1 Q15459 1.774837057 3.13064485 451 ___1 
SH2D4A Q9H788-2 2.983500322 2.909417314 270 ___1 
SLC4A7 Q9Y6M7-2 2.019486547 1.958457782 258 ___1 
SLC4A7;SLC4A10 Q9Y6M7-2 1.539581656 1.728965688 233 ___1 
SMARCA2 P51531-2 2.266889691 2.049879549 666 ___1 
SPAG9 O60271-4 2.214739641 2.829425936 203 ___2 
SPAG9 O60271-4 2.214739641 2.829425936 217 ___2 
SPEN Q96T58 1.30845205 1.728846998 1268 ___2 
SPEN Q96T58 1.30845205 1.728846998 1278 ___2 
SRSF2 Q01130-2 1.85309732 3.217895202 194 ___2 
SRSF2 Q01130-2 1.85309732 3.217895202 196 ___2 
SRSF4;SRSF5;SRSF6 Q13247-3 2.344811916 2.584620921 119 ___1 
SRSF7 Q16629-4 2.227180163 2.393246883 192 ___1 
STK11IP Q8N1F8 2.121111472 1.790851695 398 ___1 
STK26;STK24 Q9Y6E0-2 2.091792742 2.415552215 172 ___1 
SUB1 P53999 1.904804309 2.930153315 17 ___1 
SYNM O15061-2 1.384146174 3.447919379 1049 ___1 
TBC1D4 O60343-2 1.114317457 3.306923058 588 ___1 
TBCB Q99426-2 3.10568134 2.475672809 59 ___1 
THRAP3 Q9Y2W1 1.068575064 2.280786896 379 ___1 
THRAP3 Q9Y2W1 2.91059049 2.811827295 575 ___1 
TLE3 Q04726-2 1.018855254 2.122781053 238 ___2 
TMEM230 Q96A57 1.886511842 2.291961156 24 ___1 
TMPO P42166 1.251492739 2.480602093 66 ___2 
TMPO P42166 1.251492739 2.480602093 67 ___2 
TOMM22 Q9NS69 2.486785014 2.347863913 15 ___1 
TOP1 P11387 2.074464162 3.129876945 10 ___1 
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TP53BP1 Q12888 1.566558202 1.787026993 1067 ___1 
TP53BP1 Q12888 1.827933828 2.240665487 523 ___2 
TP53BP1 Q12888 1.827933828 2.240665487 525 ___2 
TP53BP1 Q12888 1.078379313 4.054224194 398 ___2 
TP53BP1 Q12888 1.078379313 4.054224194 394 ___2 
TPR P12270 1.659504493 2.052943861 2155 ___1 
TRA2A Q13595 2.23725152 5.322624683 2 ___1 
TRIM28 Q13263 2.559811354 2.394487254 473 ___1 
TSEN34 Q9BSV6 2.933628162 2.543495991 136 ___1 
TWISTNB Q3B726 1.991904537 2.080394285 316 ___1 
UBXN7 O94888 1.175793568 2.023564259 288 ___1 
UTP14A Q9BVJ6-3 2.761488914 2.916124045 401 ___1 
XRN2 Q9H0D6-2 1.002392411 2.858950723 423 ___1 
YWHAE P62258 1.122020841 2.907899754 210 ___1 
YY1 P25490 1.098869681 3.620590345 247 ___1 
ZC3H7B Q9UGR2-2 1.154866536 2.113248308 217 ___2 
ZNF326 Q5BKZ1 3.582449357 3.094586841 478 ___1 




Supplementary Table 2.4 List of decreasing phosphorylation sites in HeLa cells 
treated with doxorubicin. 
Phosphoproteomics samples from SILAC-labelled HeLa cells treated with DMSO 
(“light”, control) or 5 µM doxorubicin (“heavy”, treatment) for six hours were processed 
for LC-MS/MS analysis followed by peptide identification and quantification using 
MaxQuant (v1.5.3.8).  Phosphopeptides with a phosphosite localization probability ≥ 
0.75 and mean log2(Doxorubicin/DMSO) ratio (3/3 biological replicates) < –1 (one-
sample Student’s t-test, FDR < 0.05) are interpreted as significantly decreased. 
 
Gene Name Uniprot ID Mean log2(Doxorubicin/DMSO) –10log(p-value) 
Phosphosite 
Position Multiplicity 
ABLIM1 O14639-4 -1.008186579 3.469407928 209 ___1 
AFF4 Q9UHB7 -4.982061863 3.304217856 914 ___2 
AFF4 Q9UHB7 -5.150780042 2.169051847 913 ___2 
AFF4 Q9UHB7 -4.813322862 2.384353075 918 ___2 
AGFG1 P52594-2 -1.364496748 1.805231722 181 ___1 
AHNAK Q09666 -1.51175185 2.589110004 41 ___1 
AHNAK Q09666 -1.034849286 3.601318418 5731 ___1 
AHNAK Q09666 -2.093562206 2.102872773 5739 ___1 
AHNAK Q09666 -1.240979513 1.833448659 5857 ___1 
AHNAK Q09666 -1.307419538 2.746788507 5749 ___2 
AHNAK Q09666 -1.266950647 2.861065585 5752 ___2 
AHNAK2 Q8IVF2-3 -1.547155499 2.240511457 194 ___2 
AJUBA Q96IF1 -1.324391246 2.780907532 119 ___1 
AKAP13 Q12802-4 -1.223625302 2.542131763 983 ___1 
AKT1S1 Q96B36 -1.252607703 1.886343476 246 ___1 
ARFGEF2 Q9Y6D5 -1.460686445 4.096719338 277 ___1 
ARHGEF2 Q92974-3 -1.259120822 2.315232367 147 ___1 
BAIAP2 Q9UQB8-3 -1.236555298 2.434013454 454 ___1 
BCL9L Q86UU0-3 -1.22066617 2.730018289 88 ___1 
BUD13 Q9BRD0 -1.261236946 2.202702635 163 ___2 
BUD13 Q9BRD0 -1.261236946 2.202702635 159 ___2 
C12orf45 Q8N5I9 -1.320540547 2.025482417 178 ___1 
C5orf30 Q96GV9 -1.01078848 2.150828116 25 ___1 
CCDC86 Q9H6F5 -1.137454629 2.016502773 102 ___2 
CCNL1 Q9UK58 -1.500464559 2.454056938 335 ___2 
CDC42EP1 Q00587-2 -1.597127875 2.013420094 121 ___1 
CDC42EP4 Q9H3Q1 -1.823880593 2.936825994 64 ___1 
CDC42EP4 Q9H3Q1 -2.042021314 2.044659231 292 ___2 
CDC42EP4 Q9H3Q1 -2.042021314 2.044659231 295 ___2 
CEP170 Q5SW79-2 -2.145803253 1.858985815 1014 ___1 
CFL1 P23528 -1.005385598 2.006111409 3 ___1 
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Phosphosite 
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CFL2 Q9Y281 -1.230885386 2.580744021 3 ___1 
CSF1 P09603-3 -1.05342108 2.498711577 235 ___1 
CTNND1 O60716-8 -2.569006046 2.08997083 252 ___1 
CTNND1 O60716-8 -1.605209311 2.270085003 230 ___1 
CTNND1 O60716-8 -1.0974406 1.771524925 893 ___1 
CTNND1 O60716-8 -1.357889652 1.766308457 201 ___1 
CTNND1 O60716-8 -1.487185955 2.378418336 349 ___2 
CTNND1 O60716-8 -1.487185955 2.378418336 352 ___2 
CXorf38 Q8TB03-2 -1.020848791 1.89339031 195 ___1 
DDX21 Q9NR30 -3.069532235 2.415034335 71 ___1 
DDX21 Q9NR30 -1.543627818 2.357184091 89 ___1 
DDX21 Q9NR30 -1.008890529 3.313976802 121 ___1 
DFFA O00273 -1.315046708 2.478467705 315 ___1 
DHX57 Q6P158-3 -1.275666595 2.465050297 25 ___1 
DKC1 O60832 -1.175106605 2.437581898 21 ___1 
DOCK7 Q96N67-4 -1.456828475 2.808140082 900 ___1 
EHD1 Q9H4M9 -1.176741759 2.143166654 456 ___1 
EIF3J O75822 -1.23109591 3.262907186 11 ___1 
EIF4A3 P38919 -1.661980311 2.595117689 12 ___1 
EIF4G2 P78344 -1.277678092 2.603648165 508 ___1 
EPB41L1 Q9H4G0 -1.468859593 1.919437982 784 ___1 
FAM129A Q9BZQ8 -1.485904813 1.718599293 602 ___1 
FAT4 Q6V0I7-2 -1.032571316 1.895376674 3117 ___1 
FLNA P21333-2 -1.265611728 2.715678331 1084 ___1 
FLNB O75369-8 -1.186017891 2.075442188 983 ___1 
FMNL1 O95466 -2.044183969 3.178173716 184 ___1 
FNBP1L Q5T0N5-3 -1.079731822 2.344125626 295 ___1 
FNDC3B Q53EP0 -1.535922567 2.990346658 208 ___1 
GTF2F1 P35269 -2.072934628 1.914325768 433 ___1 
GTF3C2 Q8WUA4 -1.051711102 1.886750069 167 ___1 
HEATR6 Q6AI08 -1.56291616 4.072095355 643 ___1 
HIST1H1B P16401 -2.947252194 2.649351433 11 ___2 
HIST1H1D P16402 -3.088653485 2.770377948 18 ___1 
HIST1H1E P10412 -2.919988553 2.933474952 18 ___1 
HIST1H1E P10412 -2.020322959 2.371266984 18 ___2 
HMGA1 P17096-2 -2.119485577 2.574698605 42 ___1 
HNRNPA1 P09651-3 -1.221868396 2.109217067 4 ___2 
HNRNPA1 P09651-3 -1.221868396 2.109217067 6 ___2 
HNRNPA2B1 P22626 -1.139931321 1.795928994 259 ___1 
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Phosphosite 
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INF2 Q27J81-2 -1.686637004 2.221043458 1147 ___1 
IRF2BP2 Q7Z5L9-2 -1.904410919 2.658150985 175 ___1 
IRS2 Q9Y4H2 -1.920812885 2.143788432 1176 ___1 
IRS2 Q9Y4H2 -1.659488082 1.749791235 1162 ___2 
KIAA1522 Q9P206-2 -1.630240679 2.460431337 604 ___1 
KIF1B O60333-2 -2.757261038 2.29493457 1384 ___3 
KIF1B O60333-2 -2.757261038 2.29493457 1383 ___3 
KLC1 Q07866-6 -1.153081656 2.639548955 460 ___1 
LMNB1 P20700 -2.272111336 3.112209892 23 ___2 
LMNB1 P20700 -2.427670399 2.645745839 391 ___2 
LMNB1 P20700 -2.427670399 2.645745839 393 ___2 
LMNB1 P20700 -2.272111336 3.112209892 20 ___2 
LMNB2 Q03252 -2.427670399 2.645745839 405 ___2 
LMNB2 Q03252 -2.427670399 2.645745839 407 ___2 
LMO7 Q8WWI1-3 -1.295454701 1.836792098 714 ___1 
LRRFIP1 Q32MZ4-3 -1.21660912 1.879187382 658 ___1 
MAP1B P46821 -1.164312919 3.118287396 1378 ___1 
MAP1B P46821 -1.876564741 1.882441093 1427 ___1 
MAP1B P46821 -1.439874013 3.575981896 1653 ___1 
MAP1B P46821 -1.174640218 3.807730653 1915 ___1 
MAP1B P46821 -1.352761626 2.560831682 1376 ___2 
MAP1B P46821 -1.352761626 2.560831682 1378 ___2 
MAP1B P46821 -1.846069733 2.430011122 2209 ___2 
MAP1B P46821 -1.846069733 2.430011122 2211 ___2 
MAP1B P46821 -1.182659864 2.921476749 1298 ___2 
MAP1B P46821 -1.182659864 2.921476749 1312 ___2 
MAP1B P46821 -1.312065085 3.432370109 1265 ___3 
MAP1B P46821 -1.405690352 2.626354149 1252 ___3 
MAP4 P27816 -1.26690499 2.634975938 825 ___1 
MAP4 P27816 -1.205243965 2.110118482 571 ___1 
MAP7D1 Q3KQU3-4 -1.258776267 2.27987265 428 ___1 
MARCKS P29966 -2.319296797 2.01430562 167 ___1 
MKI67 P46013 -1.926194986 2.22297147 1329 ___1 
MKL1 Q969V6 -1.27248919 2.688959932 454 ___2 
MPRIP Q6WCQ1 -1.094599684 2.722694876 220 ___2 
MPRIP Q6WCQ1 -1.094599684 2.722694876 224 ___2 
MSL2 Q9HCI7-2 -5.314965089 3.697189769 427 ___1 
MTA1 Q13330-3 -1.060514549 2.151861283 559 ___1 
MYL12A;MYL12B;MYL9 P19105 -1.094291091 2.147427952 18 ___1 
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Phosphosite 
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MYL12A;MYL12B;MYL9 P19105 -1.489275694 1.698515979 19 ___2 
MYL12A;MYL12B;MYL9 P19105 -1.489275694 1.698515979 18 ___2 
MYO18A Q92614-2 -1.007843753 1.720216595 1639 ___2 
MYO18A Q92614-2 -1.007843753 1.720216595 1643 ___2 
NDRG1 Q92597-3 -2.544863065 1.730539903 285 ___1 
NIFK Q9BYG3 -2.268937429 3.253004036 223 ___1 
NMT1 P30419 -1.260552128 1.924503408 47 ___1 
NOLC1 Q14978 -3.167283456 2.64068527 607 ___2 
NOLC1 Q14978 -3.167283456 2.64068527 610 ___2 
NOP2 P46087-2 -1.805014928 4.195511725 728 ___1 
NOP56 O00567 -1.533662796 2.298294241 519 ___2 
NOP56 O00567 -1.533662796 2.298294241 520 ___2 
NSRP1 Q9H0G5 -1.723871668 3.035633095 275 ___1 
NUCKS1 Q9H1E3 -2.360790809 2.085229743 181 ___2 
NUCKS1 Q9H1E3 -2.360790809 2.085229743 179 ___2 
NUP98 P52948-2 -1.007203897 3.603984477 871 ___1 
OCIAD1 Q9NX40 -1.794628302 2.091684044 108 ___1 
PAICS P22234 -1.810295383 3.516824679 27 ___1 
PCM1 Q15154-2 -1.116994262 2.969427007 1675 ___1 
PDCD5 O14737 -1.025170883 3.018504037 119 ___1 
PPFIBP1 Q86W92-3 -1.041020036 1.949114005 313 ___1 
PPP1R35 Q8TAP8 -1.090385675 2.761680285 52 ___1 
PPP1R7 Q15435 -1.127146641 2.141240282 24 ___2 
PPP1R7 Q15435 -1.127146641 2.141240282 27 ___2 
PRPF38B Q5VTL8 -1.587273916 2.868424187 529 ___1 
PRPF40A O75400-2 -1.317138751 3.623202725 346 ___1 
PRPSAP2 O60256-3 -1.289063374 2.113892935 227 ___1 
PTPN2 P17706-2 -1.302081505 3.328852472 304 ___1 
PXN P49023 -1.923183084 2.239197998 118 ___1 
RBM25 P49756 -1.473005851 2.418896602 677 ___1 
RBM6 P78332 -1.822484175 2.677080244 362 ___1 
RBM8A Q9Y5S9-2 -1.521348437 2.77317826 24 ___1 








P49792 -1.300743659 2.350331764 2450 ___2 
RNASEH2B Q5TBB1-2 -1.252291123 2.028529111 240 ___1 
RPTOR Q8N122-3 -1.073676507 1.955446735 701 ___2 
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Gene Name Uniprot ID Mean log2(Doxorubicin/DMSO) –10log(p-value) 
Phosphosite 
Position Multiplicity 
RPTOR Q8N122-3 -1.073676507 1.955446735 705 ___2 
RRBP1 Q9P2E9-2 -1.275932193 1.928659227 615 ___1 
RSF1 Q96T23-2 -1.902169585 2.447358235 366 ___1 
RSF1 Q96T23-2 -1.11229223 1.857015317 1328 ___2 
SF3B1 O75533 -2.858277321 3.232956894 142 ___1 
SF3B1 O75533 -2.1625549 2.115508334 129 ___2 
SF3B1 O75533 -2.1625549 2.115508334 142 ___2 
SF3B1 O75533 -2.783142249 2.660299159 223 ___2 
SF3B1 O75533 -2.783142249 2.660299159 227 ___2 
SF3B2 Q13435 -1.284618457 2.173785262 780 ___1 
SLTM Q9NWH9 -1.402377526 3.973221483 553 ___1 
SOWAHC Q53LP3 -1.96748817 2.261633173 213 ___1 
SPAG9 O60271-4 -1.232834796 1.762227977 183 ___1 
SPEN Q96T58 -1.853628715 2.093269806 1278 ___1 
SPTBN1 Q01082 -1.142913282 2.036933847 2341 ___1 
SQSTM1 Q13501 -1.351434072 2.63365709 269 ___1 
SRSF9 Q13242 -1.874054035 2.549670537 211 ___2 
SRSF9 Q13242 -1.874054035 2.549670537 216 ___2 
STIM1 Q13586 -2.705515862 1.719334766 575 ___1 
STIM1 Q13586 -1.109986742 1.830054831 616 ___1 
STT3B Q8TCJ2 -1.846175075 3.439303285 499 ___1 
SURF2 Q15527 -1.162731647 3.199973266 190 ___2 
SURF2 Q15527 -1.162731647 3.199973266 195 ___2 
SURF6 O75683 -2.015912135 2.635870754 138 ___1 
TBC1D4 O60343-2 -1.435734153 2.281194571 341 ___1 
TCOF1 Q13428-6 -1.298047026 1.704987924 1190 ___1 
TCOF1 Q13428-6 -2.759986639 2.004831793 249 ___1 
TJAP1 Q5JTD0-4 -1.098924975 2.181995455 470 ___1 
TMPO P42166 -1.482794166 1.84807784 74 ___1 
TOMM70A O94826 -1.398898323 2.241908696 91 ___1 
TOP2A P11388 -1.223467112 2.999957483 1377 ___1 
TPM1 P09493-9 -1.848123113 2.024390015 252 ___1 
TRAM1 Q15629-2 -2.205547134 2.29076817 334 ___1 
UBAP2L Q14157-4 -1.409607927 2.10020993 409 ___1 
UPF3B Q9BZI7-2 -1.771216551 2.464992575 169 ___1 
VIM P08670 -1.743216515 2.804261265 56 ___1 
WDR44 Q5JSH3-2 -1.000814199 2.553273069 50 ___1 
WDR70 Q9NW82 -1.129128456 2.672568724 638 ___1 
WDR75 Q8IWA0 -1.059688032 2.668992406 796 ___1 
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Gene Name Uniprot ID Mean log2(Doxorubicin/DMSO) –10log(p-value) 
Phosphosite 
Position Multiplicity 
WHSC1 O96028-5 -1.390792847 1.959724473 544 ___1 
YAP1 P46937-6 -2.184196949 3.669701918 238 ___1 
YAP1 P46937-6 -1.293258111 3.640238261 109 ___1 
YBX1 P67809 -1.687808077 1.922321052 165 ___1 
ZC3H15 Q8WU90 -1.144722621 2.196232843 381 ___1 
ZYX Q15942 -1.944539428 2.184689565 281 ___1 
ZYX Q15942 -3.422180891 1.947537092 259 ___1 
ZYX Q15942 -1.609148026 2.213346604 308 ___1 





Chapter 3  
3 Exploring the apoptotic degradome of HeLa cells 
treated with doxorubicin 
3.1 Introduction 
Apoptosis, a process of programmed cell death conserved across all metazoans, is 
critical during development and serves to maintain tissue homeostasis and vigor by 
efficiently dismantling needless or diseased cells (1, 2).  To prevent excessive (atrophic) 
or insufficient (cancerous) induction, apoptosis is tightly regulated and can be triggered 
either intrinsically, via the mitochondria in response to internal stress (e.g., DNA damage 
or oxidative stress) or extrinsically, via membrane receptors in response to ligand-binding 
(e.g., death receptors or dependence receptors) (2).  A common competence of cancer 
cells is the ability to evade apoptosis and persist inappropriately (3, 4).  As such, to 
combat cancer cell survival, many chemotherapies selectively induce apoptosis by 
targeting oncogenes (e.g., protein kinases, growth factors or transcription factors) to shift 
the balance between pro- and anti-apoptotic signals towards the former (5).  Other 
therapeutic strategies induce apoptosis by targeting DNA replication or repair machinery 
(e.g., topoisomerases) to exploit the hyperproliferative phenotype of cancer cells and 
consequent increased susceptibility to DNA damage (6).  Essentially, pro-apoptotic drugs 
circumvent the persistence of cancer cells by reestablishing or rewiring apoptotic 
pathways, which ultimately triggers the activation of a family of proteases known as 
caspases (cysteine-dependent aspartate-directed proteases) (7). 
Caspases orchestrate cellular degradation by post-translationally catalyzing 
selective and irreversible proteolysis within the proteome to alter the activity, function or 
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localization of substrate proteins (8).  Expressed as inert zymogens, caspases are 
activated in a hierarchical cascade beginning with the homodimerization and 
autoproteolysis of initiator caspases (-8, -9 and -10) followed by linker-region proteolysis 
of executioner caspases (-3, -6 and -7) (8).  Identifying caspase substrates is challenging 
as individual caspases exhibit distinct substrate profiles despite sharing partially 
overlapping active-site specificities and a dominant preference for cleaving C-terminal of 
aspartic acid residues (8–10).  Moreover, isolating caspase degradomes is further 
complicated by the prospect that any substrate can be cleaved by more than one caspase 
or by other cellular proteolytic enzymes (11, 12).  Given the intricacies of protease webs, 
traditional hypothesis-driven strategies used to identify substrate selectivity and active-
site specificity are insufficient for characterizing the global cellular context of protease 
degradomes (13, 14).  As such, large-scale degradomics technologies have emerged to 
systematically evaluate proteases and characterize biologically-relevant proteolytic 
cleavage products of substrates in cell-based systems (12, 14). 
Considering the prevalence of cytotoxic cancer therapies that converge on 
apoptotic induction coupled with the notion that cellular degradomes are context-specific, 
we used the TAILS (terminal amine isotope labeling of substrates) N-terminomics 
strategy to explore the apoptotic degradome of HeLa cells treated with doxorubicin, a 
clinically-relevant chemotherapy agent (12, 15–19).  Following validation of the TAILS 
method we analyzed quantified peptides in our dataset containing experimentally 
dimethylated N-termini using TopFINDer to characterize and annotate protein termini 
(20).  Notably, approximately 10% of N-terminally dimethylated peptides that were 
quantified in our N-terminomics dataset were identified as validated substrates of 
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proteases within the TopFIND knowledgebase (20, 21).  Furthermore, mapping the 
protease motif of these peptides revealed an increased incidence of protease cleavage C-
terminal to methionine residues.  N-terminally dimethylated peptides quantified 
exclusively in the doxorubicin-treated N-terminome, by contrast, showed a preference for 
Asp residues at the P1 residue of the scissile bond.  Moreover, in consideration of 
naturally blocked N-termini within our N-terminome enrichment, we identified numerous 
N-terminally acetylated peptides with aspartic acids residues upstream of the scissile 
bond.  Finally, interrogation of the DegraBase repository, using proteins identified in our 
N-terminome enrichment, revealed a high degree of overlap and we speculate that 
identified proteins unique from the DegraBase may represent bona fide substrates of 
proteases formerly unidentified in response to doxorubicin treatment (22).  Collectively, 
this study provides a broad surveillance of proteolytic processing in HeLa cells treated 
with doxorubicin and illustrates the diversity and complexity of signaling within protease 
webs.  
3.2 Materials and Methods 
3.2.1 Doxorubicin degradome preparation 
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(Thermo Scientific) containing 10% fetal bovine serum, 100 U/mL penicillin (Life 
Technologies) and 100 µg/mL streptomycin (Life Technologies) at 37˚C in an 
atmosphere supplemented with 5% CO2.  Six biological replicates (i.e., individual culture 
plates) were treated for six hours with DMSO (control, (Fisher Scientific)) or 5 µM 
doxorubicin (treatment (LC Laboratories)).  Cells were harvested and lysed in 50 mM 
Tris-HCl pH 7.5 (Bioshop), 150 mM NaCl (Bioshop), 1% NP-40 (Bioshop) and protease 
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inhibitors (0.1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), 10 µg/mL 
pepstatin A (Bioshop), 5 µg/mL aprotinin (Bioshop) and 10 µg/mL leupeptin (Sigma-
Aldrich)) for Western blot analysis or 6 M guanidine hydrochloride (EMD Millipore), 
0.9% octyl-beta-glucopyranoside (Sigma-Aldrich) and protease inhibitors (0.1 mM 
phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), 10 µg/mL pepstatin A 
(Bioshop) and 5 µg/mL aprotinin (Bioshop)) for mass spectrometry analysis.  Lysates 
were sonicated with three, 10 second pulses on ice and subsequently cleared by 
centrifugation at 16,000 × g (15 minutes, 4˚C).  Protein concentrations were determined 
using a Bradford assay (Bio-Rad) with bovine serum albumin (Thermo Scientific) as a 
standard.  Next, samples were diluted in 2× Laemmli buffer for Western blotting or 
prepared for TAILS proteomic analysis. For TAILS, 900 µg of each lysate were 
precipitated using chloroform/methanol as follows: four sample volumes of MS-grade 
freezer-cold methanol (Fisher) were added to one volume of protein sample and the 
mixtures were vortexed.  Next, two sample volumes of freezer-cold MS-grade 
chloroform (Sigma-Aldrich) were added to one volume of protein sample and the 
mixtures were vortexed.  Subsequently, ice-cold MS-grade water (Sigma-Aldrich) was 
added, mixtures were vortexed and centrifuged at 5,200 × g (10 minutes, 4˚C).  The 
aqueous methanol layer above the interphase (protein precipitate) was discarded and 750 
µL of freezer-cold MS-grade methanol was added, mixtures were vortexed and 
centrifuged at 18,000 × g (5 minutes, 4˚C).  The supernatants were removed and 
precipitates were washed three times with 1.5 mL of freezer-cold MS-grade methanol and 
centrifuged at 18,000 × g (5 minutes, 4˚C).  Pellets were partially air dried and 
resuspended in 200 µL 6 M guanidine hydrochloride (EMD Millipore) prior to TAILS 
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processing.  Protein concentrations were determined, as above, using a Bradford assay 
(Bio-Rad). 
3.2.2 Sample preparation using TAILS 
Protein N-termini enrichment by TAILS was performed largely as described 
previously (19).  Briefly, protein samples were diluted in 6 M guanidine hydrochloride 
(EMD Millipore) to 1.5 mg/mL.  To adjust the pH to 7.5, 100 mM HEPES buffer (pH 
7.5) was added.  Cysteine residues were reduced using 5 mM dithiothreitol (Sigma-
Aldrich) (60 minutes, 37˚C) prior to cysteine carbamidomethylation using 15 mM 
iodoacetamide (Sigma-Aldrich) (30 minutes, room temperature in the dark).  To block 
excess iodoacetamide, 15 mM dithiothreitol (20 minutes, room temperature) was added.  
Next, primary amino groups were dimethylated by addition of 40 mM 12CH2O and 20 
mM NaBH312CN (light formaldehyde (Sigma), light sodium cyanoborohydride (Sigma-
Aldrich); light channel) to DMSO-treated samples or 40 mM 13CD2O and 20 mM 
NaBH312CN (heavy formaldehyde (Cambridge Isotope Laboratories), light sodium 
cyanoborohydride (Sigma-Aldrich); heavy channel; +6 Da) to doxorubicin-treated 
samples.  The pH was adjusted to 6.5 using 0.5 M hydrochloric acid and samples were 
incubated at 37˚C for 18 hours overnight with gentle agitation.  After overnight 
incubation, additional 20 mM 12CH2O (DMSO) or 13CD2O (doxorubicin) and 20 mM 
NaBH312CN were added (2h, 37˚C) to ensure completion of amine labeling.  Next, 100 
mM Tris-HCl pH 6.8 (Bioshop) was added and the pH adjusted to 6-7 to quench the 
reaction (60 minutes, 37˚C).  Note, blocking of primary amines (including all free N-
termini) in TAILS is performed at the whole protein level prior to tryptic digestion.  
Next, 600 µg DMSO-treated (light) and 600 µg doxorubicin-treated (heavy) samples 
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were combined and cleaned-up by chloroform/methanol precipitation (as described 
above), resolubilized in a small volume of NaOH and pH-neutralized (7.5-8) using 50 
mM HEPES pH 7.2 (Bioshop) and subsequently digested with mass spectrometry-grade 
trypsin at a proteome:enzyme ratio of 100:1 (w/w) for 18 hours overnight at 37˚C with 
gentle agitation.  After overnight incubation, additional mass spectrometry-grade trypsin 
(proteome:enzyme 100:1 (w/w), (Pierce)) was added and incubated for 4 hours at 37˚C 
with gentle agitation.  At this point, an aliquot of ~20 µg of each sample was reserved for 
shotgun-like analysis (pre-TAILS).  Next, samples were reacted with 3-fold excess (w/w) 
HPG-ALD polymer (Flintbox) to capture internal tryptic peptides immediately followed 
by addition of 20 mM NaBH312CN (pH between 6-7).  Samples were incubated for 18 
hours overnight at 37˚C with gentle agitation.  After overnight incubation, 100 mM Tris-
HCl pH 6.8 was added to quench the reaction (30 minutes, 37˚C).  Negative selection of 
N-termini was performed by filtering the polymer bound to tryptic peptides (~80 kDa) 
with a 10-kDa-cutoff spin-filter (Millipore) as per manufacturer’s instructions.  The N-
terminome samples were fractionated (as previously described (19)) using C18-SCX-C18 
StageTips (3 layers C18, 6 layers SCX, 6 layers C18).  The pre-TAILS samples were 
cleaned-up on C18 StageTips (6 layers) by loading the sample, washing with 2% 
acetonitrile/98% H2O/0.2% formic acid and eluting with 80% acetonitrile/20% H2O/0.2% 
formic acid.  All samples were vacuum-centrifuged and peptide concentrations were 
determined using A280 readings measured on a NanoDrop™ (Thermo Scientific).  
Samples were acidified and stored at –20˚C until mass spectrometry analysis. 
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3.2.3 Peptide Identification Using Mass Spectrometry (pre-TAILS 
samples) 
The pre-TAILS peptides were loaded onto an ACQUITY UPLC Symmetry C18 
NanoAcquity, 10K, 2G V/M, 180 µm x 20 mm, 100A, 5 µm trapping column (Waters 
Corporation, Milford, MA) via a Waters NanoAcquity UPLC, at a flow rate of 10 µL/min 
for 4 minutes using 99% buffer A (0.1% formic acid) and 1% buffer B (acetonitrile, 0.1% 
formic acid).  After trapping, peptides were eluted onto the analytical column for 
separation using a 290-minute run time. Flow was established at 300 nL/min for the 
ACQUITY UPLC Peptide BEH C18 NanoAcquity Column 10K psi, 130Am 1.7 µm x 25 
mm which was held at 35˚C. The gradient initial condition was 5% buffer B. Buffer B 
then increased to 7.5% over 1 minute, 25% over 179 minutes, 32.5% over 40 minutes, 
60% over 20 minutes, 98% over 5 minutes, then held at 98% for 5 minutes, reduced to 
2% over 5 minutes, then held at 2% for 5 minutes, increased to 98% over 5 minutes, then 
held at 98% for 5 minutes, reduced to 5% over 5 minutes and finally held at 5% for 15 
minutes for re-equilibration to the initial condition. This gradient builds in a saw-tooth 
washing stage to clean the column. The LC system was directly connected to a NanoFlex 
(Thermo Electron Corp., Waltham, MA) nanospray ionization source with a source 
voltage of 2.4 KV and was interfaced to an Orbitrap Elite, VelosPro mass spectrometer. 
The mass spectrometer was controlled by Xcalibur software (Thermo, v2.7.0) and 
operated in the data-dependent mode using an FT/IT/CID Top 20 scheme.  The MS scan 
recorded the mass-to-charge ratios (m/z) of ions over the range of 400–1450 in FT 
(resolution of 120,000 at m/z 400), positive ion, profile, full MS mode using a lock mass 
(445.120025 m/z). The 20 most abundant multiply charged ions were automatically 
selected for subsequent collisional induced dissociation in ion trap mode (IT/CID) with 
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an isolation width of 2.00 Da, rapid scan rate, centroid mode, with charge state filtering 
allowing only ions of +2, +3, and +4 charged states.  Normalized collision energy was 35 
and precursor ions were then excluded from further CID for 30 seconds. 
3.2.4 Peptide identification using mass spectrometry (TAILS 
samples) 
The TAILS peptides were loaded onto an ACQUITY UPLC Symmetry C18 
NanoAcquity, 10K, 2G V/M, 180 µm x 20 mm, 100A, 5 µm trapping column (Waters 
Corporation, Milford, MA) via a Waters NanoAcquity UPLC, at a flow rate of 10 µL/min 
for 5 minutes using 99% buffer A (0.1% formic acid) and 1% buffer B (acetonitrile, 0.1% 
formic acid).  After trapping, peptides were eluted onto the analytical column for 
separation, using a 130-minute run time. Flow was established at 300 nL/min for the 
ACQUITY UPLC Peptide BEH C18 NanoAcquity Column 10K psi, 130Am 1.7 µm x 25 
mm which was held at 35˚C. The gradient initial condition was 5% buffer B. Buffer B 
then increased to 7.5% over 1 minute, 25% over 59 minutes, 32.5% over 14 minutes, 
60% over 6 minutes, 98% over 5 minutes, then held at 98% for 5 minutes, reduced to 2% 
over 5 minutes, then held at 2% for 5 minutes, increased to 98% over 5 minutes, then 
held at 98% for 5 minutes, then reduced to 5% over 5 minutes, and finally held at 5% for 
15 minutes for re-equilibration to the initial condition. This gradient builds in a saw-tooth 
washing stage to clean the column. The LC system was directly connected to a NanoFlex 
(Thermo Electron Corp., Waltham, MA) nanospray ionization source with a source 
voltage of 2.4 KV and was interfaced to an Orbitrap Elite, VelosPro mass spectrometer. 
The mass spectrometer was controlled by Xcalibur software (Thermo, v2.7.0) and 
operated in the data-dependent mode using an FT/IT/CID Top 20 scheme.  The MS scan 
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recorded the mass-to-charge ratios (m/z) of ions over the range of 400–1450 in FT 
(resolution of 120,000 at m/z 400), positive ion, profile, full MS mode using a lock mass 
(445.120025 m/z). The 20 most abundant multiply charged ions were automatically 
selected for subsequent collisional induced dissociation in ion trap mode (IT/CID) with 
an isolation width of 2.00 Da, rapid scan rate, centroid mode, with charge state filtering 
allowing only ions of +2, +3, and +4 charged states.  Normalized collision energy was 35 
and precursor ions were then excluded from further CID for 30 seconds. 
3.2.5 Data analysis of raw mass spectra 
Raw mass spectra were analyzed using MaxQuant (v1.5.3.8) and searched against 
the Swissprot-Uniprot sequence database (homo sapiens taxon, accessed December 26, 
2015).  Group-specific parameters were set using a Multiplicity of 2, with “light” and 
“heavy” dimethylation of peptide amino-termini and lysine residues designated as 
+28.0313 Da and +34.0631 Da.  Protease selectivity was set to ‘Semi-specific free N-
terminus’ using ArgC or AspC with a maximum of 2 missed cleavages.  The decoy-
database was set to “Revert” and the minimum number of amino acids in a peptide was 
set to 5, with a 1% FDR for peptide spectrum matches (PSMs) and 5% FDR for protein 
matches.  Cysteine carbamidomethylation (+57.0215 Da) was set as a fixed modification 
while methionine oxidation (+15.9949 Da), light and heavy N-terminal dimethylation 
(+28.0313 Da and +34.0631 Da), N-terminal acetylation (+42.0106 Da), N-terminal 
glutamine cyclization (–17.0266 Da), N-terminal glutamate cyclization (–18.0106 Da) 
and N-terminal carbamidomethylated cysteine cyclization (–17.0266 Da) were set as 
variable modifications (with the number of variable modifications per peptide set to 5 and 
minimum score for modified peptides set to 40).  Mass tolerances for parent ion mass 
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(MS) and fragment ion mass (MS/MS) were set to 4.5 ppm and 0.5 Da, respectively.  The 
option for second peptide search was selected, as was the use of “Match Between Runs”, 
using default matching parameters for respective pairs of samples between biological 
replicates.  
3.3 Results 
3.3.1 Verifying enrichment of the N-terminome for HeLa cells 
treated with doxorubicin 
Using a quantitative N-terminomics strategy known as TAILS, we profiled native 
and proteolytic N-termini in HeLa cells treated with doxorubicin, a clinically-relevant 
cancer chemotherapy agent (15, 19, 23).  Briefly, following proteome reduction and 
alkylation, unmodified protein N-termini and lysine side chain primary amines were 
blocked by isotopic dimethyl labeling.  Corresponding light (DMSO, control) and heavy 
(doxorubicin, treatment) proteomes were combined and digested with trypsin.  The N-
terminome (i.e., naturally blocked N-termini, unblocked N-termini and protease-
generated neo-N-termini) was then enriched using the negative selection TAILS strategy 
whereby internal tryptic peptides are reacted with HPG-ALD polymer (binds primary 
amines) and subsequently depleted by filtration.  Lastly, both the pre-enrichment trypsin 
digested proteome (preTAILS) and post-enrichment N-terminome (TAILS) were 
analyzed by LC-MS/MS and raw mass spectra were processed using MaxQuant 
(v1.5.3.8) with an FDR ≤ 1% for peptide spectrum matches (PSMs) (Figure 3.1). 
To assess the quality of our enrichment strategy, we systematically compared 
PSMs identified in the pre-enrichment (preTAILS) and post-enrichment (TAILS) datasets 




Figure 3.1 TAILS proteomic workflow for evaluating protease activity in HeLa cells 
treated with doxorubicin. 
Six biological replicates (i.e., individual culture plates) of HeLa cells were treated with 
DMSO (control) or 5 µM doxorubicin (treatment) for six hours.  Harvested cells were 
lysed and primary amines (i.e., protein N-termini and lysine residues) were dimethylated 
using light (DMSO, +28 Da, open circles) or heavy (doxorubicin-treatment, +34 Da, 
black circles) formaldehyde.  Light and heavy proteomes were pooled 1:1 (w/w) and 
digested with trypsin (preTAILS sample).  Using an HPG-ALD polymer to covalently 
bind primary amines, internal tryptic peptides were captured whereas native and neo-N-
termini blocked naturally or by isotopic dimethyl labeling were unreactive.  The 
unreactive N-terminome was subsequently enriched by negative selection using a 
filtration spin column (TAILS sample).  Fractionated samples were analyzed using LC-














































































































































Figure 3.2 Flowchart illustrating preTAILS and TAILS data analysis. 
MaxQuant (v1.5.3.8) was used to search preTAILS and TAILS raw mass spectra to 
identify peptides with unmodified or blocked N-termini (blue).  Independently, 
dimethylated (N-term) peptides in the TAILS dataset were searched using ArgC protease 
selectivity to isolate isotopically blocked internal peptides cleaved by proteases (purple).  
Dimethylated peptides with ‘H/L = valid’ ratios were considered quantitatively while 
peptides with ‘H/L = NaN’ (i.e., heavy intensity >> 0 and light intensity = 0) were 
considered qualitatively.  Acetylated (N-term) peptides in the TAILS dataset were 
searched using AspC protease selectivity to qualitatively isolate naturally blocked 
peptides cleaved by caspases (green).  Peptide spectrum matches were searched at an 
FDR ≤ 1%.  
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identifications than the TAILS dataset (Figure 3.3A).  However, the TAILS dataset 
included 21% (3354 vs 2774) more unique protein identifications (Figure 3.3B) and 
approximately four times (852 vs 169) more protein identifications from peptides with 
dimethylated N-termini than the preTAILS dataset (Figure 3.3C).  Moreover, the 
percentage of N-terminally blocked PSMs is markedly higher at 76% in the TAILS 
dataset in comparison to only 7% in the preTAILS dataset, which corresponds to ~10 
times more N-terminally blocked peptides identified in the TAILS dataset (Figure 3.4A).  
Importantly, the distribution of N-terminal modifications observed in the preTAILS 
dataset is comparable to the TAILS dataset indicating that the TAILS strategy enriches 
for all blocked N-termini proportionately (Figure 3.4B).  Natural N-terminal 
modifications including acetylation (~50%) and glutamate cyclization (~2%) together 
with experimentally dimethylated N-termini (~30%) collectively account for ~80% of all 
identified N-terminally blocked peptides.  The remaining 20% is attributed to N-terminal 
cyclization of glutamine (~15%) and carbamidomethylated cysteine (~5%) residues, 
which occur as known side reactions under the conditions employed (24).  In summary, 
using a high confidence FDR of ≤ 1% for PSMs, comparative analysis of our preTAILS 
and TAILS datasets confirmed efficient removal of internal tryptic peptides and 
successful isolation of the N-terminome for HeLa cells treated with DMSO or 
doxorubicin across six biological replicates. 
3.3.2 Analysis of N-terminally dimethylated peptides quantified 
within the N-terminome of HeLa cells treated with 
doxorubicin 
The protein level isotopic dimethyl labeling used in the TAILS N-terminomics 





Figure 3.3 Summary of blocked and unblocked peptide spectrum matches identified 
in preTAILS and TAILS N-terminome enrichment. 
Venn diagrams illustrate the overlap of A) unique peptides, B) unique proteins and C) 
unique proteins identified from N-terminally dimethylated peptides for preTAILS and 
























Figure 3.4 Distribution of N-terminal modifications for peptides identified in 
preTAILS and TAILS. 
A) Percentage of N-terminally blocked and unmodified internal tryptic peptides identified 
in the pre-enrichment (preTAILS) sample and post-enrichment (TAILS) sample. B) 
Proportion of peptides identified with dimethylated, acetylated or cyclized (glutamine, 





































enables quantitative comparison between peptide intensities identified in heavy (5 µM 
doxorubicin, treatment) and light (DMSO, control) HeLa N-terminomes (Figure 3.2). In 
total, we identified 994 dimethylated peptides with valid H/L log2 ratios and within our 
analysis of N-terminally dimethylated peptides quantified in our N-terminomics dataset, 
we only included peptides with valid log2(H/L) ratios if they were represented in at least 
four biological replicates (Supplementary Table 3.1).   
Surveying the log2(H/L) ratios of N-terminally dimethylated peptides quantified 
in both control and doxorubicin-treated HeLa cell N-terminomes revealed a positively 
skewed distribution that centers around peptides with a log2(H/L) ratio between –0.5 and 
0, which indicated a higher incidence of proteolysis in the control N-terminome than the 
doxorubicin-treated N-terminome (Figure 3.5).  To characterize and annotate protein 
termini from the N-terminally dimethylated peptides quantified in our N-terminomics 
dataset, we used an N-terminomics web tool called TopFINDer (or TopFIND ExploRer, 
v3.0), which facilitates information retrieval from the TopFIND knowledgebase (20, 21).  
TopFIND is an analysis resource that curates the identity of protein termini and details 
evidence of curated starts, proteolytic processing, alternative translation or alternative 
splicing while also indicating whether the queried peptide sequence was previously 
observed in other terminomics experiments deposited in the knowledgebase (Figure 
3.6A-B) (20, 21).  Interrogation of the TopFIND knowledgebase using N-terminally 
dimethylated peptides quantified in our N-terminomics dataset revealed that ~30% of the 
peptides we isolated were previously observed using diverse terminomics strategies 
including COFRADIC (COmbined FRActional DIagonal Chromatography) and 







Figure 3.5 Quantitative analysis of N-terminally dimethylated peptides. 
A histogram representing the log2 ratios of corresponding heavy (doxorubicin-treated) 
and light (DMSO-treated) peptides with dimethylated N-termini from the TAILS N-









































Figure 3.6 TopFINDer analysis of N-terminally dimethylated peptides. 
Using the web tool TopFINDer (v3.0) (20, 21), we analyzed our quantitative TAILS data 
to map identified N-termini to biological processes. A) The distribution and B) overlap of 
termini evidences retrieved from TopFIND include alternative splicing (Alternatively 
Spliced), UniProt annotated termini (Curated Start), termini observed in non-protease 
related terminomics experiments (Experimentally Observed), protease cleavage 
(Cleaved), alternative translation (Alternatively Translated) and termini not annotated in 
the TopFIND repository (Neo-N-termini). C) Barplot showing the number of cleavages 






























































































































substrates of various proteases (Figure 3.6C) and ~30% of our queried peptides were 
mapped to alternative splicing, alternative translation or as annotated protein termini.  
Interestingly, around 25% of our queried dataset was not identified in any of the 
aforementioned classifications surveyed by TopFIND. 
3.3.3 Qualitative characterization of peptides and corresponding 
proteins identified in the N-terminome of HeLa cells treated 
with doxorubicin 
Continuing with the analysis for N-terminally dimethylated peptides quantified in 
our N-terminomics dataset, we mapped each peptide sequence within the corresponding 
protein sequence to identify the P1 residue which, in terms of classic protease cleavage 
nomenclature, is the residue amino-terminal to the scissile bond (25).  Comparing the 
identity of the P1 residue to canonical protease specificities can provide insight into the 
protease or protease family responsible for generating the cleaved peptides identified in 
our N-terminomics analysis (13).  Specifically, considering caspases have a dominant 
specificity for aspartic acid and are activated in response to doxorubicin treatment to 
facilitate apoptotic induction, we postulate that peptides identified in our datasets with a 
P1 aspartic acid are putative substrates of caspases (8, 15–17).  For the N-terminally 
dimethylated peptides quantified in our N-terminomics dataset, we observed a broad 
spectrum of residues at P1 with methionine exhibiting striking representation (Figure 
3.7A).  Next, we evaluated the frequency of P1 residues in N-terminally dimethylated 
peptides quantified exclusively in the doxorubicin-treated N-terminome (i.e., N-
terminally dimethylated peptides with a heavy intensity >> 0 and light intensity = 0) 





Figure 3.7 Analysis of peptides and corresponding proteins identified in the N-
terminome of HeLa cells treated with doxorubicin. 
A) Distribution of P1 amino acids for peptides identified quantitatively (N-terminally 
dimethylated peptides quantified in both control and doxorubicin-treated N-terminomes) 
or B) qualitatively (N-terminally dimethylated peptides identified exclusively in the 
doxorubicin-treated N-terminome and N-terminally acetylated peptides with C-terminal 
































peptides quantified in both heavy and light channels, we observed a higher incidence of 
P1 aspartic acid residues (Figure 3.7B).  Moreover, when we considered peptides with 
naturally acetylated N-termini using AspC as the protease specificity in our MaxQuant 
search (Figure 3.2, Supplementary Table 3.3), we identified an additional 118 peptides 
with aspartic acid residues in the P1 position (Figure 3.7B).  Subsequently, we compared 
proteins identified in our N-terminome enrichment to the DegraBase repository of 
apoptotic N-termini to identify proteins that were previously observed within apoptotic 
degradomes (22).  Approximately 70% of proteins corresponding to N-terminally 
dimethylated peptides in our N-terminomics dataset overlapped with the DegraBase 
repository while only 27% of proteins corresponding to N-terminally acetylated peptides 
in our N-terminomics dataset overlapped with the DegraBase repository (Figure 3.8).  
Lastly, we performed Gene Ontology analysis of proteins identified in our N-terminomics 
enrichment, which illustrated the diversity of biological processes influenced by the N-
terminome (Figure 3.9) (26, 27).  
3.4 Discussion 
Pro-apoptotic drugs designed to circumvent the persistence of cancer cells by 
reestablishing or rewiring apoptotic pathways ultimately converge on the activation of the 
caspase family of proteases to systematically facilitate cellular degradation (7).  In this 
work, we investigate the proteolytic landscape of HeLa cells treated with doxorubicin 
using the TAILS N-terminomic strategy developed by Kleifeld et al., (19).  Clinically 
administered as a cancer chemotherapy, doxorubicin triggers apoptosis by introducing 




Figure 3.8 Percentage of proteins from HeLa N-terminomes treated with 
doxorubicin identified in the DegraBase repository. 
Overlap of proteins in the DegraBase and unique proteins from our N-terminomics 
analysis including those identified from A) N-terminally dimethylated peptides quantified 
in both control and doxorubicin-treated N-terminomes, B) N-terminally dimethylated 
peptides quantified exclusively in the doxorubicin-treated N-terminome and C) N-




































Figure 3.9 Gene Ontology (GO) analysis of proteins identified in the N-terminome of 
HeLa cells treated with doxorubicin. 
Proteins corresponding to peptides identified quantitatively or qualitatively in the N-
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enzyme topoisomerase II (prevents uncoiling and introduces breaks) and by intercalation 
into DNA (stalls polymerases) (15, 16). 
3.4.1 Evaluating the TAILS N-terminome enrichment of HeLa cells 
treated with doxorubicin 
We verified enrichment of the N-terminome of HeLa cells treated with 
doxorubicin across six biological replicates (i.e., individual culture plates) by 
comprehensively comparing PSMs (FDR ≤ 1%) identified in the pre-enrichment sample 
(preTAILS) to PSMs identified in the post-enrichment sample (TAILS).  Despite 
identifying a marginally higher number of unique peptides in the preTAILS dataset, 
which is unsurprising given the relative complexity of peptides expected in pre- and post-
enrichment samples, the TAILS dataset revealed 10% more unique protein identifications 
and four times more unique protein identifications for N-terminally dimethylated 
peptides.  Consistent with the literature, we observed a >10-fold enrichment of all N-
terminally blocked peptides in the TAILS dataset and to ensure that the enrichment was 
unbiased, we verified that the distribution of N-terminal modifications in the preTAILS 
dataset was indistinguishable from the TAILS dataset (14, 24).  In summary, extensive 
analysis of the preTAILS and TAILS datasets revealed robust N-terminome enrichment 
across six biological replicates of HeLa cells treated with doxorubicin. 
3.4.2 Interpretation and analysis of N-terminally dimethylated 
peptides quantified within the N-terminome of HeLa cells 
treated with doxorubicin 
The quantitative N-terminomics dataset consists of all N-terminally dimethylated 
peptides identified in at least four biological replicates with valid log2(H/L) ratios (i.e., 
corresponding peptides containing experimentally dimethylated N-termini quantified in 
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both the light channel (DMSO) and heavy channel (doxorubicin)). Surveying the 
log2(H/L) ratios of N-terminally dimethylated peptides quantified in our N-terminomics 
dataset, we observed a positively skewed distribution with the majority of peptides 
exhibiting negative log2 ratios.  A negative log2 ratio indicates that the identified peptide 
occurred at higher frequency in the control N-terminome implying that there is an 
increased incidence of proteolysis in the control N-terminome than in the doxorubicin-
treated N-terminome.  This finding is biologically counterintuitive considering treating 
HeLa cells with doxorubicin intrinsically activates the caspase family of proteases, which 
target and cleave numerous protein substrates to execute apoptotic cell death (7, 15–17, 
28).  However, given that caspases are essentially inactive in the control N-terminome, a 
peptide representing a neo-N-terminus, generated as a consequence of caspase cleavage 
in the doxorubicin-treated N-terminome, would not have a valid H/L ratio because the 
corresponding peptide would not exist in the non-apoptotic control N-terminome.  With 
this in mind, we speculate that N-terminally dimethylated peptides quantified in our N-
terminomics dataset are largely representative of protein termini generated as a 
consequence of homeostatic proteolysis and, considering the prevalence of negative log2 
ratios, suggests that steady state protease activity or substrate selectivity may be 
modulated in response to doxorubicin treatment.  Concerning the abovementioned N-
terminally dimethylated peptides quantified exclusively in the doxorubicin-treated N-
terminome, note that these peptides are analyzed separately as part of the qualitative 
assessment of our N-terminomics data (discussed in section 3.4.3).   
To gain insight into the mechanisms responsible for generating the protein termini 
in our N-terminomics dataset of quantified N-terminally dimethylated peptides, we 
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queried the dataset using the TopFINDer web tool (20).  Three biological processes (i.e., 
alternative splicing, alternative translation and proteolytic processing) are responsible for 
generating protein species with distinct termini (20). While less than 0.01% of our 
findings were documented as termini associated with alternative splicing or translation, 
approximately 10% were attributed to proteolytic processing by various proteases 
including cathepsins, caspases and HTRA2, a mitochondrial serine protease. The 
cathepsin family of proteases are generally responsible for homeostatic protein turnover 
while caspases and HTRA2 are involved in the execution of apoptotic cell death (11, 29, 
30).  In addition to mapping protein termini to biological processes, TopFINDer verified 
that ~30% of protein termini identified in our study were previously identified in other 
terminomics experiments deposited in the knowledgebase, which further reinforces the 
findings in our N-terminome enrichment. Overall, approximately 25% of protein termini 
were not attributed to criteria within the TopFIND knowledgebase and we speculate that 
a proportion of these may represent instances of proteolytic processing specific to 
doxorubicin treatment in HeLa cells. 
3.4.3 Qualitative assessment of peptides and corresponding 
proteins identified in the N-terminome of HeLa cells treated 
with doxorubicin. 
To characterize the cleavage motifs for all peptides identified in the N-terminome 
of HeLa cells treated with doxorubicin we followed classic protease nomenclature.  
Briefly, classic protease cleavage nomenclature references residues located N-terminal of 
the scissile bond as P1, P2, P3...Pn and residues located C-terminal as P1’, P2’, P3’...Pn’ 
(25).  Considering the diversity of proteases, describing cleavage motifs can provide 
insight into the protease or protease family responsible for generating the protein termini 
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observed in our N-terminome enrichment (13).  Characterization of N-terminally 
dimethylated peptides identified quantitatively in both control and doxorubicin-treated N-
terminomes revealed a broad distribution of residues in the P1 position with methionine 
exhibiting striking representation.  We venture that the prevalence of P1 methionine 
residues is reflective of methionine aminopeptidases, which co-translationally catalyze 
the excision of N-terminal methionine residues which, although poorly understood, is 
estimated to occur in approximately 80% of the proteome (31).  To complement the 
analysis of protease motifs, we interrogated the DegraBase repository for proteins 
corresponding to N-terminally dimethylated peptides identified quantitatively in both 
control and doxorubicin-treated N-terminomes.  Briefly, the DegraBase is an open-source 
repository generated using a subtiligase-based, positive enrichment mass spectrometry 
strategy for comparison of healthy and apoptotic N-terminomes (22).  Interestingly, 
~70% of the proteins identified in our quantitative TAILS dataset overlapped with 
proteins documented in the DegraBase repository (22). 
Next, for N-terminally dimethylated peptides quantified exclusively in the 
doxorubicin-treated N-terminome, we observed primarily aspartic acid residues in the P1 
position.  Caspases demonstrate a dominant specificity for aspartic acid and as they are 
activated in response to doxorubicin treatment to facilitate apoptotic pathways, we 
propose that peptides identified with a P1 aspartic acid are putative substrates of caspases 
(8, 15–17).  This notion is reinforced by Mahrus et al., (32), in an N-terminomics analysis 
of untreated Jurkat cells, which revealed that protein N-termini containing a P1 aspartic 
acid residue occurred in less than 5% of identified N-termini.  Moreover, interrogation of 
the DegraBase repository using proteins identified from N-terminally dimethylated 
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peptides quantified exclusively in the doxorubicin-treated N-terminome, revealed an 
overlap of ~75% indicating that the majority of these proteins are documented in 
previously established apoptotic degradomes (22). 
To further investigate potential substrates of caspases, we expanded our N-
terminome assessment to include N-terminally acetylated peptides.  Approximately 80% 
of eukaryotic protein N-termini are blocked by acetylation and this modification 
precludes the N-terminal dimethyl labeling used in the TAILS strategy (33).  To 
determine if N-terminally acetylated peptides in our N-terminome enrichment are 
potential substrates of caspase-mediated proteolysis, we used AspC protease selectivity in 
our MaxQuant search to qualitatively isolate peptides naturally blocked by acetylation 
with P1 aspartic acid residues.  Strikingly, we identified >100 N-terminally acetylated 
peptides with P1 aspartic acid residues suggesting that many naturally blocked protein 
termini are cleaved by caspases in response to doxorubicin treatment.  Furthermore, 
~30% of the proteins identified from these peptides overlapped with proteins catalogued 
in the DegraBase repository (22).  Intriguingly, the unidentified 70% may represent 
putative substrates of caspases not previously annotated in response to doxorubicin 
treatment.  
Lastly, we examined the Gene Ontology of all proteins corresponding to 
identified peptides, which ultimately illustrates the scope of biological processes 
impacted within the N-terminome of HeLa cells treated with doxorubicin (26, 27).  
Moreover, the diverse array of biological processes represented by the protein termini 
identified in the N-terminome of doxorubicin-treated HeLa cells suggests that the 
corresponding proteins are important components of vital cellular processes.  In 
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summary, this study encompasses a comprehensive exploration of proteolytic processing 
in HeLa cells treated with doxorubicin and emphasizes the diversity and complexity of 
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Supplementary Table 3.1 Number of peptides in the N-terminomics dataset with 
quantified H/L ratios across six biological replicates. 
  








*Indicates the number of biological replicates containing a 








Supplementary Table 3.2 Comprehensive list of N-terminally dimethylated peptides 
quantified exclusively in the doxorubicin-treated N-terminome. 
 





AP5Z1 O43299-3 D TEVD/GAVA 5  
VIM P08670 D SLAD/AINT 3 x 
ACTN1 P12814-2 D DHYD/SQQT 5 x 
NCK1 P16333-2 D SVPD/SASP 2 x 
MAP4 P27816-7 D SLAD/ALTE 2 x 
PLEC Q15149-7 D DALD/GPAA 2 x 
CBLL1 Q75N03-2 D DHTD/NELQ 4 x 
ZC3H18 Q86VM9-2 D DVRD/TVLE 3 x 
BOD1L1 Q8NFC6 D SEVD/TSAG 1 x 
MICAL1 Q8TDZ2-2 D DKTD/TGMP 2  
LIMS2 Q7Z4I7 M ___M/TGSN 1 x 
CDKN2AIPNL Q96HQ2-2 M ___M/VGGE 2 x 
VCP P55072 P QAAP/CVLF 1  
SLC39A10 Q9ULF5 R TRKR/EAPH 1 x 
PDZRN3 Q9UPQ7-2 R LLRR/DVEA 1 x 




Supplementary Table 3.3 Comprehensive list of N-terminally acetylated peptides 
with AspC protease specificity. 
 
Gene Names Proteins P1 P4–P4’ DegraBase 
EDC4 Q6P2E9-2 D AAAD/TLQG x 
PARG Q86W56-5 D AERD/VVYF x 
PKM P14618-2 D AMAD/TFLE x 
ALOX5 P09917-5 D AMKD/LTYA  
UNC13A Q9UPW8 D ATPD/KVPA  
SPAG9 O60271-5 D CEKD/VLQG x 
MBD4 O95243-3 D CISD/AGAC  
DPH5 Q9H2P9-3 D DAKD/ITVK  
DNAH17 Q9UFH2-2 D DEKD/QETL  
EFCAB13 Q8IY85-2 D DLKD/FLMK  
MX2 P20592 D DLMD/RGTE  
NAA25 Q14CX7-2 D DNRD/LNVF  
POLR1A O95602 D EEND/DEDM  
OSBPL8 Q9BZF1-3 D EESD/TDTS x 
FAM20C Q8IXL6-2 D EIRD/VTRD  
OTUD4 Q01804-5 D ENLD/LSKD x 
LRRIQ1 Q96JM4-2 D ENVD/RQTI  
LAMA5 O15230-2 D ERCD/VCAE x 
PGGT1B P53609-2 D ERLD/FLRD  
AKAP9 Q99996-4 D ESKD/CVLT x 
HMG20A Q9NP66-2 D ESND/LATT  
CDCA7 Q9BWT1-5 D EVRD/ALLD x 
FAT4 Q6V0I7-2 D FHID/PLRG  
TOPORS Q9NS56-2 D FKMD/NFSP  
MRPS9 P82933 D GKHD/VTCT x 
FAM160A2 Q8N612 D GKLD/WAEG  
SLC6A3 Q01959 D GLID/EFQL  
TENM4 Q6N022 D GRRD/YDVL  
PNLIPRP1 P54315 D GTRD/FVAC  
PRDM6 Q9NQX0-2 D HFID/GGEP  
SYNE1 Q8NF91-7 D HMLD/SYCH x 
UBL3 O95164 D HVYD/NWPM  
POLR1A O95602 D ICPD/MYIN  
IFI44L Q53G44 D ICRD/NKIY  
PHF2 O75151 D IDTD/TKPG  
TMEM63B Q5T3F8-2 D IKDD/EIRD  
166 
 
Gene Names Proteins P1 P4–P4’ DegraBase 
ATG4D Q86TL0 D KAGD/WYGP  
TAX1BP1 Q86VP1-3 D KDQD/KTDT x 
UBQLN1 Q9UMX0-4 D KDQD/TLSQ x 
PPP1R12A O14974-5 D KEKD/SKGT x 
TUBB6 Q9BUF5 D KEVD/EQML  
MGAM2 Q2M2H8-3 D KFHD/HLEF  
ADAMTSL1 Q8N6G6-2 D KFPD/KEIL  
PHF3 Q92576-2 D KHSD/NEAE x 
COPS8 Q99627 D KLLD/QCEN  
GBP3 Q9H0R5-4 D KLQD/EELD x 
MICALCL Q6ZW33 D KLVD/SLEE  
RASGRP2 Q7LDG7-3 D LDLD/KGCT x 
PPP1R12A O14974-5 D LEKD/DSTD x 
TRIM50 Q86XT4-2 D LKLD/PATA  
CASP10 Q92851-7 D LLKD/SLPK x 
CARD6 Q9BX69 D LNMD/RSRK  
GPATCH1 Q9BRR8 D LPRD/YRPV  
EPB42 P16452-3 D LSKD/KQVE  
FEM1C Q96JP0 D MEKD/GYGM  
IFI44L Q53G44 D MGLD/GAEG  
CCNE1 P24864-2 D MKED/GGAE  
TGS1 Q96RS0 D MKVD/LVSF x 
SYCE3 A1L190 D MLSD/LNKD  
HSPA4L O95757 D MQVD/QEEG  
RORB Q92753-1 D MSRD/AVKF  
UBL7 Q96S82 D NMLD/TLVP  
KIF26B Q2KJY2 D NRCD/ICAT  
RGS9 O75916-2 D NVLD/YGLD  
FKRP Q9H9S5 D PALD/RPAA  
HINT1 P49773 D PGGD/TIFG x 
TTC38 Q5R3I4 D PLRD/CQAW  
AHNAK Q09666 D PRLD/FEGP x 
PREP P48147 D QKKD/TEIF  
SPATA22 Q8NHS9-3 D QMLD/DIPE  
CLCA4 Q14CN2-2 D RAAD/EAVI  
KIAA1161 Q6NSJ0 D RAVD/QDKV  
STAT6 P42226-2 D RGQD/GSPQ  
LRRN3 Q9H3W5 D RIKD/MNFK  
NEURL1 O76050-2 D RIND/SAVM  
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Gene Names Proteins P1 P4–P4’ DegraBase 
ZSCAN32 Q9NX65-3 D RKLD/LPVL  
ELOA3 Q8NG57 D RLRD/AREQ  
C4orf19 Q8IY42 D RNGD/SRAP  
FAM47C Q5HY64 D RPQD/RPSS  
LIG3 P49916-4 D SAGD/GFHG x 
SMARCA2 P51531-2 D SEKD/AKQI x 
ECHS1 P30084 D SFQD/CYSS x 
NTAN1 Q96AB6 D SFSD/HAQC  
SERPINB12 Q96P63-2 D SKLD/RIKT  
AXDND1 Q5T1B0-2 D SKYD/TLKI  
HARBI1 Q96MB7 D SLQD/CAVL  
RYR3 Q15413-3 D SPRD/QEIK  
TTLL6 Q8N841-2 D SRLD/KEVK  
TTC41P Q6P2S7-2 D STGD/EETK  
EYS Q5T1H1-1 D TEKD/GHFR  
ABCC1 P33527-8 D TIHD/PNPC  
CSDE1 O75534-2 D TIKD/RNGK x 
LMOD1 P29536-2 D TKKD/DEKV  
FKBP9P1 Q75LS8 D TNQD/RNGD  
CCDC14 Q49A88-2 D TSRD/EQDF  
DOCK9 Q9BZ29-6 D TVKD/ESLA  
SLC12A7 Q9Y666 D TVRD/TTAA x 
ANKRD26 Q9UPS8 D TYVD/EVHK  
CREB3L3 Q68CJ9-4 D VAAD/AVPG  
NDUFAF6 Q330K2-2 D VIYD/IASQ  
MTMR7 Q9Y216-2 D VNRD/YRVC  
RABGAP1L Q5R372-2 D VPKD/RDKF  
DHX36 Q9H2U1-3 D VVKD/LLNF x 
NAV1 Q8NEY1-5 D WFID/LWNN x 
POP1 Q99575 D WNQD/ICKS x 
B3GNT3 Q9Y2A9 D YLQD/HDPG  
LOXHD1 Q8IVV2-3 D YMKD/GSLR  
CDH6 P55285-2 D YSVD/RHTD  
MIB2 Q96AX9-9 L GHAL/AVRK  




Chapter 4  
4 Expanding the biochemical toolbox for monitoring the 
functional interplay between protein kinases and 
caspases 
4.1 Introduction 
Apoptosis is the process of cell death generally characterized by cellular collapse 
in the absence of an inflammatory response (1). Perturbations to apoptotic signaling 
underscores numerous pathogenic processes emphasizing the importance of apoptotic 
regulation (1, 2).  Excessive apoptosis causes atrophy while evasion of apoptosis, a 
common competence of cancer cells, permits damaged or malignant cells to persist 
inappropriately (1, 3, 4).  Two major enzymatic components responsible for apoptotic 
regulation are caspases and protein kinases.  During apoptosis, caspases orchestrate 
cellular degradation through proteolytic digestion of key structural and enzymatic 
proteins (5, 6).  Meanwhile, protein kinases serve to globally fine-tune the equilibrium 
between signals directing cell survival and cell death by catalyzing post-translational 
phosphorylation of substrate proteins (7).  Mounting evidence describing crosstalk 
between caspases and protein kinases reveals that phosphorylation events directly impact 
caspase-mediated proteolysis (7, 8).  Here, we are interested in the burgeoning 
relationship previously established between protein kinase CK2 and caspase-mediated 
proteolysis. 
Protein kinase CK2 is a ubiquitously expressed enzyme essential for eukaryotic 
cell survival.  Structurally, CK2 functions as a heterotetramer composed of two 
regulatory subunits (designated as CK2β, encoded by CSNK2B) that each interact with a 
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catalytic isoform (CK2α and/or CK2α’, encoded by CSNK2A1 and CSNK2A2 genes, 
respectively) to form a holoenzyme (CK2α2β2, CK2α’2β2 or CK2αα’β2) (9). Catalytically, 
protein kinase CK2 transfers the gamma phosphate from ATP (or GTP) to serine, 
threonine and, less frequently, tyrosine residues located within an acidophilic consensus 
motif (designated as S/T-X-X-D/E/pS/pY) (10–14).  Typically, protein kinase activity is 
stringently regulated; however, CK2 is distinguished from other protein kinases because 
it is constitutively active and displays enigmatic regulation (15). With >2,000 putative 
CK2 phosphorylation sites in the human proteome, CK2 serves as a critical regulatory 
mechanism for a multitude of vital cellular pathways, including apoptosis (10).  Although 
no oncogenic gain-of-function mutants of CK2 are known, levels of the protein kinase are 
often elevated in various cancers and transcript expression profiles deposited in the 
Oncomine database reveal variable expression profiles for CK2 subunits in neoplastic 
tissues (15, 16).  Down-regulation of CK2 sensitizes cells to both intrinsically and 
extrinsically induced apoptosis while overexpression is protective against 
pharmacological induction of apoptosis (17–19).  One current theory is that cancers 
develop a ‘non-oncogenic addiction’ to elevated levels of CK2, which fosters cancer 
progression by stimulating cell growth and proliferation while promoting resistance to 
apoptosis (20–22).  
Recent evidence highlights the convergence of CK2 phosphorylation on the 
caspase family of proteases.  Initiator caspases (-8, -9, and -10) are activated by pro-
domain dimerization while executioner caspases (-3, -6, and -7) exist as zymogens until 
activated by linker-region proteolysis, which occurs predominantly by initiator caspases 
(23). During apoptosis, caspases use a cysteine side chain to selectively catalyze 
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irreparable cleavage of peptide bonds (24).  A salient feature of caspases is a dominant 
specificity for cleaving on the C-terminal side of aspartic acid residues, typically in 
regions exhibiting extended loop conformations (23–25). The activation of caspases 
initiates irreversible apoptotic signaling and as such, several mechanisms stringently 
regulate these cleavage events (23).  A study by Tözsér et al., (26), suggests that 
phosphorylation near caspase recognition sites is sufficient to block substrate cleavage 
which corresponds to a study by Desagher et al., (27), showing that caspase-8 cleavage of 
the pro-apoptotic protein BID is blocked by CK2 phosphorylation. Pertinent to this study 
are investigations using computational approaches validated in vitro by Duncan et al., 
(28), and Turowec et al., (29), who first suggested that overlap between the acidophilic 
consensus sequence for CK2 phosphorylation and caspase recognition sites may facilitate 
a larger spectrum of caspase regulation by CK2 (Figure 4.1). In support of their findings 
is an analysis of the phosphoproteome by Dix et al., (30), illustrating extensive crosstalk 
between protein kinases and caspases and suggesting that phosphorylation of caspase 
substrates can both promote or inhibit cleavage by caspases.  More recently, Turowec et 
al., (31), used an N-terminomics approach that supports the finding that phosphorylation 
can both positively and negatively regulate caspase cleavage events (Figure 4.2).  
To continue characterizing the relationship between CK2 phosphorylation and 
caspase cleavage, we are interested in developing a FRET-based (Förster resonance 
energy transfer) biosensor to monitor the relationship between CK2 phosphorylation and 






Figure 4.1 The general consensus sequence of protein kinase CK2 overlaps with the 
predicted recognition sequence of caspase-3. 
Caspase-3 cleaves peptide bonds C-terminal to aspartic acid residues and shows 
increased specificity for peptide sequences containing acidic residues.  Protein kinase 
CK2 phosphorylates serine and/or threonine residues in acidic peptide sequences.  
Accumulating evidence suggests that overlap between the acidophilic consensus 
sequence for CK2 phosphorylation and caspase recognition sites facilitates a larger 
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Figure 4.2 Classic protease cleavage nomenclature for referencing residues in 
caspase recognition sequences. 
Residues located N-terminal of the aspartic acid residue directing cleavage are referred to 
as P1, P2, P3...Pn and sites located C-terminal are referred to as P1’, P2’, P3’...Pn’ (55). 
Phosphorylation of serine, threonine or tyrosine residues located proximal to the scissile 




























study protein-protein interactions, protein-DNA interactions, protein conformational 
changes and also for real-time analysis of protease activity (32, 33). Briefly, excitation 
and emission of a fluorophore (the “donor”) allows for excitation of a second fluorophore 
(the “acceptor”) as a result of overlapping spectra between donor emission and acceptor 
excitation wavelengths (Figure 4.3A). For FRET to occur, the two fluorophores must be 
in close proximity of less than 10 nm (34). The FRET biosensor used in this study was 
developed by Ai et al., (35), and encodes mAmetrine (GFP variant) as the donor 
fluorophore and tdTomato (Ds-Red variant) as the acceptor fluorophore separated by a 
linker region containing a caspase-3 cleavage motif.  Cleavage of the linker separates the 
fluorophores and quantification of decreased FRET emission serves as an indication of 
caspase-3 activity (Figure 4.3B).  
In this study, we performed a systematic evaluation of peptide substrates to assess 
determinants for CK2 phosphorylation within caspase cleavage motifs and evaluated the 
impact of phosphorylation on caspase cleavage.  Moreover, to expand the biochemical 
toolbox for defining the spatial and temporal evolution of apoptotic CK2–caspase 
networks, we manipulated an established caspase-3 FRET biosensor using exploratory 
sequences balancing the determinants for CK2 phosphorylation within putative caspase 
motifs identified from our peptide studies.   
4.2 Materials and Methods 
4.2.1 Peptide synthesis 
Individual peptides were synthesized at a 2 µmol scale using an Automated 




Figure 4.3 FRET biosensor schematic illustrating FRET loss following caspase 
cleavage of linker region. 
A) The caspase-3 FRET biosensor, developed by Ai et al., (35), encodes the fluorophore 
mAmetrine (a variant of GFP) tethered to the fluorophore tdTomato (a variant of DsRed) 
by an amino acid linker containing a caspase-3 recognition site.  B) In the presence of 
active caspase-3, the linker region is cleaved, which separates the fluorophores and 
produces a quantifiable loss of FRET signal.  
Ametrine
tdTomato
λem = 581 nm
λex = 406 nm λem = 526 nm











chemistry.  The PARP1 and pro-caspase-3-based peptide series were generated with a C-
terminal lysine-dinitrophenol (lysine-DNP) conjugate residue (Fmoc-Lys(dinitrophenol)-
OH, (Bachem)) and capped with an N-terminal tryptophan residue (Fmoc-Trp-OH, 
(Sigma-Aldrich)) and biotin (Sigma-Aldrich).  Phosphorylated peptides in each series 
were synthesized using phosphoserine (Fmoc-Ser(Ser[PO(OBzl)-OH]-OH), (AnaSpec 
Inc.)).  The Golgin-160 peptide series was purchased from ChinaPeptides (Shanghai, 
China) and each peptide was provided with quality control data for both HPLC 
chromatography and mass spectrometry as verification of purity (>95%) and peptide 
identity, respectively.  Candidate peptides with overlapping caspase-3 cleavage and 
protein kinase CK2 phosphorylation motifs were generated with an N-terminal 
tryptophan residue (Fmoc-Trp-OH, (Sigma-Aldrich)).  Some peptides were synthesized 
with an N-terminal lysine-DNP conjugate residue (Fmoc-Lys(dinitrophenol)-OH, 
(Bachem)) and a C-terminal lysine-biotin conjugate residue (Fmoc-Lys(biotin)-OH, 
(AnaSpec Inc.)) while others were synthesized with biotin (Sigma-Aldrich) on the N-
terminus and the lysine-DNP conjugate residue (Fmoc-Lys(dinitrophenol)-OH, 
(Bachem)) on the C-terminus.  The inclusion of the N-terminal tryptophan residue served 
two purposes: it enabled peptide concentration estimates using absorbance at 280 nm and 
was used to monitor peptide proteolysis as tryptophan fluorescence is internally quenched 
in the presence of DNP.  Biotin was included in peptides to enable capture by 
streptavidin.  All peptides were resuspended in 250 mM HEPES (pH 7.5), diluted to a 
working stock concentration of 1 mM and mass spectrometry was used to confirm 
peptide identities. Supplementary Table 4.1 contains a comprehensive list of peptide 
sequences used in this study. 
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4.2.2 FRET biosensor plasmid cloning 
The original pmAmetrine-DEVD-tdTomato plasmid was a gift from Robert 
Campbell (Addgene plasmid # 18879) consisting of an N-terminal GFP-derivative 
(mAmetrine, λex = 406 nm, λem = 526 nm) and a C-terminal tandem dimeric derivative of 
DsRed (tdTomato, λex = 554 nm, λem = 581 nm) separated by a linker containing a 
caspase-3 cleavage motif (35).  The mAmetrine-DEVD-tdTomato biosensor was 
subcloned from the mammalian expression vector pEYFP-Nuc (Clontech) into a pET28c 
vector (EMD Biosciences).  To introduce novel linker sequences into the pmAmetrine-
DEVD-tdTomato FRET biosensor, we designed complementary oligonucleotide cassettes 
containing sticky end overhangs compatible with restriction sites flanking the caspase-3 
linker sequence in the original biosensor.  An existing KpnI restriction site located 5’ of 
the caspase-3 linker was used and, after removal of existing EcoRI sites in the backbone 
of the pET28c vector using Klenow blunting, a unique EcoRI restriction site was 
introduced 3’ of the caspase-3 linker using site-directed mutagenesis (Forward primer: 5’-
gaggtcatcaaagaattcatgcgcttcaaggtgcgc-3’, Reverse primer: 5’-
gcgcaccttgaagcgcatgaattctttgatgacctc-3’).  Briefly, the 5’ ends of each oligonucleotide 
were phosphorylated using T4 polynucleotide kinase (New England Biolabs® Inc.).  
Next, complementary oligonucleotides were mixed, boiled at 95˚C for 10 minutes and 
slow-cooled to 25˚C to achieve complementary annealing.  Annealed oligonucleotide 
cassettes were ligated into the pmAmetrine-DEVD-tdTomato construct digested with 
KpnI-HF (New England Biolabs® Inc.) and EcoRI-HF (New England Biolabs® Inc.) 
restriction enzymes.  Subsequently, ligation reactions were transformed into BL21 (DE3) 
competent Escherichia coli cells, colonies were selected and purified plasmid DNA was 
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sequenced (London Regional Genomics Centre) to confirm plasmid identity.  
Supplementary Table 4.2 contains a comprehensive list of FRET biosensor constructs 
used in this study including the corresponding sense and anti-sense oligonucleotide 
sequences used for linker cloning. 
4.2.3 Recombinant protein expression and purification: caspases, 
protein kinase CK2 and FRET biosensors 
Bacterial expression plasmids pET23b-Casp3-His (Addgene plasmid # 11821), 
pET23b-Casp7-His (Addgene plasmid # 11825) and pET15b-Casp8-delta-DED 
(Addgene plasmid # 11827) were a gift from Guy Salvesen and used to purify caspases-3, 
-7 and -8, respectively (36).  The histidine-tagged recombinant caspases were expressed 
in BL21 (DE3) Escherichia coli cells and purified as previously described (37) using 
Chelating Sepharose Fast Flow (GE Healthcare) resin charged with nickel ions.  Activity 
of purified caspases was assessed as previously described (37) using active site titration. 
Purification of protein kinase CK2α2β2 holoenzyme and CK2α or CK2α’ 
catalytic-only subunits was achieved using a two-step chromatographic procedure by 
FPLC.  Briefly, untagged CK2α or CK2α’ (catalytic subunit isoforms) and CK2β 
(regulatory subunit) were expressed in BL21 (DE3) Escherichia coli cells using 1 mM 
IPTG and lysed in a buffer containing 300 mM NaCl (Bioshop) and 25 mM Tris-HCl pH 
8.5 (Bioshop) supplemented with protease inhibitors (1 mM phenylmethylsulfonyl 
fluoride (PMSF) (Sigma-Aldrich), 10 µg/mL pepstatin A (Bioshop), 1 µg/mL aprotinin 
(Bioshop) and 1 µg/mL leupeptin (Sigma-Aldrich)).  To generate CK2α2β2 holoenzyme, 
lysates from CK2α and CK2β were incubated together for 16 hours at 4˚C to allow 
heterotetrameric holoenzyme complexes to form.  Lysates for CK2α2β2 holoenzyme and 
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CK2 catalytic-only subunits were independently purified using a phosphocellulose 
(Whatman) chromatography column equilibrated with 300 mM NaCl (Bioshop) and 25 
mM Tris-HCl pH 8.5 (Bioshop).  Following protein application and washing, a gradient 
elution was performed using 1 M NaCl (Bioshop) and 25 mM Tris-HCl pH 8.5 
(Bioshop), as the high-salt component.  The second step for purification was performed 
using Sephacryl S-300 High Resolution (GE Healthcare) size exclusion chromatography 
equilibrated with 500 mM NaCl (Bioshop) and 25 mM Tris-HCl pH 8.5 (Bioshop).  
Following size exclusion, proteins were concentrated and re-buffered in 500 mM NaCl 
(Bioshop) and 25 mM Tris-HCl pH 8.5 (Bioshop) by ultrafiltration using Amicon Ultra-
15 Centrifugal Filter Units with a 30 kDa molecular weight cutoff (EMD Millipore) and 
diluted 1 in 2 using glycerol.  Enzymatic activity of purified CK2α2β2 holoenzyme and 
CK2α/CK2α’ were evaluated with a kinase assay (described in section 4.2.4) using a 
standard DSD peptide (EZBiolabs).   
The original pmAmetrine-DEVD-tdTomato plasmid was a gift from Robert 
Campbell (Addgene plasmid # 18879, (35)).  As described in section 4.2.2, the 
mAmetrine-DEVD-tdTomato biosensor was subcloned into pET28b with a 6× N-
terminal histidine-tag and FRET biosensors with linker variants were generated (section 
4.2.2).  The parental and variant recombinant FRET biosensors were expressed in BL21 
(DE3) Escherichia coli cells using 1 mM IPTG and lysed in a buffer containing 50 mM 
NaCl (Bioshop), 20 mM Tris-HCl pH 7.5 (Bioshop), 1 mM EDTA (Sigma) and 0.5 mM 
EGTA (Sigma) supplemented with protease inhibitors (1 mM phenylmethylsulfonyl 
fluoride (PMSF) (Sigma-Aldrich), 10 µg/mL pepstatin A (Bioshop), 1 µg/mL aprotinin 
(Bioshop) and 1 µg/mL leupeptin (Sigma-Aldrich)).  Proteins were loaded onto Chelating 
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Sepharose Fast Flow (GE Healthcare) resin charged with nickel ions and eluted with a 
step-wise gradient of 50-500 mM imidazole (Bioshop) in buffer containing 50 mM NaCl 
(Bioshop), 20 mM Tris-HCl pH 7.5 (Bioshop), 1 mM EDTA (Sigma) and 0.5 mM EGTA 
(Sigma).  Purified proteins were concentrated and re-buffered in 200 mM NaCl (Bioshop) 
and 50 mM Tris-HCl pH 8.0 (Bioshop) by ultrafiltration using Amicon Ultra-15 
Centrifugal Filter Units with a 50 kDa molecular weight cutoff (EMD Millipore).   
The concentration of all purified proteins was determined with a BCA assay 
(Thermo Scientific) using bovine serum albumin (BSA) (Thermo Scientific) as a protein 
standard and stored at –80˚C. 
4.2.4 Kinase assays 
Peptide kinase assays using recombinant CK2α2β2 holoenzyme and CK2α were 
performed in triplicate with 100 µM of peptide substrate and 100 ng of CK2 at 30˚C for 
10 minutes in a buffer containing 50 mM Tris-HCl (Bioshop), 150 mM NaCl (Bioshop), 
10 mM MgCl2 (Bioshop) and 100 µM ATP (New England Biolabs® Inc.) supplemented 
with 0.2 µCi [!-32P]-ATP (specific activity 3000 Ci/mol, PerkinElmer).  Reactions were 
initiated by addition of recombinant protein kinase CK2 and terminated by addition of 
excess EDTA pH 8.0 (Sigma). Activity assays for protein kinase CK2 performed using a 
standard DSD peptide (EZBiolabs), amino acid sequence RRRDDDSDDD, were spotted 
on P81 phosphocellulose paper (Whatman) and washed in 1% phosphoric acid three 
times followed by a final wash in 95% ethanol. Biotinylated peptides were spotted on 
SAM2 streptavidin membrane (Promega) and washed twice in 0.1% SDS/TBS (Bioshop), 
twice in 2 M NaCl (Bioshop), twice in 2 M NaCl (Bioshop) with 1% H3PO4 (VWR), 
twice in distilled water and once in 95% ethanol.  Membranes were dried under a heat 
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lamp and exposed on a phosphor storage screen.  Peptide phosphorylation was visualized 
by a STORM 820 Phosphorimager (Molecular Dynamics) and quantified using 
ImageQuant software (v5.2) and a standard curve of known [!-32P]-ATP concentrations. 
Phosphorylation of the caspase-8 FRET biosensor was achieved using 100 ng of 
recombinant CK2α’ and 500 µg of protein substrate at 30˚C for 1 hour in a buffer 
containing 50 mM Tris-HCl (Bioshop), 150 mM NaCl (Bioshop), 10 mM MgCl2 
(Bioshop) and 100 µM ATP (New England Biolabs® Inc.).  Reactions were terminated by 
addition of 2× Laemmli buffer and boiled at 95˚C for 5 minutes.  Samples were 
subsequently loaded onto SDS-PAGE and transferred to an Immobilon-FL 
polyvinylidene difluoride (PVDF) membrane (Millipore) using standard procedures.  
Phosphorylation of the caspase-8 FRET biosensor linker region was detected with the 
anti-phospho-pro-caspase-3 antibody as described in section 4.2.7. 
4.2.5 Caspase assays 
Recombinant caspase assays using 200 nM caspase-3, 600 nM caspase-7 and 100 
nM caspase-8 were performed on peptide substrates synthesized with a tryptophan-DNP 
FRET pair.  Caspase cleavage of peptide substrates (100 µM) was measured by 
monitoring tryptophan fluorescence (λex = 280 nm, λem = 355 nm) on a SpectraMax M5 
fluorescence plate reader (Molecular Devices).  When tryptophan and DNP are in close 
proximity, they form a FRET pair where tryptophan fluorescence is quenched by DNP.  
Proteolytic cleavage of peptides with this FRET pair liberates tryptophan from internal 
quenching by DNP, allowing peptide cleavage to be monitored through tryptophan 
fluorescence. Caspase-3 and -7 reactions were conducted in a buffer containing 100 mM 
NaCl (Bioshop), 20 mM PIPES pH 7.4 (Sigma), 5% (w/v) sucrose (EMD Millipore), 
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0.1% (w/v) CHAPS (Bioshop) and 5 mM DTT (Sigma) for 10 minutes at 37˚C.  Caspase-
8 reactions were conducted in 1 M sodium citrate (Bioshop) and 35 mM 
NaH2PO4/Na2HPO4 pH 7.4 (Bioshop) at 37˚C for 5 minutes.  Caspase reactions were 
terminated by addition of excess irreversible pan-caspase inhibitor z-VAD-FMK 
(Calbiochem) and diluted 1 in 4 for fluorescence detection.  Dephosphorylation of 
peptides prior to caspase cleavage was achieved using an excess of recombinant 
bacteriophage λ phosphatase in Protein MetalloPhosphatase buffer (New England 
Biolabs® Inc.) with 1 mM MnCl2 for 1 hour at 37˚C.  Reactions were performed in 
quadruplicate and the mean fluorescence of phosphorylated versus nonphosphorylated 
peptides were compared using analysis of variance and a Tukey’s test. 
Caspase assays using recombinant FRET biosensors were performed using 250 
nM of substrate and titration of either caspase-3 (0-1 µM) or caspase-8 (0-5 µM).  
Caspase-3 reactions were conducted in a buffer containing 100 mM NaCl (Bioshop), 20 
mM PIPES pH 7.4 (Sigma), 5% (w/v) sucrose (EMD Millipore), 0.1% (w/v) CHAPS 
(Bioshop) and 5 mM DTT (Sigma) for 1 hour at 37˚C.  Caspase-8 reactions were 
conducted in 1 M sodium citrate (Bioshop) and 35 mM NaH2PO4/Na2HPO4 pH 7.4 
(Bioshop) at 37˚C for 5 minutes.  Reactions were terminated by addition of excess 
irreversible pan-caspase inhibitor z-VAD-FMK (Calbiochem).  Caspase cleavage of 
FRET biosensors was evaluated by SDS-PAGE to quantify uncleaved and cleaved 
fragments for each FRET biosensor.  Coomassie Blue-R250 (Bio-Rad) stained SDS-
PAGE gels were imaged using an Odyssey® Classic Imager (LI-COR) at 700 nm and 
densitometric analysis was performed using Odyssey® software (v3.0).  To assess 
caspase-3 cleavage using FRET fluorescence, samples were excited at 406 nm and FRET 
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emission spectra from 450-650 nm were measured with a Synergy HI microplate reader 
(BioTek) using Gen5 data analysis software (v2.08). 
4.2.6 Mammalian cell culture: transfection, harvest and lysis 
HeLa cells were cultured in DMEM containing 10% fetal bovine serum (FBS), 
100 U/mL penicillin (Life Technologies) and 100 µg/mL streptomycin (Life 
Technologies) at 37˚C in an atmosphere supplemented with 5% CO2.  Transient 
transfection of FRET biosensors and myc-CK2α’ were achieved using PolyJet™ DNA In 
Vitro Transfection Reagent (FroggaBio) as recommended.  For phosphorylation of the 
transiently transfected caspase-8 FRET biosensor, cells were treated with 1 µM okadaic 
acid (Bioshop) for 1 hour at 37˚C prior to harvesting.  Induction of apoptosis was 
achieved by treating cells with 50 µM etoposide for 21 hours at 37˚C.  Harvested cells 
were lysed in 50 mM Tris-HCl pH 7.5 (Bioshop), 150 mM NaCl (Bioshop), 1% NP-40 
(Bioshop) supplemented with protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride 
(PMSF) (Sigma-Aldrich), 10 µg/mL pepstatin A (Bioshop), 5 µg/mL aprotinin (Bioshop) 
and 10 µg/mL leupeptin (Sigma-Aldrich)).  Lysates were sonicated with three, 10 second 
pulses on ice and subsequently cleared by centrifugation at 16,000 × g for 15 minutes at 
4˚C.  The supernatant was retained and protein concentrations were determined by BCA 
assay (Thermo Scientific) using bovine serum albumin (BSA) (Thermo Scientific) as a 
protein standard. 
4.2.7 Western blotting 
Protein samples were prepared by dilution with Laemmli buffer (38) containing 
beta-mercaptoethanol and boiled for 5 minutes at 95˚C prior to separation by SDS-PAGE 
in Tris-Glycine buffer.  Subsequently, proteins were transferred to an Immobilon-FL 
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polyvinylidene difluoride (PVDF) membrane (Millipore) using standard procedures.  A 
broad range pre-stained protein marker (BLUeye, FroggaBio) was used as an indicator of 
molecular weight.  Membranes were blocked for one hour at ambient room temperature 
in 5% BSA/TBST and subsequently probed with primary antibodies diluted in 1% 
BSA/TBST for 16 hours at 4˚C including: anti-DsRed (Clontech, #632496), anti-GFP 
(Abcam, #ab3277), anti-phospho-pro-caspase-3 (generated against 
GIEpTDpSGVDDMAC, YenZym Antibodies) and anti-c-myc-biotin (Sigma, #B7554).  
IRDye® secondary antibodies GAR-800 (LI-COR, #926-32211) and GAM-680 (LI-COR, 
#925-68070) diluted in 1% BSA/TBST were incubated for 45 minutes at ambient room 
temperature.  Membranes were imaged using an Odyssey® Classic Imager (LI-COR) at 
700 nm and 800 nm wavelengths and densitometric analysis was performed using 
Odyssey® software (v3.0). 
4.2.8 Sensitized emission FRET microscopy 
HeLa cells cultured in phenol red-free DMEM (Invitrogen) were transiently 
transfected with the mAmetrine-DEVD-tdTomato FRET biosensor and treated with 50 
µM etoposide for 21 hours to induce apoptosis.  FRET was monitored in live-cells by 
sensitized emission FRET microscopy using a Nikon Ti Eclipse inverted microscope. 
4.3 Results 
4.3.1 In vitro characterization of the mAmetrine-DEVD-tdTomato 
FRET biosensor 
The mAmetrine-DEVD-tdTomato biosensor, developed by Ai et al., (35), 
contains mAmetrine (a GFP variant) as the N-terminal donor fluorophore and tdTomato 
(a Ds-Red variant) as the C-terminal acceptor fluorophore, which are separated by a 
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linker region containing a caspase-3 recognition motif.  Proteolysis of the caspase-3 
linker liberates the fluorophores producing a decrease in FRET emission.  We 
endeavored to manipulate the caspase-3 linker region to generate FRET biosensors that 
monitor the impact of protein kinase CK2 phosphorylation in proximity to a caspase 
cleavage site.  Prior to developing novel FRET biosensors, we characterized the original 
mAmetrine-DEVD-tdTomato FRET biosensor to establish a positive control for 
assessing the variant FRET biosensors.  Recombinant His-mAmetrine-DEVD-tdTomato 
was expressed from a pET28c vector and purified using nickel affinity chromatography.  
Purified protein was loaded onto SDS-PAGE and detected using Coomassie Blue at the 
expected molecular weight of ~80 kDa.  For detection by Western Blot, we used 
antibodies directed against GFP and Ds-Red to target mAmetrine and tdTomato, 
respectively (Figure 4.4A).  To profile the emission spectra of purified His-mAmetrine-
DEVD-tdTomato (“Parent” FRET biosensor) we analyzed fluorescence of the protein at 
an excitation wavelength of 406 nm and generated an emission spectrum from 450-650 
nm.  Raw intensity data was normalized to the intensity at 525 nm where we observed a 
large peak representing mAmetrine emission and a smaller peak at 580 nm representing 
FRET emission of tdTomato (Figure 4.4B). 
FRET is a quantum-mechanical process occurring when the absorption spectrum 
of an acceptor fluorophore (tdTomato) overlaps with the emission spectrum of a donor 
fluorophore (mAmetrine) (34, 35).  The energy is coupled through fluorescent dipoles in 
a non-radiative transfer analogous to energy transferred by a radio antenna (39).  A vital 
consideration for manipulating the caspase-3 linker region of the mAmetrine-DEVD-




Figure 4.4 Characterization of the parental caspase-3 FRET biosensor. 
The parental caspase-3 FRET biosensor, developed by Ai et al., (35), was subcloned into 
a bacterial expression vector, expressed and purified.  A) The molecular weight of the 
purified recombinant FRET biosensor was estimated at ~80 kDa by SDS-PAGE and 
Coomassie Blue staining.  The recombinant FRET biosensor was also detected by 
Western blotting using anti-DsRed and anti-GFP antibodies to detect the tdTomato and 
mAmetrine fluorophores, respectively.  B) FRET biosensors with shortened or 
lengthened linker sequences were developed and purified to assess the impact of linker 
length on the fluorescence emission profile of the parental FRET biosensor.  Using 
fluorometry, the emission spectra of the parental recombinant FRET biosensor excited at 
406 nm showed peaks at 525 nm (representing mAmetrine donor-only emission) and 580 
nm (representing FRET emission). In vitro caspase-3 cleavage of the parental 
recombinant FRET biosensor was assayed by titration of recombinant caspase-3 (0-1 
µM).  Cleavage was characterized by C) SDS-PAGE and quantification of bands 
corresponding to the full-length FRET biosensor (yellow), the mAmetrine (green) 
cleavage fragment and the tdTomato (orange) cleavage fragment (relative proportions are 
presented in a stacked barplot for each concentration of caspase-3) and D) evaluating 
FRET emission at 580 nm (λex = 406 nm).  Caspase-3 reactions terminated using the 








































































































energy transfer details that FRET efficiency varies with respect to distance between 
fluorophores with FRET occurring only when separation is less than 10 nm (34, 39).  As 
such, we developed “Short” and “Long” linker variants of the His-mAmetrine-DEVD-
tdTomato biosensor to evaluate the impact of linker length on FRET efficiency (Figure 
4.4B).  Shortening the linker sequence by 7 residues had no impact on FRET emission 
while a linker sequence expanded by 8 residues reduced FRET emission at 580 nm. 
To characterize caspase cleavage of the His-mAmetrine-DEVD-tdTomato FRET 
biosensor, we performed assays using a titration of recombinant caspase-3.  To confirm 
cleavage of the caspase-3 linker and separation of the fluorophores, we processed 
samples using SDS-PAGE and quantified bands corresponding to the full-length FRET 
biosensor (~80 kDa), the N-terminal mAmetrine (~25 kDa) cleavage fragment and the 
tdTomato (~55 kDa) cleavage fragment (Figure 4.4C).  Concurrently, we analyzed the 
samples using fluorometry by monitoring emission spectra from 450-650 nm using an 
excitation wavelength of 406 nm.  Raw intensity data was normalized to the mAmetrine 
peak at 525 nm and in response to increasing caspase-3 concentrations, we observed a 
decrease in FRET efficiency at 580 nm (Figure 4.4D).   
Finally, we transiently transfected the mAmetrine-DEVD-tdTomato FRET 
biosensor in the pEYFP-Nuc mammalian expression vector into HeLa cells to evaluate 
FRET efficiency using live-cell imaging.  HeLa cells were treated with 50 µM etoposide 
to induce apoptosis and cells were imaged every 30 minutes for 21 hours (Figure 4.5A).  
FRET efficiency in cells was quantified using sensitized emission FRET with a healthy 




Figure 4.5 Live-cell imaging of the parental FRET biosensor transfected into HeLa 
cells treated with etoposide. 
The parental FRET biosensor was subcloned into a mammalian expression vector and 
transfected into HeLa cells.  Cells were treated with 50 µM etoposide and imaged using a 
Nikon Eclipse Ti inverted microscope.  Using sensitized emission FRET, cells were 
imaged at 30 minute intervals for 21 hours.  The coloured bar (top left of each image) 
corresponds to pseudo-colouring for FRET efficiency within cells expressing the FRET 
biosensor.  Representative images from four time points are shown in A) with a blue 
arrow indicating a healthy cell exhibiting ~60% FRET efficiency and a yellow arrow 
indicating an apoptotic cell displaying <10% FRET efficiency at the 21-hour time 
point.  B)  Quantification of FRET efficiency for the healthy cell and apoptotic cell 




























characteristic cell rounding and membrane blebbing phenotype associated with apoptosis) 
exhibiting ~10% FRET efficiency at the 21-hour time point (Figure 4.5B). 
4.3.2 Development and in vitro characterization of a novel 
caspase-8 FRET biosensor 
Prior to optimizing novel FRET biosensor linker sequences containing 
overlapping protein kinase CK2 phosphorylation sites and caspase-3 cleavage motifs, we 
inserted a biologically validated caspase-8 cleavage site in pro-caspase-3 previously 
identified, both in vitro and in cells, as a substrate of protein kinase CK2 (28, 29).  
Phosphorylation of the serine and threonine residues in the caspase-8 cleavage motif in 
pro-caspase-3, identified as IET174DS176GVD (P4–P4’), is preferentially catalyzed by the 
CK2α’ catalytic isoform in the absence of the regulatory subunit CK2β (40).  To ascertain 
whether the fluorophores in the novel caspase-8 FRET biosensor were spatially 
positioned to enable FRET, we compared the emission spectra of the caspase-8 FRET 
biosensor and the original mAmetrine-DEVD-tdTomato FRET biosensor.  Measuring 
emission from 450-650 nm using an excitation wavelength of 406 nm, we observed a 
marked increase in FRET emission at 580 nm for the novel caspase-8 FRET biosensor 
(Figure 4.6A).  To assess cleavage of the caspase-8 FRET biosensor we performed a 
titration of recombinant caspase-8 and processed samples using SDS-PAGE by 
quantifying bands corresponding to the full-length FRET biosensor (~80 kDa), the N-
terminal mAmetrine (~25 kDa) cleavage fragment and the tdTomato (~55 kDa) cleavage 
fragment (Figure 4.6B).  Concurrently, we analyzed the samples using fluorometry by 
monitoring emission spectra from 450-650 nm using an excitation wavelength of 406 nm.  




Figure 4.6 Characterization of a novel caspase-8 FRET biosensor containing a 
linker sequence modeled after the caspase-8 cleavage site in pro-caspase-3. 
A) Emission spectra of the caspase-8 FRET biosensor and original mAmetrine-DEVD-
tdTomato FRET biosensor.  B) In vitro caspase-8 cleavage of the recombinant FRET 
biosensor was assayed by titration of recombinant caspase-8 (0-5 µM) and reactions were 
terminated by z-VAD-FMK.  Caspase-cleavage was assessed by quantifying FRET 
emission at 580 nm (λex = 406 nm) and by quantifying SDS-PAGE bands corresponding 
to the full-length FRET biosensor (yellow), the mAmetrine (green) cleavage fragment 
and the tdTomato (orange) cleavage fragment (relative proportions are presented in a 
stacked barplot for each concentration of caspase-8).  Spectra represent mean emissions 
of three independent reactions and error bars represent the standard deviation.  C) In vitro 
caspase-8 cleavage of nonphosphorylated and phosphorylated caspase-8 FRET biosensor.  
Phosphorylation of the caspase-8 FRET biosensor was performed by incubation with 
recombinant CK2α’ while proteolysis was achieved by incubation with 1 µM 
recombinant caspase-8.  Caspase activity was quenched by z-VAD-FMK and CK2α’ 
activity was inhibited by excess EDTA  D) To assess phosphorylation of the caspase-8 
FRET biosensor in cells, the biosensor was co-transfected into HeLa cells with a 
construct expressing myc-CKα’.  Cells were treated with 1 µM okadaic acid for 1 hour at 
37˚C to inhibit phosphatase activity and phosphorylation of the caspase-8 FRET 
biosensor was detected by Western blot. Western blots for B) and C) are representative of 
three independent replicates.  
GFP (red channel)
phospho-caspase-3 (green channel)
- + - +

















































































increasing caspase-8 concentrations, we observed a decrease in FRET efficiency at 580 
nm (Figure 4.6B).  Next, we investigated the effect of phosphorylation on caspase 
cleavage of the caspase-8 FRET biosensor.  The caspase-8 FRET biosensor was 
phosphorylated by recombinant CK2α’ and subsequently treated with recombinant 
caspase-8.  Using a phospho-specific antibody targeting threonine 174 and serine 176, we 
observed phosphorylation of the caspase-8 FRET biosensor, which correlated with a 
modest decrease in caspase-8 cleavage.   
Finally, we investigated both phosphorylation and cleavage of the caspase-8 
FRET biosensor in HeLa cells.  As the pro-caspase-3 site inserted in the linker region of 
the FRET biosensor is preferentially phosphorylated by free catalytic CK2α’, we 
transiently co-transfected the caspase-8 FRET biosensor into HeLa cells with a plasmid 
expressing myc-CK2α’.  Western blot analysis revealed that the caspase-8 FRET 
biosensor can be both expressed and phosphorylated in cells (Figure 4.6D).  Next, we 
transiently transfected the caspase-8 FRET biosensor into HeLa cells and used various 
apoptotic stimuli (staurosporine, TNFα/cycloheximide or etoposide) to activate cellular 
caspases and induce apoptosis.  Using Western blotting, we monitored expression of the 
transiently expressed caspase-8 biosensor and report that cleavage fragments for 
mAmetrine and tdTomato were not detected.  
4.3.3 Systematic characterization of the effect of serine and 
phosphoserine within caspase motifs on susceptibility to 
caspase cleavage 
To guide the development of novel FRET biosensor linker sequences, we 
explored the effect of serine and phosphoserine within caspase motifs on susceptibility to 
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caspase cleavage.  Peptide series modeled after caspase-3/-7 motifs (Golgin-160 and 
PARP1) and a caspase-8 motif (pro-caspase-3) were developed with serine and 
phosphoserine residues positioned P5-P4’ and P4-P3’, respectively (Supplementary Table 
4.1).  Observations that caspases-3 and -7 display specificity beyond the canonical P4–
P1’ motif prompted the use of a peptide series that is broader than the caspase-8 peptide 
series (41).  Cleavage of the caspase-3/-7 (Golgin-160 and PARP1) and caspase-8 (pro-
caspase-3) peptide series were monitored using fluorescence of a tryptophan-DNP FRET 
pair whereby proteolysis alleviates internal quenching of tryptophan fluorescence by 
DNP (Figure 4.7).  Given extensive motif similarity between caspases-3 and -7, it is 
unsurprising that cleavage of the Golgin-160 and PARP1 peptide series produced 
essentially indistinguishable results (25, 42).  Consistent with the literature, we observed 
decreased catalysis when serine residues, positioned at P4 and P3, replaced canonical 
aspartic acid and glutamic acid residues, respectively (25, 43).  Generally, the presence of 
phosphoserine within caspase-3 and -7 motifs negatively regulated caspase-mediated 
substrate conversion including modest, model-specific inhibitory effects at P3 and P5 
(Figure 4.7A).  Evaluating caspase-8 cleavage of the pro-caspase-3 peptide series 
revealed that phosphoserine in the P3 position had no effect on cleavage while 
phosphoserine at P4, P2, P1’ and P2’ inhibited caspase-8 cleavage.  Furthermore, we 
observed no significant difference between serine and phosphoserine at P3’ suggesting 
that caspase-8 cleavage is relatively unaffected by prime side phosphorylation beyond 




Figure 4.7 Comparing the relative activities of caspases -3, -7 and -8 using model 
peptides containing serine or phosphoserine residues positioned within 
corresponding consensus motifs. 
Peptide substrates were synthesized with a C-terminal lysine-DNP to internally quench 
fluorescence of an N-terminal tryptophan residue.  To evaluate caspase cleavage of 
peptide substrates, fluorescence of liberated tryptophan residues was measured at 355 nm 
after excitation at 280 nm.  Peptide substrates modeled after A) Golgin-160 and B) 
PARP1 were assayed with 200 nM caspase-3 and 600 nM caspase-7 for 10 minutes at 
37˚C.  Peptides modeled after the caspase-8 cleavage site within C) pro-caspase-3 were 
assayed with 100 nM caspase-8 for 5 minutes at 37˚C.  All reactions were terminated by 
addition of excess z-VAD-FMK, an irreversible pan-caspase inhibitor.  Error bars 
represent the standard deviation of four independent reactions.  Caspase activity toward 
phosphorylated peptides and nonphosphorylated counterparts were compared using 
analysis of variance and Tukey’s test.  For caspase-3 cleavage of Golgin-160, P4, P3, P1, 
P2, P3, and P4 phosphopeptide versus nonphosphorylated peptide pairs had p-values 
0.0001, whereas all other pairs had a p value 0.05.  For caspase-7 cleavage of Golgin-
160, P4, P3, P2, P3, and P4 phosphopeptide versus nonphosphorylated peptide pairs had 
p values 0.0001, whereas all other pairs had a p-value 0.05.  For caspase cleavage of 
PARP1, all pairs had p-values 0.0001, except for the P3 pair, which had a p value 0.05.  
Caspase cleavage of PARP1 peptides containing serine or phosphoserine substitutes of 
aspartic acid at P4 were not measurable at 200 nM of caspase-3 or 600 nM of caspase-7, 
so caspase concentrations were increased 5-fold (*).  For pro-caspase-3-based peptides, 
all pairs had p values 0.001, except for the P3 and P3 pair, which had p values 0.05.  Data 





4.3.4 Developing novel caspase-3 FRET biosensors to monitor 
CK2–caspase networks 
Following our evaluation of the effect of phosphorylation on caspase cleavage, we 
designed various peptide sequences to assess protein kinase CK2 phosphorylation of 
serine residues positioned within putative caspase motifs.  Using recombinant CK2α2β2 
holoenzyme (Figure 4.8A) or CK2α (Figure 4.8B) we performed kinase assays using [!-
32P]-ATP to analyze phosphorylation of substrate peptides in comparison to biotinylated 
positive (WRRRDDDSDDDDDD) and negative (WRRRDDDADDDDDD) control 
peptides.  Largely, peptides exhibiting phosphate incorporation levels comparable to the 
positive control contained a serine residue in the P2 or P1’ position of the putative 
caspase motif with acidic residues positioned downstream in the +1 and +3 positions 
(relative to the phosphoacceptor). 
Collectively, using the results of our peptide studies, we designed several 
candidate caspase-3 FRET biosensors.  Preliminary investigations focused on assessing 
baseline FRET emission levels to infer the dynamic range of each reporter and secondly, 
we characterized candidate FRET biosensors using both SDS-PAGE and fluorometry to 
assess susceptibility to caspase-3 cleavage.  Remarkably, majority of the novel caspase-3 
FRET biosensors showed comparable or greater FRET efficiency than the parent 
mAmetrine-DEVD-tdTomato FRET biosensor and twelve of the biosensors exhibited 
susceptibility to caspase-3 cleavage above a minimum threshold of 60% (Figure 4.9, 
Supplementary Figure 4.1).  Collectively, these results establish the potential of CK2–





Figure 4.8 Evaluation of protein kinase CK2 phosphorylation of peptides designed 
as candidate FRET linker sequences. 
To evaluate protein kinase CK2 phosphorylation in the context of caspase-3 recognition 
motifs, biotinylated peptides were synthesized by positioning phosphoserine residues 
proximal to candidate caspase-3 cleavage sites containing prime-side acidic (aspartic acid 
or glutamic acid) residues.  Candidate peptides were incubated with A) CK2α2β2 
holoenzyme or with B) the CK2α catalytic-only subunit and [!-32P]-ATP.  Negative 
((biotin)WRRRDDDADDDDDD) and positive ((biotin)WRRRDDDSDDDDDD) control 
peptides for CK2 phosphorylation were included in both datasets.  Reactions were 
incubated for 10 minutes at 30˚C and activity of protein kinase CK2 was terminated by 
addition of excess EDTA.  Incorporation of [!-32P] was visualized by autoradiography 





Figure 4.9 Caspase-3 cleavage of candidate FRET biosensors containing 
phosphorylation sites proximal to caspase-3 cleavage motifs. 
FRET linker sequences optimized for CK2 phosphorylation proximal to caspase-3 
cleavage motifs were subcloned into the linker region of the mAmetrine-DEVD-
tdTomato FRET biosensor developed by Ai et al., (35).  A-L) In vitro cleavage of 
candidate FRET biosensors by titration of recombinant caspase-3 (0-1 µM).  Cleavage 
was evaluated by assessing the spatial separation of the FRET fluorophores using SDS-
PAGE and quantification of bands corresponding to the full-length FRET biosensor 
(yellow), the mAmetrine (green) cleavage fragment and the tdTomato (orange) cleavage 
fragment (relative proportions are presented in a stacked barplot, left) and by evaluating 
FRET emission at 580 nm using an excitation wavelength of 406 nm (emission spectra, 
right).  Caspase-3 reactions were incubated for 1 hour at 37˚C and terminated using the 
irreversible pan-caspase inhibitor z-VAD-FMK.  SDS-PAGE and fluorometry data is 
representative of three independent reactions and corresponds to FRET biosensors that 
exhibited caspase-3 cleavage above a minimum threshold of 60%. See next page for 


































































































































































































































































































































































































































































protein kinase CK2 phosphorylation and caspase cleavage events in live cells during 
apoptosis. 
4.4 Discussion 
Negative regulation of apoptosis by protein kinase CK2 is propagated directly 
through phosphorylation of apoptotic machinery or indirectly through phosphorylation of 
substrates targeted by caspases. Studies by Duncan et al., (28), and Turowec et al., (29), 
have highlighted the prevalence of overlapping protein kinase CK2 consensus sequences 
and caspase motifs within the proteome.  Furthermore, documented examples, such as 
BID (27), Max (44), HS1 (45), Presenilin-2 (46), Connexin 45.6 (47), YY1 (48) as well 
as PTEN (49), suggest that CK2-mediated phosphorylation within caspase cleavage 
motifs attenuate apoptotic induction or propagation by shielding caspase substrates from 
cleavage.  However, recent proteomics studies by Dix et al., (30), and Turowec et al., 
(31), introduce evidence that phosphorylation of caspase motifs may also serve to 
promote caspase cleavage.  To expand the biochemical toolbox for defining the spatial 
and temporal evolution of apoptotic CK2–caspase networks, we manipulated an 
established caspase-3 FRET biosensor using exploratory sequences balancing 
determinants for CK2 phosphorylation within putative caspase motifs.   
4.4.1 Verifying FRET emission and caspase-3 cleavage for the 
mAmetrine-DEVD-tdTomato FRET biosensor 
The mAmetrine-DEVD-tdTomato biosensor was selected for our study as a 
template for developing novel sensors (35).  Advantages of this biosensor are that it is 
already optimized for caspase cleavage, the donor fluorophore mAmetrine is a near-ideal 
donor for tdTomato displaying minimal spectral bleed-through and finally, it is an 
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intramolecular FRET biosensor system, which are generally more suitable for single cell 
FRET microscopy (35).  Preliminary studies on the original mAmetrine-DEVD-tdTomato 
biosensor were performed to assess methods of detection and to evaluate the dynamicity 
of FRET emission in both recombinant and cellular environments (35). Characterization 
of the mAmetrine-DEVD-tdTomato biosensor also provided control data for comparison 
with the novel FRET biosensors we developed. 
4.4.2 Evaluation of a novel caspase-8 FRET biosensor in vitro and 
in HeLa cells 
Initially, we generated a caspase-8 FRET biosensor containing the pro-caspase-3 
site shown to be phosphorylated by protein kinase CK2α’ both in vitro and in cells (40).  
We demonstrated that recombinant protein kinase CK2α’ and recombinant caspase-8 
robustly phosphorylated and cleaved the caspase-8 FRET biosensor, respectively.  We 
also showed that CK2α’-mediated phosphorylation of the caspase-8 FRET biosensor in 
vitro reduced cleavage by recombinant caspase-8.  Furthermore, co-transfection of the 
caspase-8 biosensor and myc-CK2α’ resulted in phosphorylation of the biosensor in 
HeLa cells.   
To test the susceptibility of the caspase-8 FRET biosensor to caspase cleavage in 
live cells, we transiently transfected the biosensor into HeLa cells and used various 
apoptotic stimuli to stimulate caspase activation.  Using Western blotting, we were able 
to detect the full-length caspase-8 FRET biosensor but were unable to detect cleavage 
fragments for mAmetrine or tdTomato in HeLa cell lysates treated with the various 
apoptotic stimuli.  With the notion that initiator caspases typically exhibit intrinsically 
weaker activity than executioner caspases and considering that activation of less than 1% 
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of caspase-8 proteins is sufficient to propagate the apoptotic program in HeLa cells, we 
speculate that the molar ratio between active cellular caspase-8 in combination with the 
over-expression of the caspase-8 biosensor was insufficient for detecting substrate 
cleavage by Western blotting (50–52).  Furthermore, selective localization of caspase-8 
to different subcellular compartments during apoptosis may have also contributed to the 
lack of cleavage of the caspase-8 FRET biosensor observed in HeLa cells (53). 
4.4.3 Influence of serine and phosphoserine within caspase motifs 
on susceptibility to caspase cleavage 
Substitution of unmodified residues within and beyond the canonical P4–P1’ 
caspase motif can influence caspase activity (30, 41).  Considering phosphorylated 
residues are both structurally bulky and negatively charged, we systematically evaluated 
the effect of serine and phosphoserine, using model peptide substrates for caspases-3, -7 
and -8, to guide the development of novel FRET biosensors containing phosphosites 
within caspase motifs (31).  Largely, the impact of serine or phosphoserine within the 
caspase-3 and -7 model peptide series, representing P5–P4’, was either neutral or 
inhibitory.  Consistent with studies by Stennicke et al., (43), and Thornberry et al., (25), 
we observed reduced caspase cleavage when serine replaced canonical residues at P4 and 
P2, respectively.  Furthermore, serine positioned at P1’ exhibited a modest reduction in 
cleavage, a result that is not entirely congruent with previous observations that serine has 
no effect at P1’ (43).  Consistent with the literature, positioning phosphoserine within the 
canonical P4-P1’ caspase motif, with the exception of P3, completely abolished caspase 
cleavage and beyond the canonical motif, we observed similar results when 
phosphoserine is positioned at P2’ while phosphoserine at P3’ and P4’ exhibited more 
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modest inhibitory effects.  In terms of P3, Dix et al., (30), demonstrated that in some 
instances, phosphorylation at P3 has the capacity to promote cleavage whereas similar to 
Tözsér et al., (26), P3 phosphorylation did not overtly alter caspase cleavage of our 
peptide substrates.  We speculate that this discordance is either a consequence of 
experimental reaction conditions (i.e., enzyme concentration, buffer conditions, peptide 
length, etc.) or suggests that the effect of phosphoserine at P3 requires determinants 
beyond the context of short, unstructured peptide substrates.  Evidence that the S5 
binding site (interacts with P5) of caspases-3 and -7 directs selectivity prompted our 
inclusion of P5 within our peptide series (41, 54).  Phosphorylation at P5 did not exhibit 
caspase-specific effects but rather, the Golgin-160-based peptide was unaffected while 
the PARP1-based peptide exhibited reduced cleavage suggesting that P5 determinants 
may be context-specific.   
Showing similar trends as caspases-3 and -7 and, in accordance with the literature, 
phosphoserine at P4, P2, P1’ and P2' inhibited caspase-8 cleavage (26, 28). Interestingly, 
literature examples of substrates negatively regulated by caspase-8 phosphorylation (i.e., 
pro-caspase-3 (28, 40) and BID (27)), are phosphorylated at two sites within the caspase 
motif suggesting that phosphorylation may have a graduated effect on caspase-8 
cleavage.  Finally, in contrast to positive regulation observed by Dix et al., (30), we 
observed no effect when P3 was phosphorylated.   
4.4.4 Evaluating novel caspase-3 FRET biosensors designed to 
monitor CK2–caspase networks 
Additional studies using peptide substrates to evaluate phosphorylation of 
putative caspase motifs indicated that CK2-mediated phosphorylation is enhanced when 
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the serine phosphoacceptor is positioned in P2 or P1’ with acidic residues located 
downstream in the +1 and +3 positions (relative to the phosphoacceptor).  These findings 
align with previously established CK2 consensus motifs defined as pS/pT-X-X-E/D/pS 
and with the characterization of CK2 as protein kinase that preferentially phosphorylates 
acidophilic sequences (10, 11).  Finally, the candidate caspase-3 FRET biosensors we 
developed, containing linker sequences with CK2 phosphorylation sites overlapping 
putative caspase-3 cleavage motifs, demonstrated a broad range of FRET efficiencies and 
susceptibility to caspase-3 cleavage.  Many of the candidate caspase-3 FRET biosensors 
showed greater FRET efficiency than the parent mAmetrine-DEVD-tdTomato FRET 
biosensor, indicating that they exhibit a broader dynamic range for measuring proteolysis.  
Furthermore, several of the biosensors displayed cleavage ratios similar to the parent 
mAmetrine-DEVD-tdTomato biosensor suggesting that they may serve as substrates for 
activated caspase-3 in cell expression systems. 
Overall, this study provides a systematic approach to developing FRET 
biosensors to monitor the spatial and temporal aspects of phosphorylated caspase 
cleavage motifs.  We successfully identified the impact of serine and phosphoserine 
determinants within caspase cleavage motifs and developed a number of prospective 
CK2–caspase-3 FRET biosensors.  Future evaluations identifying the effect of 
phosphorylation on caspase cleavage of our candidate biosensors will help expand the 
biochemical toolbox for monitoring the relationship between protein kinase CK2 
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Supplementary Table 4.1 Comprehensive list of peptide substrates. 
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Supplementary Table 4.2 Comprehensive list of recombinant FRET biosensors. 
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Supplementary Figure 4.1 Candidate FRET biosensors ineffectively cleaved by 
caspase-3. 
A-N) In vitro cleavage of candidate FRET biosensors was performed by titration of 
recombinant caspase-3 (0-1 µM).  Cleavage was evaluated by assessing the spatial 
separation of the FRET fluorophores using SDS-PAGE and quantification of bands 
corresponding to the full-length FRET biosensor (yellow), the mAmetrine (green) 
cleavage fragment and the tdTomato (orange) cleavage fragment (relative proportions are 
presented in a stacked barplot, left) and by evaluating FRET emission at 580 nm using an 
excitation wavelength of 406 nm (emission spectra, right).  Caspase-3 reactions were 
incubated for 1 hour at 37˚C and terminated using the irreversible pan-caspase inhibitor 
z-VAD-FMK.  SDS-PAGE and fluorometry data is representative of three independent 
reactions and corresponds to FRET biosensors that exhibited ineffective caspase-3 













































































































































































































































































































































































































































































































































Chapter 5  
5 DISCUSSION 
5.1 Overview 
Post-translational modifications exponentially expand the complexity of the 
human proteome and diversify the signaling capacity of cells.  Protein kinases and 
proteases are responsible for catalyzing two fundamentally distinct post-translational 
modifications—phosphorylation and proteolysis—that play essential roles in maintaining 
the balance between cell survival and cell death (1–4).  Protein phosphorylation is 
physiologically reversible whereas proteolysis is distinguished from other post-
translational modifications by being essentially irreversible (4, 5).  The intersection of 
these post-translational systems, as a fundamental regulatory mechanism in biological 
processes, is reinforced by accumulating evidence of direct interactions between protein 
kinases and proteases in apoptosis, a process of programmed cell death (1, 2, 6–9). 
Responsible for eliminating unneeded, unnecessary or diseased cells, apoptosis is 
essential for normal development and tissue homeostasis in multicellular organisms (10).  
To generate, transduce or amplify signals within apoptotic networks, both 
phosphorylation and proteolysis function by influencing the activity, localization or fate 
of specific protein substrates (4, 5, 11).  Predictably, perturbations to regulatory post-
translational networks in apoptosis have important implications in a variety of 
pathologies and for this reason, the phosphotransferases and proteases responsible for 
mediating these modifications are often targeted for therapeutic intervention or monitored 
as diagnostic or prognostic markers (3, 4, 12–14).  In this work, we explore the functional 
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dialogue between protein kinases and proteases by using diverse strategies to characterize 
the amplitude of phosphorylation and proteolysis in apoptosis. 
5.2 Summary of Research Contributions 
5.2.1 Examining the apoptotic kinome and mapping the 
phosphorylation landscape in HeLa cells treated with 
doxorubicin 
Motivated by accumulating evidence detailing the bidirectional relationship 
between protein kinases and proteases, in chapter 2 of this thesis we investigated the 
impact of apoptotic-driven proteolysis on phosphotransferase signaling and employed 
complementary strategies to globally examine both the apoptotic kinome and 
phosphoproteome (1, 2). 
First, we systematically interrogated the DegraBase dataset, published by 
Crawford et al., (15), to investigate the global impact of apoptotic proteolytic processing 
of phosphotransferases.  Examination of protein kinases revealed that the human kinome 
is profoundly impacted by proteolysis during apoptosis and correspondingly, we also 
observed extensive cleavage of both catalytic and regulatory phosphatase subunits.  
Moreover, roughly half of the phosphotransferases identified in the DegraBase contained 
an aspartic acid (or glutamic acid) residue in the P1 position suggesting that the caspase 
family of proteases is largely responsible for kinome and phosphatome proteolysis during 
apoptosis (16–18).  
As a logical extension of the DegraBase findings, we used two complementary 
quantitative proteomics strategies to explore both the apoptotic kinome and the apoptotic 
phosphoproteome of HeLa cells treated with doxorubicin.  To evaluate kinome 
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reprogramming, protein kinases from healthy (DMSO) and apoptotic (doxorubicin) 
proteomes were captured using multiplexed inhibitor beads (MIBs) and identified using 
mass spectrometry.  Isolating ~30% of the human kinome, we observed enrichment of 
protein kinases across all major kinase groups comparable to the distribution of kinase 
groups represented within the entire complement of the human kinome.  Moreover, 25% 
of our kinome enrichment dataset overlapped with protein kinases identified in the 
DegraBase (15).  Within our kinome profiling dataset, we observed up- and down-
regulation of protein kinases including Bub1 (19–21) and Fyn (22–27), which are both 
implicated as regulators of apoptosis.  
Consistent with observations from our profile suggesting distinct variations within 
the kinome, we observed widespread hypo- and hyper-phosphorylation of numerous 
phosphosites in our complementary evaluation of the doxorubicin-induced 
phosphoproteome.  Analyzing our data using PHOXTRACK to identify kinase–substrate 
relationships revealed extensive perturbations to protein kinases ATR, ATM and CK2.  
With respect to substrates of both ATR and ATM, we observed hyper-phosphorylation 
indicating that these protein kinases are up-regulated in response to doxorubicin 
treatment.  Intriguingly, analysis of CK2 substrates revealed bidirectional alterations in 
phosphorylation site occupancies, which suggests that CK2 activity is coordinated by 
mechanisms that facilitate distinct phosphorylation events. 
Collectively, our comprehensive analysis of the DegraBase revealed that during 
apoptosis an extensive proportion of the human kinome and phosphatome are targeted by 
proteases, which emphasizes the direct impact of apoptotic-driven proteolysis on the 
phosphotransferases responsible for regulating phosphoproteome signaling.  Moreover, 
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using quantitative high-throughput proteomics approaches we were able to systematically 
evaluate the apoptotic kinome and characterize the consequent topography of the 
phosphorylation landscape in HeLa cells treated with doxorubicin. 
5.2.2 Exploring the apoptotic degradome of HeLa cells treated 
with doxorubicin 
A common competence of cancer cells is the ability to evade apoptosis and persist 
inappropriately (28, 29).  To combat cancer cell survival, pro-apoptotic drugs are widely 
used to circumvent the persistence of cancer cells by reestablishing or rewiring apoptotic 
pathways.  Given that apoptotic degradomes are context-specific, in chapter 3 of this 
thesis we explored the proteolytic landscape of HeLa cells treated with doxorubicin using 
a quantitative N-terminomics strategy known as TAILS (terminal amine isotope labeling 
of substrates) (30). 
Consistent with the literature, we observed a >10-fold enrichment of all N-
terminally blocked peptides in the TAILS dataset and to ensure that the enrichment was 
unbiased, we verified that the distribution of N-terminal modifications in the pre-
enrichment (preTAILS) dataset was indistinguishable from the post-enrichment (TAILS) 
N-terminome dataset (31, 32).  Analysis of N-terminally dimethylated peptides quantified 
in both control and doxorubicin-treated N-terminomes revealed a positively skewed 
distribution of log2(H/L) ratios with the majority of peptides exhibiting negative log2 
ratios.  This indicated that the incidence of proteolysis in the control N-terminome was 
higher than in the doxorubicin-treated N-terminome. We speculate that this finding is 
largely representative of protein termini generated as a consequence of homeostatic 
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proteolysis, which would suggest that steady state protease activity or substrate 
selectivity may be modulated in response to doxorubicin treatment.  
Characterization of protease cleavage motifs for N-terminally dimethylated 
peptides quantified in both control and doxorubicin-treated N-terminomes revealed a 
broad distribution of residues in the P1 position with methionine exhibiting striking 
representation, which we speculate is reflective of methionine aminopeptidases (33). 
Distinctively, we observed primarily aspartic acid residues in the P1 position of N-
terminally dimethylated peptides quantified exclusively in the doxorubicin-treated N-
terminome.  Considering caspases demonstrate a dominant specificity for aspartic acid 
residues in the P1 position and are activated in response to doxorubicin treatment, we 
postulate that peptides identified with a P1 aspartic acid residue are putative substrates of 
caspases (17, 34–36).  With this in mind, we identified an additional 118 peptides with an 
aspartic acid residue in the P1 position when we considered naturally N-terminally 
acetylated peptides in our N-terminome enrichment.  Finally, to illustrate the scope of 
biological processes impacted within the N-terminome of HeLa cells treated with 
doxorubicin, we examined the Gene Ontology of all proteins corresponding to peptides 
identified in our N-terminome. 
Collectively, this work provides a broad surveillance of the proteolytic landscape 
of HeLa cells treated with doxorubicin and illustrates the diversity and complexity of 
signaling within protease webs.  
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5.2.3 Expanding the biochemical toolbox for monitoring the 
functional interplay between protein kinases and caspases 
Protein kinase CK2, a critical regulator of vital cell processes, has emerged as a 
key regulatory participant within apoptotic caspase circuitry.  In chapter 4 of this thesis 
we used peptide-centric studies to evaluate the impact of phosphorylation within caspase 
motifs, which guided the development of FRET biosensors using exploratory sequences 
balancing determinants for CK2 phosphorylation within putative caspase motifs. 
First, we verified an established mAmetrine-DEVD-tdTomato caspase-3 FRET 
biosensor by assessing the dynamics of FRET both in vitro and in live cells (37).  Next, 
to evaluate the consequences of manipulating the linker sequence of the mAmetrine-
DEVD-tdTomato FRET biosensor, we inserted a documented caspase-8 cleavage site 
regulated by CK2 phosphorylation found in pro-caspase-3 (38, 39).  Remarkably, the 
caspase-8 FRET biosensor displayed an increased dynamic range for FRET emission and 
was also susceptible to both CK2 phosphorylation and caspase-8 cleavage in vitro 
whereby phosphorylation of the biosensor blocked cleavage by caspase-8. 
To guide the development of novel FRET biosensor linker sequences, we used a 
peptide-centric approach to explore the effect of serine and phosphoserine within 
caspase-3, -7 and -8 motifs on susceptibility to caspase cleavage.  Within the peptide 
series for caspase-3 and -7, we observed a modest reduction in cleavage with serine 
positioned at P4, P2 and P1’ whereas the presence of phosphoserine throughout the motif 
was largely inhibitory to caspase cleavage.  In terms of phosphoserine, caspase-8 showed 
inhibition similar to observations for caspases-3 and-7 but was generally unaffected by 
serine residues.  Additional studies using peptide substrates to evaluate CK2 
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phosphorylation of putative caspase substrates, revealed that P2 or P1’ were optimal 
positions for the phosphorylatable serine residue with acidic residues positioned 
downstream in the +1 and +3 positions (relative to the phosphoacceptor). 
Using the results of our peptide studies, we designed several candidate caspase-3 
FRET biosensors.  Initial investigations focused on assessing baseline FRET emission 
levels to infer the dynamic range of each reporter and secondly, we characterized 
candidate FRET biosensors using both SDS-PAGE and fluorometry to assess 
susceptibility to caspase-3 cleavage.  Majority of the novel caspase-3 FRET biosensors 
demonstrated comparable or greater FRET efficiency than the parent mAmetrine-DEVD-
tdTomato FRET biosensor and twelve exhibited susceptibility to caspase-3 cleavage. 
Overall, this chapter described a systematic approach to developing FRET 
biosensors to monitor the spatial and temporal aspects of phosphorylated caspase 
cleavage motifs.  Future evaluations identifying the effect of phosphorylation on caspase 
cleavage of our candidate biosensors will help expand the biochemical toolbox for 
monitoring the relationship between protein kinase CK2 phosphorylation and caspase 
cleavage events in live cells during apoptosis.  
5.3 Implications and perspectives 
5.3.1 Clinical considerations of surveying proteoforms using 
proteomics 
Post-translational modifications exponentially increase the complexity and 
diversity of the proteome and expand the flexibility of regulatory mechanisms for 
responding or adapting to stimuli (40–45).  To understand the circuitry of post-
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translational regulatory systems within biological or pathological states, both the 
enzymes and corresponding substrates responsible for switching signaling nodes on or off 
need to be defined and characterized.  As demonstrated by the proteomics strategies used 
in this thesis, technological advances in mass spectrometry coupled with the emergence 
of novel enrichment strategies have enabled high-throughput quantitative measurements 
for profiling the stoichiometric dynamics of post-translational modifications (32, 41, 46–
48). 
Notably, the biochemical fingerprint of post-translational modifications is 
context-dependent and varies between cell types and in response to drug therapies, which 
introduces unique considerations within the field of precision medicine (41, 49, 50).  
With advances to comparative clinical proteomics, the baseline geography of post-
translational modifications within patient samples could be evaluated to elucidate the 
impact of drug-therapies within post-translational signaling networks (50).  Furthermore, 
surveillance of post-translational modification signatures could be used clinically to 
establish diagnostic or prognostic biomarkers for various pathologies (14, 50, 51).  
Overall, mass spectrometry is an accurate and sensitive platform and adapting proteomics 
strategies, such as those used in our study, to clinically survey the ubiquitous and 
dynamic nature of post-translational modifications would expand our understanding of 
pathological processes and potentially guide treatment regimens. 
5.3.2 Inherent challenges of interpreting phosphoproteomics and 
degradomics data 
As demonstrated in this thesis, the sensitivity of mass spectrometry instruments 
coupled with innovative enrichment techniques has enabled high-throughput detection, 
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identification and quantification of both phosphorylation and proteolysis in cells.  The 
magnitude of data acquired using these proteomics approaches is essentially unrivalled 
when compared to conventional reductionist methods and herein lies an inherent 
challenge: data analysis and interpretation.  Post-translational modifications are 
participants in both housekeeping and regulatory pathways and deciphering the biological 
role and relevance of each modification identified in high-throughput datasets is a 
complex task. 
Protein kinases are responsible for the phosphorylation of substrate proteins and 
while monitoring phosphoproteome dynamics is globally informative, identifying the 
protein kinases responsible for specific substrate modifications is essential to defining 
protein kinase circuitry.  Isolating individual protein kinases responsible for 
phosphorylating specific sites is largely approached using bioinformatics.  Protein 
kinases typically target specific amino acid consensus sequences and bioinformatics tools 
use this information, often in combination with structural characteristics, to predict 
kinase–substrate relationships (52).  These tools are useful for gaining broad insights 
regarding the complement of phosphorylation motifs enriched in a dataset but given that 
they are based on predictive algorithms, the evidence is insufficient for validating novel, 
biologically-relevant kinase–substrate interactions.  Numerous databases also exist that 
contain phosphorylation site information derived from phosphoproteomics datasets or 
experimentally-validated examples.  These databases are useful for cross-referencing 
identified phosphosites; however, with the multiplicity of databases available, 
information is often broadcasted across multiple resources.  Fortunately, there are 
centralized databases, such as PhosphoSitePlus (53, 54) which contains curated 
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information about documented post-translational modifications, that are valuable and 
reliable; however, again, these resources lack the comprehensive evidence required to 
delineate novel kinase–substrate interactions. 
Encountering many of the described challenges in the evaluation of our own 
phosphoproteomics data, we elected to use a recently developed tool for interpreting 
comprehensive phosphoproteomics datasets called PHOXTRACK (55).  This tool relates 
phosphosite sequences from a phosphoproteomics dataset to experimentally-validated 
kinase-specific phosphosites curated in databases (such as PhosphoSitePlus (53)) to 
enrich for regulated kinases (55).  While this tool does not circumvent the challenge of 
identifying novel kinase–substrate interactions, it is a valuable strategy for identifying 
experimentally-documented kinase–substrate relationships within a phosphoproteomics 
dataset and provides insights regarding global regulation of the correlated protein kinases.   
Other considerations regarding the analysis of phosphoproteomics data is that 
detection and identification is contingent on phosphosite occupancy and therefore 
interpretations are largely focused on the protein kinases responsible for delivering 
phosphates to substrate proteins.  However, mounting evidence informs that the global 
balance of phosphorylation is critical for transmitting signals rather than the antiquated 
notion that pathways are simply switched on and off by protein kinases or phosphatases 
(5).  This suggests that the absence of a phosphate is as important as the presence of a 
phosphate on a substrate protein and highlights the role of phosphatases as regulatory 
participants in phosphoproteome dynamics. 
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Similar challenges are encountered when evaluating proteolytic landscapes using 
degradomics strategies.  Proteases were historically considered indiscriminate protein-
degrading enzymes employed exclusively for protein catabolism, but more recently have 
emerged as diverse signaling molecules involved in the regulation of various biological 
processes (4).  Unlike protein kinases, proteases are largely non-specific and rely on 
complex networks of proteins to confer specificity and substrate selectivity (4).  
Consequently, predictive tools are impractical for assigning proteases to identified 
cleavage sites.  Furthermore, repositories of cleavage sites are informative; however, 
analogous to databases detailing phosphorylation sites, these resources are unsuitable for 
defining novel protease–substrate interactions.  That said, the TopFIND knowledgebase 
is a unique analysis platform that maps the origins of protein termini, which can help 
remove noise from N-terminomics experiments attributed to alternative splicing, 
alternative translation or basal proteolysis.  Ultimately, at present, the identification of 
specific proteolytic cleavage products requires complementary approaches to 
biochemically validate the biological context of protease–substrate interactions. 
Overall, mass spectrometry-based proteomics are a powerful strategy for 
deciphering the complex circuitry of post-translational regulatory systems.  As high-
sensitivity mass spectrometry instruments become more accessible, the influx of 
information derived from proteomic investigations will expand exponentially.  A major 
goal in the future will be to develop improved bioinformatics tools to functionally 





The interplay between phosphorylation and proteolysis has emerged as an 
intricate regulatory mechanism for fine-tuning the balance between cell survival and cell 
death. Complex integration of these post-translational regulatory systems in biological 
and pathological processes has underscored the requirement for high-throughput 
strategies to globally assess the intersection of phosphotransferase and protease networks.   
Collectively, this thesis demonstrates the application of complementary kinomic, 
phosphoproteomic and terminomic strategies to evaluate the context-specific amplitude 
of phosphorylation and proteolysis in HeLa cells treated with doxorubicin.  Furthermore, 
our work on biosensors highlights the importance of developing reciprocal strategies to 
subsequently monitor the spatial and temporal evolution of specific kinase–protease 
interactions in live cells.  Ultimately, large-scale studies investigating phosphorylation 
and proteolysis continue to expand our understanding of apoptosis and provide insights 
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